take O
together O
, O
result O
demonstrate O
that O
sgt1/sgt1b O
be O
require O
for O
cor O
- O
induce O
chlorosis O
and O
subsequent O
necrotic O
disease O
development O
in O
tomato B-Plant
and O
arabidopsis O
. O

sgt1 O
be O
therefore O
a O
component O
of O
the O
cor O
/ O
ja O
- O
mediate O
signal O
transduction O
pathway O
. O

oshma3 O
, O
a O
p1b O
- O
type O
of O
atpase O
affect O
root O
- O
to O
- O
shoot O
cadmium O
translocation O
in O
rice B-Plant
by O
mediate O
efflux O
into O
vacuole O
. O

the O
cadmium O
( O
cd O
) O
over O
- O
accumulate O
rice B-Plant
( O
oryza B-Plant
sativa I-Plant
) O
cv O
cho O
- O
ko O
- O
koku O
be O
previously O
show O
to O
have O
an O
enhanced O
rate O
of O
root O
- O
to O
- O
shoot O
cd O
translocation O
. O

this O
trait O
be O
control O
by O
a O
single O
recessive O
allele O
locate O
at O
qcdt7 O
. O

in O
this O
study O
, O
use O
positional O
clone O
and O
transgenic O
strategy O
, O
heavy O
metal O
atpase O
3 O
( O
oshma3 O
) O
be O
identify O
as O
the O
gene O
that O
control O
root O
- O
to O
- O
shoot O
cd O
translocation O
rate O
. O

the O
subcellular O
localization O
and O
cd O
- O
transport O
activity O
of O
the O
gene O
product O
be O
also O
investigate O
. O

the O
allele O
of O
oshma3 O
that O
confer O
high O
root O
- O
to O
- O
shoot O
cd O
translocation O
rate O
( O
oshma3mc O
) O
encode O
a O
defective O
p(1b O
) O
-atpase O
transporter O
. O

oshma3 O
fuse O
to O
green O
fluorescent O
protein O
be O
localize O
to O
vacuolar O
membrane O
in O
plant O
and O
yeast O
. O

an O
oshma3 O
transgene O
complement O
cd O
sensitivity O
in O
a O
yeast O
mutant O
that O
lack O
the O
ability O
to O
transport O
cd O
into O
vacuole O
. O

by O
contrast O
, O
oshma3mc O
do O
not O
complement O
the O
cd O
sensitivity O
of O
this O
yeast O
mutant O
, O
indicate O
that O
the O
oshma3mc O
transport O
function O
be O
lose O
. O

propose O
that O
the O
root O
cell O
cytoplasm O
of O
cd O
- O
overaccumulat O
rice B-Plant
plant O
have O
more O
cd O
available O
for O
loading O
into O
the O
xylem O
as O
a O
result O
of O
the O
lack O
of O
oshma3-mediated O
transportation O
of O
cd O
to O
the O
vacuole O
. O

this O
defect O
result O
in O
cd O
translocation O
to O
the O
shoot O
in O
high O
concentration O
. O

these O
datum O
demonstrate O
the O
importance O
of O
vacuolar O
sequestration O
for O
cd O
accumulation O
in O
rice B-Plant
. O

spatial O
distribution O
of O
arsenic O
and O
temporal O
variation O
of O
concentration O
in O
rice B-Plant
. O

in O
order O
to O
gain O
insight O
into O
the O
transport O
and O
distribution O
of O
arsenic O
( O
as O
) O
in O
intact O
rice B-Plant
( O
oryza B-Plant
sativa I-Plant
) O
plant O
and O
unloading O
into O
the O
rice B-Plant
grain O
, O
investigate O
the O
spatial O
distribution O
of O
as O
and O
the O
temporal O
variation O
of O
as O
concentration O
in O
whole O
rice B-Plant
plant O
at O
different O
growth O
stage O
. O

to O
the O
good O
of O
knowledge O
, O
this O
be O
the O
first O
time O
that O
such O
a O
study O
have O
be O
perform O
. O

inductively O
couple O
plasma O
mass O
spectroscopy O
( O
icp O
- O
ms O
) O
and O
high O
- O
performance O
liquid O
chromatography O
( O
hplc)-icp O
- O
ms O
be O
use O
to O
analyze O
total O
as O
concentration O
and O
speciation O
. O

moreover O
, O
synchrotron O
- O
base O
x O
- O
ray O
fluorescence O
( O
sxrf O
) O
be O
use O
to O
investigate O
in O
situ O
as O
distribution O
in O
the O
leaf O
, O
internode O
, O
node O
and O
grain O
. O

total O
as O
concentration O
of O
vegetative O
tissue O
increase O
during O
the O
2 O
wk O
after O
flower O
. O

the O
concentration O
of O
dimethylarsinic O
acid O
( O
dma O
) O
in O
the O
caryopsis O
decrease O
progressively O
with O
development O
, O
whereas O
inorganic O
as O
concentration O
remain O
stable O
. O

the O
ratio O
of O
as O
content O
between O
neighboring O
leaf O
or O
between O
neighboring O
internode O
be O
c. O

0.6 O

. O

sxrf O
reveal O
as O
accumulation O
in O
the O
center O
of O
the O
caryopsis O
during O
early O
development O
and O
then O
in O
the O
ovular O
vascular O
trace O
. O

these O
result O
indicate O
that O
there O
be O
different O
control O
on O
the O
unloading O
of O
inorganic O
as O
and O
dma O
""";""" O
the O
latter O
accumulate O
mainly O
in O
the O
caryopsis O
before O
flower O
, O
whereas O
inorganic O
as O
be O
mainly O
transport O
into O
the O
caryopsis O
during O
grain O
filling O
. O

moreover O
, O
node O
appear O
to O
serve O
as O
a O
check O
- O
point O
in O
as O
distribution O
in O
rice B-Plant
shoot O
. O

hypoxia O
responsive O
gene O
expression O
be O
mediate O
by O
various O
subset O
of O
transcription O
factor O
and O
mirnas O
that O
be O
determine O
by O
the O
actual O
oxygen O
availability O
. O

reduce O
oxygen O
availability O
be O
not O
only O
associate O
with O
flooding O
, O
but O
occur O
also O
during O
growth O
and O
development O
. O

be O
largely O
unknown O
how O
hypoxia O
be O
perceive O
and O
what O
signaling O
cascade O
be O
involve O
in O
activate O
adaptive O
response O
. O

analyse O
the O
expression O
of O
over O
1900 O
transcription O
factor O
( O
tf O
) O
and O
180 O
microrna O
primary O
transcript O
( O
pri O
- O
mirnas O
) O
in O
arabidopsis O
root O
expose O
to O
different O
hypoxic O
condition O
by O
mean O
of O
quantitative O
pcr O
. O

also O
analyse O
the O
promoter O
of O
gene O
induce O
by O
hypoxia O
with O
respect O
to O
over O
- O
represent O
dna O
element O
that O
can O
act O
as O
potential O
tf O
bind O
site O
and O
in O
vivo O
interaction O
be O
verify O
. O

identify O
various O
subset O
of O
tf O
that O
respond O
differentially O
through O
time O
and O
in O
an O
oxygen O
concentration O
- O
dependent O
manner O
. O

the O
regulatory O
potential O
of O
select O
tf O
and O
predict O
dna O
bind O
element O
be O
validate O
. O

although O
the O
expression O
of O
pri O
- O
mirnas O
be O
differentially O
regulate O
under O
hypoxia O
, O
only O
one O
correspond O
mature O
mirna O
change O
accordingly O
. O

putative O
target O
transcript O
of O
the O
mirnas O
be O
not O
significantly O
affect O
. O

result O
show O
that O
the O
regulation O
of O
hypoxia O
- O
induce O
gene O
be O
control O
via O
simultaneous O
interaction O
of O
various O
combination O
of O
tf O
. O

under O
anoxic O
condition O
, O
an O
additional O
set O
of O
tf O
be O
induce O
. O

regulation O
of O
gene O
expression O
via O
mirnas O
appear O
to O
play O
a O
minor O
role O
during O
hypoxia O
. O

comparison O
of O
seasonal O
variation O
in O
water O
- O
use O
efficiency O
calculate O
from O
the O
carbon O
isotope O
composition O
of O
tree O
ring O
and O
flux O
datum O
in O
a O
temperate O
forest O
. O

tree O
- O
ring O
delta(13 O
) O
c O
be O
often O
interpret O
in O
term O
of O
intrinsic O
water O
- O
use O
efficiency O
( O
wue O
) O
use O
a O
carbon O
isotope O
discrimination O
model O
establish O
at O
the O
leaf O
level O
. O

examine O
whether O
intra O
- O
ring O
delta(13 O
) O
c O
could O
be O
use O
to O
assess O
variation O
in O
intrinsic O
wue O
( O
w(g O
) O
, O
the O
ratio O
of O
carbon O
assimilation O
and O
stomatal O
conductance O
to O
water O
) O
and O
variation O
in O
ecosystem O
wue O
( O
w(t O
) O
, O
the O
ratio O
of O
c O
assimilation O
and O
transpiration O
) O
at O
a O
seasonal O
scale O
. O

intra O
- O
ring O
delta(13 O
) O
c O
be O
measure O
in O
-30 O
to O
60-mum O
- O
thick O
slice O
in O
eight O
oak B-Plant
tree O
( O
quercus B-Plant
petraea I-Plant
) O
. O

canopy O
w(g O
) O
be O
simulate O
use O
a O
physiologically O
process O
- O
base O
model O
. O

high O
between O
- O
tree O
variability O
be O
observe O
in O
the O
seasonal O
variation O
of O
intra O
- O
ring O
delta(13 O
) O
c. O

six O
tree O
show O
significant O
positive O
correlation O
between O
w(g O
) O
calculate O
from O
intra O
- O
ring O
delta(13 O
) O
c O
and O
canopy O
w(g O
) O
average O
over O
several O
day O
during O
latewood O
formation O
. O

these O
result O
suggest O
that O
latewood O
be O
a O
seasonal O
recorder O
of O
w(g O
) O
trend O
, O
with O
a O
temporal O
lag O
correspond O
to O
the O
mixing O
time O
of O
sugar O
in O
the O
phloem O
. O

these O
six O
tree O
also O
show O
significant O
negative O
correlation O
between O
photosynthetic O
discrimination O
delta O
calculate O
from O
intra O
- O
ring O
delta(13 O
) O
c O
, O
and O
ecosystem O
w(t O
) O
, O
during O
latewood O
formation O
. O

despite O
the O
observe O
between O
- O
tree O
variability O
, O
these O
result O
indicate O
that O
intra O
- O
ring O
delta(13 O
) O
c O
can O
be O
use O
to O
access O
seasonal O
variation O
in O
past O
w(t O
) O
. O

resistance O
and O
recovery O
of O
soil O
microbial O
community O
in O
the O
face O
of O
alliaria B-Plant
petiolata I-Plant
invasion O
. O

invader O
can O
gain O
ecological O
advantage O
because O
of O
evolutionary O
novelty O
, O
but O
little O
be O
know O
about O
how O
these O
novel O
advantage O
will O
change O
over O
time O
as O
the O
invader O
and O
invaded O
community O
evolve O
in O
response O
to O
each O
other O
. O

invasive O
plant O
often O
gain O
such O
an O
advantage O
through O
alteration O
of O
soil O
microbial O
community O
. O

in O
soil O
community O
sample O
from O
site O
along O
a O
gradient O
of O
invasion O
history O
with O
alliaria B-Plant
petiolata I-Plant
, O
microbial O
richness O
tend O
to O
decline O
, O
but O
the O
community O
's O
resistance O
to O
a. B-Plant
petiolata I-Plant
's O
effect O
generally O
increase O
with O
increase O
history O
of O
invasion O
. O

however O
, O
sensitive O
microbial O
taxa O
appear O
to O
recover O
in O
the O
two O
old O
site O
, O
lead O
to O
an O
increase O
in O
richness O
, O
but O
consequent O
decrease O
in O
resistance O
. O

this O
may O
be O
because O
of O
evolutionary O
change O
in O
the O
a. B-Plant
petiolata I-Plant
population O
, O
which O
tend O
to O
reduce O
investment O
to O
allelopathic O
compound O
over O
time O
. O

these O
result O
show O
that O
, O
over O
time O
, O
microbial O
community O
can O
develop O
resistance O
to O
an O
invasive O
plant O
but O
at O
the O
cost O
of O
low O
richness O
. O

however O
, O
over O
long O
time O
- O
scale O
evolution O
in O
the O
invasive O
specie O
may O
allow O
for O
the O
recovery O
of O
soil O
microbial O
community O
. O

growth O
- O
mediate O
stress O
escape O
: O
convergence O
of O
signal O
transduction O
pathway O
activate O
upon O
exposure O
to O
two O
different O
environmental O
stress O
. O

plant O
can O
escape O
from O
specific O
environmental O
stress O
through O
active O
growth O
strategy O
. O

here O
, O
compare O
two O
such O
stress O
- O
escape O
syndrome O
to O
investigate O
whether O
plant O
use O
conserve O
signal O
transduction O
pathway O
to O
escape O
from O
different O
stress O
. O

full O
submergence O
be O
a O
threat O
to O
terrestrial O
plant O
as O
cut O
off O
access O
to O
oxygen O
and O
co(2 O
) O
. O

proximate O
neighbor O
, O
in O
contrast O
, O
take O
away O
resource O
such O
as O
light O
. O

both O
submergence O
and O
shade O
can O
be O
escape O
through O
rapid O
shoot O
elongation O
. O

analyse O
the O
precise O
kinetic O
and O
physiological O
control O
of O
petiole O
elongation O
response O
to O
shade O
and O
submergence O
in O
the O
flood O
- O
tolerant O
specie O
rumex B-Plant
palustris I-Plant
. O

find O
that O
petiole O
elongation O
induce O
by O
submergence O
and O
that O
induce O
by O
shade O
occur O
with O
similar O
kinetic O
, O
both O
involve O
cell O
expansion O
. O

these O
response O
be O
induce O
by O
two O
different O
signal O
, O
elevated O
ethylene O
and O
a O
reduced O
red O
: O
far O
- O
red O
light O
ratio O
( O
r O
: O
fr O
) O
, O
respectively O
. O

a O
downstream O
target O
for O
ethylene O
be O
abscisic O
acid O
, O
but O
low O
r O
: O
fr O
appear O
to O
act O
independently O
of O
this O
hormone O
. O

gibberellin O
, O
however O
, O
appear O
to O
be O
essential O
to O
both O
ethylene- O
and O
low O
r O
: O
fr O
- O
induce O
petiole O
elongation O
. O

propose O
that O
gibberellin O
and O
expansin O
, O
a O
family O
of O
cell O
wall O
- O
loosen O
protein O
, O
represent O
element O
of O
a O
conserved O
growth O
machinery O
that O
be O
activate O
by O
stress O
- O
specific O
signaling O
event O
to O
regulate O
escape O
from O
stress O
. O

do O
quantitative O
vessel O
and O
pit O
character O
account O
for O
ion O
- O
mediate O
change O
in O
the O
hydraulic O
conductance O
of O
angiosperm O
xylem O
? O
the O
hydraulic O
conductance O
of O
angiosperm O
xylem O
have O
be O
suggest O
to O
vary O
with O
change O
in O
sap O
solute O
concentration O
because O
of O
intervessel O
pit O
property O
. O

the O
magnitude O
of O
the O
' O
ionic O
effect O
' O
be O
link O
with O
vessel O
and O
pit O
dimension O
in O
20 O
angiosperm O
specie O
cover O
13 O
family O
include O
six O
lauraceae B-Plant
specie O
. O

a O
positive O
correlation O
be O
find O
between O
ionic O
effect O
and O
vessel O
group O
parameter O
, O
especially O
the O
portion O
of O
vessel O
wall O
in O
contact O
with O
neighbouring O
vessel O
. O

specie O
with O
intervessel O
contact O
fraction O
( O
f(c O
) O
) O
value O
& O
lt O
""";""" O
0.1 O

show O
an O
ionic O
effect O
between O
2 O
% O
and O
17 O
% O
, O
while O
specie O
with O
f(c O
) O
value O
> O
0.1 O

exhibit O
a O
response O
between O
10 O
% O
and O
32 O
% O
. O

the O
ionic O
effect O
increase O
linearly O
with O
the O
mean O
fraction O
of O
the O
total O
vessel O
wall O
area O
occupy O
by O
intervessel O
pit O
as O
well O
as O
with O
the O
intervessel O
contact O
length O
. O

however O
, O
no O
significant O
correlation O
occur O
between O
the O
ionic O
effect O
and O
total O
intervessel O
pit O
membrane O
area O
per O
vessel O
, O
vessel O
diameter O
, O
vessel O
length O
, O
vessel O
wall O
area O
, O
and O
intervessel O
pit O
membrane O
thickness O
. O

quantitative O
vessel O
and O
pit O
character O
be O
suggest O
to O
contribute O
to O
interspecific O
variation O
of O
the O
ionic O
effect O
, O
whereas O
chemical O
property O
of O
intervessel O
pit O
membrane O
be O
likely O
to O
play O
an O
additional O
role O
. O

contrast O
impact O
of O
climate O
- O
drive O
flower O
phenology O
on O
change O
in O
alien O
and O
native O
plant O
specie O
distribution O
. O

plant O
phenology O
be O
particularly O
sensitive O
to O
climate O
and O
a O
key O
indicator O
of O
environmental O
change O
. O

globally O
, O
first O
flower O
date O
( O
ffd O
) O
have O
advance O
by O
several O
day O
per O
decade O
in O
response O
to O
recent O
climate O
warming O
, O
but O
, O
while O
early O
flowering O
should O
allow O
plant O
distribution O
to O
increase O
, O
a O
link O
between O
ffd O
and O
range O
change O
have O
not O
be O
observe O
. O

here O
show O
for O
347 O
specie O
that O
the O
extent O
to O
which O
ffd O
have O
respond O
to O
climate O
warming O
be O
link O
to O
the O
degree O
to O
which O
relative O
distribution O
have O
change O
over O
30 O
yr O
across O
the O
british O
isles O
. O

native O
plant O
specie O
whose O
phenology O
do O
not O
track O
climate O
change O
decline O
in O
distribution O
, O
whereas O
specie O
that O
become O
more O
widespread O
all O
exhibit O
early O
flowering O
. O

in O
contrast O
, O
alien O
neophyte O
show O
both O
a O
strong O
phenological O
response O
to O
warm O
and O
a O
more O
marked O
increase O
in O
distribution O
, O
but O
no O
link O
between O
the O
two O
. O

these O
trend O
be O
consistent O
both O
for O
relative O
change O
in O
the O
national O
distribution O
and O
for O
local O
abundance O
. O

at O
the O
national O
scale O
, O
the O
more O
recently O
an O
alien O
specie O
become O
establish O
in O
britain O
, O
the O
more O
likely O
be O
to O
increase O
in O
distribution O
irrespective O
of O
ffd O
, O
suggest O
that O
recent O
change O
in O
alien O
specie O
distribution O
be O
decouple O
from O
climate O
and O
drive O
by O
other O
factor O
. O

a O
new O
, O
vapour O
- O
phase O
mechanism O
for O
stomatal O
response O
to O
humidity O
and O
temperature O
. O

a O
new O
mechanism O
for O
stomatal O
response O
to O
humidity O
and O
temperature O
be O
propose O
. O

unlike O
previously O
- O
propose O
mechanism O
, O
which O
rely O
on O
liquid O
water O
transport O
to O
create O
water O
potential O
gradient O
within O
the O
leaf O
, O
the O
new O
mechanism O
assume O
that O
water O
transport O
to O
the O
guard O
cell O
be O
primarily O
through O
the O
vapour O
phase O
. O

under O
steady O
- O
state O
condition O
, O
guard O
cell O
be O
assume O
to O
be O
in O
near O
- O
equilibrium O
with O
the O
water O
vapour O
in O
the O
air O
near O
the O
bottom O
of O
the O
stomatal O
pore O
. O

as O
the O
water O
potential O
of O
this O
air O
vary O
with O
change O
air O
humidity O
and O
leaf O
temperature O
, O
the O
resultant O
change O
in O
guard O
cell O
water O
potential O
produce O
stomatal O
movement O
. O

a O
simple O
, O
closed O
- O
form O
, O
mathematical O
model O
base O
on O
this O
idea O
be O
derive O
. O

the O
new O
model O
be O
parameteriz O
for O
a O
previously O
publish O
set O
of O
datum O
and O
be O
show O
to O
fit O
the O
datum O
as O
well O
as O
or O
good O
than O
exist O
model O
. O

the O
model O
contain O
mathematical O
element O
that O
be O
consistent O
with O
previously O
- O
propose O
mechanistic O
model O
base O
on O
liquid O
flow O
as O
well O
as O
empirical O
model O
base O
on O
relative O
humidity O
. O

as O
such O
, O
provide O
a O
mechanistic O
explanation O
for O
the O
realm O
of O
validity O
for O
each O
of O
these O
approach O
. O

cadmium O
uptake O
and O
sequestration O
kinetic O
in O
individual O
leaf O
cell O
protoplast O
of O
the O
cd O
/ O
zn O
hyperaccumulator O
thlaspi B-Plant
caerulescen I-Plant
. O

hyperaccumulator O
store O
accumulate O
metal O
in O
the O
vacuole O
of O
large O
leaf O
epidermal O
cell O
( O
storage O
cell O
) O
. O

for O
investigate O
cadmium O
uptake O
, O
incubate O
protoplast O
obtain O
from O
leaf O
of O
thlaspi B-Plant
caerulescen I-Plant
( O
ganges O
ecotype O
) O
with O
a O
cd O
- O
specific O
fluorescent O
dye O
. O

a O
fluorescence O
kinetic O
microscope O
be O
use O
for O
selectively O
measure O
cd O
- O
uptake O
and O
photosynthesis O
in O
different O
cell O
type O
, O
so O
that O
physical O
separation O
of O
cell O
type O
be O
not O
necessary O
. O

few O
minute O
after O
addition O
, O
cadmium O
accumulate O
in O
the O
cytoplasm O
before O
transport O
into O
the O
vacuole O
. O

this O
demonstrate O
that O
vacuolar O
sequestration O
be O
the O
rate O
- O
limit O
step O
in O
cadmium O
uptake O
into O
protoplast O
of O
all O
leaf O
cell O
type O
. O

during O
accumulation O
in O
the O
cytoplasm O
, O
cd O
- O
rich O
vesicle O
- O
like O
structure O
be O
observe O
. O

cd O
uptake O
rate O
into O
epidermal O
storage O
cell O
be O
high O
than O
into O
standard O
- O
sized O
epidermal O
cell O
and O
mesophyll O
cell O
. O

this O
show O
that O
the O
preferential O
heavy O
metal O
accumulation O
in O
epidermal O
storage O
cell O
, O
previously O
observe O
for O
several O
metal O
in O
intact O
leaf O
of O
various O
hyperaccumulator O
specie O
, O
be O
due O
to O
difference O
in O
active O
metal O
transport O
and O
not O
difference O
in O
passive O
mechanism O
like O
transpiration O
stream O
transport O
or O
cell O
wall O
adhesion O
. O

dipsacus B-Plant
fullonum I-Plant
, O
syn O
dipsacus B-Plant
sylvestris I-Plant
, O
be O
a O
species O
of O
flower O
plant O
know O
by O
the O
common O
name O
wild B-Plant
teasel I-Plant
or O
full B-Plant
's I-Plant
teasel I-Plant
, O
although O
the O
latter O
name O
be O
usually O
apply O
to O
the O
cultivate O
species O
dipsacus B-Plant
sativus I-Plant
. O

-PRON- O
be O
native O
to O
eurasia O
and O
north O
africa O
, O
but O
-PRON- O
be O
know O
in O
the O
americas O
, O
southern O
africa O
, O
australia O
and O
new O
zealand O
as O
an O
introduce O
specie O
and O
often O
a O
noxious O
weed O
. O

-PRON- O
form O
large O
monoculture O
( O
displace O
other O
specie O
) O
in O
area O
-PRON- O
invade O
that O
have O
favorable O
climate O
and O
none O
of O
-PRON- O
biological O
control O
specie O
. O

the O
inflorescence O
be O
a O
cylindrical O
array O
of O
lavender B-Plant
flower O
which O
dry O
to O
a O
cone O
of O
spine O
- O
tip O
hard O
bract O
. O

-PRON- O
may O
be O
10 O
centimeter O
long O
. O

-PRON- O
be O
a O
herbaceous O
biennial O
plant O
( O
rarely O
short O
- O
live O
perennial O
plant O
) O
grow O
to O
1ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“2.5 O

metre O
( O
3.3ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“8.2 O

ft O
) O
tall O
. O

matelea O
be O
a O
genus O
of O
flower O
plant O
in O
the O
dogbane O
family O
, O
apocynaceae O
. O

-PRON- O
contain O
about O
200 O
specie O
, O
which O
be O
commonly O
know O
as O
milkvine O
. O

debia O
be O
a O
genus O
of O
flower O
plant O
in O
the O
rubiaceae O
family O
. O

the O
genus O
be O
find O
from O
the O
indian O
subcontinent O
to O
south O
- O
central O
china O
and O
the O
philippines O
. O

bulbophyllum B-Plant
absconditum I-Plant
, O
know O
as O
the O
' O
hidden O
bulbophyllum O
, O
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

-PRON- O
be O
name O
the O
hidden O
bulbophyllum O
because O
of O
-PRON- O
miniature O
flower O
which O
elude O
be O
find O
due O
to O
camouflage O
. O

-PRON- O
be O
find O
in O
rainforest O
in O
indonesia O
and O
certain O
part O
of O
oceania O
such O
as O
vanuatu O
and O
new O
caledonia O
. O

-PRON- O
be O
a O
warm O
- O
grow O
epiphyte O
find O
in O
elevation O
of O
900 O
to O
1700 O
meter O
. O

betula B-Plant
michauxii I-Plant
, O
newfoundland B-Plant
dwarf I-Plant
birch I-Plant
, O
be O
a O
species O
of O
birch B-Plant
which O
be O
native O
to O
newfoundland O
from O
which O
-PRON- O
get O
introduce O
to O
nova O
scotia O
and O
quebec O
. O

the O
species O
be O
0.5 O

metre O
( O
1 O
ft O
8 O
in O
) O
tall O
and O
have O
a O
wintergreen O
smell O
. O

the O
leaf O
be O
obovate O
and O
have O
glabrous O
surface O
. O

infructescence O
be O
cylindric O
, O
erect O
, O
short O
, O
and O
0.5ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“0.8 O

centimetre O
( O
0.20ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“0.31 O

in O
) O
long O
. O

the O
fruit O
ripe O
by O
fall O
and O
be O
as O
glabrous O
as O
the O
leaf O
. O

this O
list O
contain O
person O
name O
in O
the O
bible O
of O
minor O
notability O
, O
about O
whom O
either O
nothing O
or O
very O
little O
be O
know O
, O
aside O
from O
any O
family O
connection O
. O

plinia B-Plant
cauliflora I-Plant
, O
the O
brazilian B-Plant
grapetree I-Plant
, O
jaboticaba B-Plant
or O
jabuticaba O
, O
be O
a O
tree O
in O
the O
family O
myrtaceae O
, O
native O
to O
minas O
gerais O
, O
goiÃƒÆ’Ã‚Â¡s O
and O
sÃƒÆ’Ã‚Â£o O
paulo O
state O
in O
brazil O
. O

related O
specie O
in O
the O
genus O
myrciaria O
, O
often O
refer O
to O
by O
the O
same O
common O
name O
, O
be O
native O
to O
brazil O
, O
argentina O
, O
paraguay O
, O
peru O
and O
bolivia O
. O

the O
tree O
be O
grow O
for O
-PRON- O
purplish O
- O
black O
, O
white O
- O
pulp O
fruit O
-PRON- O
can O
be O
eat O
raw O
or O
be O
use O
to O
make O
jelly O
, O
juice O
or O
wine O
. O

vrydagzynea O
be O
a O
genus O
of O
flower O
plant O
from O
the O
orchid O
family O
, O
orchidaceae O
. O

-PRON- O
be O
native O
to O
southeast O
asia O
, O
southern O
china O
, O
and O
new O
guinea O
with O
a O
few O
specie O
in O
queensland O
and O
on O
some O
island O
of O
the O
pacific O
. O

specie O
accept O
as O
of O
june O
2014 O
: O
guettarda O
be O
a O
plant O
genus O
in O
the O
family O
rubiaceae O
. O

most O
of O
these O
plant O
be O
know O
by O
the O
common O
name O
velvetseed O
. O

estimate O
of O
the O
number O
of O
specie O
range O
from O
about O
50 O
to O
162 O
. O

most O
of O
the O
specie O
be O
neotropical O
. O

twenty O
be O
find O
in O
new O
caledonia O
and O
one O
reach O
australia O
. O

a O
few O
other O
be O
find O
on O
island O
and O
in O
coastal O
area O
of O
the O
indian O
and O
pacific O
oceans O
. O

three O
specie O
( O
g. B-Plant
odorata I-Plant
, O
g. B-Plant
scabra I-Plant
, O
g. B-Plant
speciosa I-Plant
) O
be O
know O
in O
cultivation O
. O

guettarda B-Plant
argentea I-Plant
provide O
edible O
fruit O
. O

the O
type O
specie O
for O
the O
genus O
be O
guettarda B-Plant
speciosa I-Plant
. O

-PRON- O
be O
a O
tree O
of O
coastal O
habitat O
, O
up O
to O
18 O
m O
( O
59 O
ft O
) O
in O
height O
. O

-PRON- O
be O
grow O
as O
an O
ornamental O
. O

guettarda O
be O
name O
by O
linnaeus O
in O
1753 O
in O
-PRON- O
book O
species O
plantarum O
. O

this O
generic O
name O
be O
in O
honour O
of O
the O
18th O
century O
french O
naturalist O
jean O
- O
ÃƒÆ’Ã‚Â©tienne O
guettard O
. O

the O
genus O
guettarda O
be O
much O
in O
need O
of O
revision O
. O

molecular O
phylogenetic O
study O
have O
find O
-PRON- O
to O
be O
several O
time O
polyphyletic O
with O
some O
of O
-PRON- O
clade O
paraphyletic O
over O
small O
genera O
. O

firs O
( O
abies O
) O
be O
a O
genus O
of O
48ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“56 O
specie O
of O
evergreen O
coniferous O
tree O
in O
the O
family O
pinaceae O
. O

-PRON- O
be O
find O
through O
much O
of O
north O
and O
central O
america O
, O
europe O
, O
asia O
, O
and O
north O
africa O
, O
occur O
in O
mountain O
over O
most O
of O
the O
range O
. O

fir O
be O
most O
closely O
related O
to O
the O
genus O
cedrus O
( O
cedar B-Plant
) O
. O

douglas B-Plant
fir I-Plant
be O
not O
TRUE O
fir O
, O
be O
of O
the O
genus O
pseudotsuga O
. O

-PRON- O
be O
large O
tree O
, O
reach O
height O
of O
10ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“80 O
m O
( O
33ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“262 O
ft O
) O
tall O
with O
trunk O
diameter O
of O
0.5ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“4 O

m O
( O
1 O
ft O
8 O
inÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“13 O
ft O
1 O
in O
) O
when O
mature O
. O

fir O
can O
be O
distinguish O
from O
other O
member O
of O
the O
pine O
family O
by O
the O
way O
in O
which O
-PRON- O
needle O
- O
like O
leaf O
be O
attach O
singly O
to O
the O
branch O
with O
a O
base O
resemble O
a O
suction O
cup O
, O
and O
by O
-PRON- O
cone O
, O
which O
, O
like O
those O
of O
TRUE B-Plant
cedar I-Plant
( O
cedrus O
) O
, O
stand O
upright O
on O
the O
branch O
like O
candle O
and O
disintegrate O
at O
maturity O
. O

identification O
of O
the O
different O
specie O
be O
base O
on O
the O
size O
and O
arrangement O
of O
the O
leaf O
, O
the O
size O
and O
shape O
of O
the O
cone O
, O
and O
whether O
the O
bract O
scale O
of O
the O
cone O
be O
long O
and O
exsert O
, O
or O
short O
and O
hide O
inside O
the O
cone O
. O

cryptarrhena O
be O
a O
genus O
of O
orchid B-Plant
( O
family O
orchidaceae O
) O
. O

-PRON- O
consist O
of O
3 O
know O
specie O
, O
native O
to O
the O
new O
world O
tropics O
. O

bonnemaisoniaceae O
be O
a O
family O
of O
red O
algae B-Plant
in O
the O
order O
bonnemaisoniales O
. O

kelloggia O
be O
a O
plant O
genus O
in O
the O
bedstraw B-Plant
and O
madder O
family O
rubiaceae O
. O

hibiscadelphus O
be O
a O
genus O
of O
malvaceae O
from O
the O
subfamily O
malvoideae O
endemic O
to O
hawaiÃƒÅ Ã‚Â»i O
. O

-PRON- O
be O
know O
by O
the O
native O
hawaiians O
as O
hau B-Plant
kuahiwi I-Plant
which O
mean O
mountain O
hibiscus O
. O

the O
latin O
name O
mean O
brother O
of O
hibiscus O
. O

-PRON- O
be O
distinctive O
for O
-PRON- O
peculiar O
flower O
, O
which O
do O
not O
fully O
open O
. O

mirabilis B-Plant
longiflora I-Plant
, O
sweet B-Plant
four I-Plant
o'clock I-Plant
, O
be O
a O
species O
of O
flower O
plant O
native O
to O
the O
southwestern O
united O
states O
from O
arizona O
to O
texas O
and O
northern O
mexico O
. O

-PRON- O
be O
night O
- O
flowering O
, O
the O
flower O
be O
mostly O
white O
, O
strongly O
scented O
, O
and O
long O
and O
narrow O
in O
form O
, O
approach O
17 O
centimeter O
in O
maximum O
length O
. O

glycosmis O
be O
a O
genus O
of O
flower O
plant O
in O
the O
citrus O
family O
, O
rutaceae O
. O

-PRON- O
be O
in O
the O
subfamily O
aurantioideae O
, O
which O
also O
include O
genus O
citrus O
. O

-PRON- O
be O
a O
genus O
of O
the O
subtribe O
clauseninae O
, O
which O
be O
know O
technically O
as O
the O
remote O
citroid O
fruit O
tree O
. O

the O
distribution O
of O
the O
genus O
include O
southeast O
asia O
and O
australia O
. O

gomesa O
be O
a O
genus O
of O
flower O
plant O
from O
the O
orchid O
family O
, O
orchidaceae O
. O

-PRON- O
contain O
about O
80 O
- O
100 O
specie O
, O
all O
native O
to O
south O
america O
. O

specie O
include O
gomesa B-Plant
radican I-Plant
. O

epidendrum O
, O
abbreviate O
epi O
in O
the O
horticultural O
trade O
, O
be O
a O
large O
neotropical O
genus O
of O
the O
orchid O
family O
. O

with O
more O
than O
1,500 O
specie O
, O
some O
author O
describe O
-PRON- O
as O
a O
mega O
- O
genus O
. O

the O
genus O
name O
( O
from O
greek O
Ãƒâ€°Ã¢â‚¬ÂºpÃƒâ€°Ã‚Â¨ O
, O
epi O
and O
ÃƒÅ½Ã‚Â´ÃƒÅ½Ã‚Â­ÃƒÅ½Ã‚Â½ÃƒÅ½Ã‚Â´ÃƒÂÃ‚ÂÃƒÅ½Ã‚Â¿ÃƒÅ½Ã‚Â½ O
, O
dendron O
, O
upon O
tree O
) O
refer O
to O
-PRON- O
epiphytic O
growth O
habit O
. O

when O
carl O
linnaeus O
name O
this O
genus O
in O
1763 O
, O
-PRON- O
include O
in O
this O
genus O
all O
the O
epiphytic O
orchid B-Plant
know O
to O
-PRON- O
. O

although O
few O
of O
these O
orchid B-Plant
be O
still O
include O
in O
the O
genus O
epidendrum O
, O
some O
specie O
of O
epidendrum O
be O
nevertheless O
not O
epiphytic O
. O

lemon B-Plant
balm O
( O
melissa B-Plant
officinali I-Plant
) O
, O
balm O
, O
common B-Plant
balm I-Plant
, O
or O
balm O
mint B-Plant
, O
be O
a O
perennial O
herbaceous O
plant O
in O
the O
mint O
family O
lamiaceae O
and O
native O
to O
south O
- O
central O
europe O
, O
the O
mediterranean O
basin O
, O
iran O
, O
and O
central O
asia O
, O
but O
now O
naturalize O
in O
the O
americas O
and O
elsewhere O
. O

-PRON- O
grow O
to O
a O
maximum O
height O
of O
70ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“150 O
cm O
( O
28ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“59 O
in O
) O
. O

the O
leaf O
have O
a O
mild O
lemon B-Plant
scent O
similar O
to O
mint B-Plant
. O

during O
summer O
, O
small O
white O
flower O
full O
of O
nectar O
appear O
. O

-PRON- O
be O
not O
to O
be O
confuse O
with O
bee O
balm O
( O
genu O
monarda O
) O
, O
although O
the O
white O
flower O
attract O
bee O
, O
hence O
the O
genus O
melissa O
( O
greek O
for O
honey O
bee O
) O
. O

the O
leaf O
be O
use O
as O
a O
herb O
, O
in O
tea O
, O
and O
also O
as O
a O
flavouring O
. O

the O
plant O
be O
use O
to O
attract O
bee O
for O
honey O
production O
. O

-PRON- O
be O
grow O
as O
an O
ornamental O
plant O
and O
for O
-PRON- O
oil O
( O
to O
use O
in O
perfumery O
) O
. O

the O
tea B-Plant
of O
lemon B-Plant
balm O
, O
the O
essential O
oil O
, O
and O
the O
extract O
be O
use O
in O
traditional O
and O
alternative O
medicine O
, O
include O
aromatherapy O
. O

the O
plant O
have O
be O
cultivate O
at O
least O
since O
the O
16th O
century O
, O
but O
research O
be O
still O
be O
conduct O
to O
establish O
the O
safety O
and O
effect O
of O
lemon B-Plant
balm O
. O

crobylanthe O
be O
a O
monotypic O
genus O
of O
flower O
plant O
in O
the O
rubiaceae O
family O
. O

the O
genus O
contain O
only O
one O
specie O
, O
viz O
. O

crobylanthe B-Plant
pellacalyx I-Plant
, O
which O
be O
endemic O
to O
sarawak O
. O

this O
be O
a O
partial O
list O
of O
meaning O
of O
minor O
planet O
name O
. O

see O
meaning O
of O
minor O
planet O
name O
for O
a O
list O
of O
all O
such O
partial O
list O
. O

as O
minor O
planet O
discovery O
be O
confirm O
, O
-PRON- O
be O
give O
a O
permanent O
number O
by O
the O
iau O
's O
minor O
planet O
center O
, O
and O
the O
discoverer O
can O
then O
submit O
name O
for O
-PRON- O
, O
follow O
the O
iau O
's O
naming O
convention O
. O

the O
list O
below O
concern O
those O
minor O
planet O
in O
the O
specified O
number O
- O
range O
that O
have O
receive O
name O
, O
and O
explain O
the O
meaning O
of O
those O
name O
. O

asphodelus B-Plant
aestivus I-Plant
, O
the O
summer O
asphodel B-Plant
, O
be O
a O
species O
of O
asphodel B-Plant
, O
a O
common O
western O
mediterranean O
geophyte O
with O
a O
short O
vertical O
rhizome O
and O
basal O
leaf O
. O

-PRON- O
flower O
be O
actinomorphic O
, O
pinkish O
- O
white O
, O
with O
six O
perianth O
segment O
, O
14ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“19 O
mm O
long O
and O
six O
stamen O
of O
the O
same O
length O
, O
in O
two O
whorl O
. O

-PRON- O
distribution O
be O
limit O
to O
the O
western O
mediterranean O
, O
mainly O
find O
in O
portugal O
and O
spain O
on O
the O
european O
mainland O
. O

there O
have O
be O
a O
lot O
of O
confusion O
over O
the O
nomenclature O
and O
taxonomy O
of O
the O
specie O
, O
especially O
in O
confusion O
with O
asphodelus B-Plant
ramosus I-Plant
. O

-PRON- O
grow O
in O
dry O
grassland O
, O
phrygana O
and O
on O
rocky O
or O
sandy O
ground O
. O

satyrium O
be O
a O
genus O
of O
orchid B-Plant
. O

the O
kew O
plant O
list O
for O
2010 O
list O
85 O
full O
specie O
as O
accept O
, O
ignore O
synonym O
, O
subspecie O
and O
hybrid O
etc O
. O

about O
ten O
be O
still O
unresolved O
at O
the O
time O
. O

most O
of O
the O
specie O
occur O
in O
sub O
- O
saharan O
africa O
and O
madagascar O
. O

the O
range O
of O
four O
specie O
extend O
to O
asia O
, O
mainly O
in O
india O
and O
sri O
lanka O
. O

hybridization O
occur O
between O
several O
specie O
, O
complicate O
molecular O
phylogenetic O
study O
, O
especially O
those O
rely O
on O
mitochondrial O
and O
chloroplast O
dna O
sequence O
. O

the O
genus O
most O
closely O
related O
to O
satyrium O
be O
presume O
to O
be O
pachites O
, O
which O
together O
with O
satyrium O
make O
up O
the O
subtribe O
satyriinae O
of O
the O
diseae O
. O

historically O
other O
specie O
with O
helmet O
- O
shape O
flower O
e.g. O

acera O
, O
chamorchis O
and O
platanthera O
, O
often O
be O
include O
in O
the O
genus O
satyrium O
, O
but O
far O
from O
belong O
in O
the O
same O
genus O
, O
-PRON- O
no O
longer O
be O
include O
even O
within O
the O
satyriinae O
, O
but O
within O
the O
tribe O
orchideae O
. O

elymus O
be O
a O
genus O
of O
perennial O
plant O
with O
approximately O
150 O
specie O
in O
the O
grass O
family O
, O
relate O
to O
rye B-Plant
, O
wheat B-Plant
, O
and O
other O
widely O
grow O
cereal O
grain O
. O

elymus O
be O
a O
cosmopolitan O
genus O
, O
represent O
by O
specie O
across O
all O
continent O
of O
the O
world O
. O

common O
name O
include O
couch B-Plant
grass I-Plant
, O
wildrye B-Plant
and O
wheatgrass B-Plant
. O

many O
specie O
once O
consider O
member O
of O
elymus O
be O
now O
regard O
as O
better O
suit O
to O
other O
genera O
: O
agropyron O
, O
anthosachne O
, O
brachypodium O
, O
cenchrus O
, O
crithopsis O
, O
heteranthelium O
, O
jouvea O
, O
kengyilia O
, O
leymus O
, O
psathyrostachys O
, O
stenostachys O
, O
taeniatherum O
, O
thinopyrum O
etc O
. O

the O
following O
specie O
be O
recognise O
by O
the O
plant O
list O
: O
scleroderma O
citrinum O
, O
commonly O
know O
as O
the O
common O
earthball O
, O
pigskin O
poison O
puffball O
, O
or O
common O
earth O
ball O
, O
be O
the O
most O
common O
specie O
of O
earthball O
in O
the O
uk O
and O
occur O
widely O
in O
wood O
, O
heathland O
and O
in O
short O
grass O
from O
autumn O
to O
winter O
. O

scleroderma O
citrinum O
have O
two O
synonym O
, O
scleroderma O
aurantium O
( O
vaill O
. O

) O
and O
scleroderma O
vulgare O
horn O
. O

earthball O
be O
superficially O
similar O
to O
, O
and O
consider O
look O
- O
alike O
of O
, O
the O
edible O
puffball O
, O
but O
whereas O
the O
puffball O
have O
a O
single O
opening O
on O
top O
through O
which O
the O
spore O
be O
disperse O
, O
the O
earthball O
just O
break O
up O
to O
release O
the O
spore O
. O

moreover O
, O
scleroderma O
citrinum O
have O
much O
firm O
flesh O
and O
a O
dark O
gleba O
( O
interior O
) O
much O
earlier O
in O
development O
than O
puffball B-Plant
. O

scleroderma O
citrinum O
have O
no O
stem O
but O
be O
attach O
to O
the O
soil O
by O
mycelial O
cord O
. O

the O
peridium O
, O
or O
outer O
wall O
, O
be O
thick O
and O
firm O
, O
usually O
ochre O
yellow O
externally O
with O
irregular O
wart O
. O

the O
earthball O
may O
be O
parasitiz O
by O
pseudoboletus O
parasiticus O
. O

pinellia B-Plant
ternata I-Plant
( O
chinese O
: O
ÃƒÂ¥Ã‚ÂÃ…Â ÃƒÂ¥Ã‚Â¤Ã‚Â O
, O
japanese O
: O
ÃƒÂ£Ã¢â‚¬Å¡Ã‚Â«ÃƒÂ£Ã†â€™Ã‚Â©ÃƒÂ£Ã¢â‚¬Å¡Ã‚Â¹ÃƒÂ£Ã†â€™Ã¢â‚¬Å“ÃƒÂ£Ã¢â‚¬Å¡Ã‚Â·ÃƒÂ£Ã†â€™Ã‚Â£ÃƒÂ£Ã¢â‚¬Å¡Ã‚Â¯ O
) O
, O
crow B-Plant
- I-Plant
dipper I-Plant
, O
be O
a O
plant O
native O
to O
china O
, O
japan O
, O
and O
korea O
, O
but O
also O
grow O
as O
an O
invasive O
weed O
in O
part O
of O
europe O
( O
austria O
, O
germany O
) O
and O
north O
america O
( O
california O
, O
ontario O
, O
northeastern O
united O
states O
) O
. O

the O
leaf O
be O
trifoliate O
, O
while O
the O
flower O
be O
of O
the O
spathe O
and O
spadix O
form O
typical O
of O
plant O
in O
araceae O
. O

abutilon O
be O
a O
large O
genus O
of O
flower O
plant O
in O
the O
mallow O
family O
, O
malvaceae O
. O

-PRON- O
be O
distribute O
throughout O
the O
tropic O
and O
subtropic O
of O
the O
americas O
, O
africa O
, O
asia O
, O
and O
australia O
. O

general O
common O
name O
include O
indian B-Plant
mallow I-Plant
and O
velvetleaf B-Plant
in O
russian O
, O
ornamental O
variety O
be O
commonly O
know O
as O
the O
room B-Plant
maple I-Plant
. O

the O
genus O
name O
be O
an O
18th O
- O
century O
new O
latin O
word O
that O
come O
from O
the O
arabic O
ÃƒÂ¢Ã¢â€šÂ¬Ã¢â€žÂ¢abÃƒâ€¦Ã‚Â« O
- O
ÃƒÂ¡Ã‚Â¹Ã‚Â­Ãƒâ€žÃ‚Â«lÃƒâ€¦Ã‚Â«n O
( O
ÃƒËœÃ‚Â£ÃƒËœÃ‚Â¨Ãƒâ„¢Ã‹â€  O
ÃƒËœÃ‚Â·Ãƒâ„¢Ã…Â Ãƒâ„¢Ã¢â‚¬Å¾Ãƒâ„¢Ã‹â€ Ãƒâ„¢Ã¢â‚¬Â  O
) O
, O
the O
name O
give O
by O
avicenna O
to O
this O
or O
a O
similar O
genus O
. O

caulokaempferia O
be O
a O
group O
of O
plant O
in O
the O
ginger O
family O
describe O
as O
a O
genus O
in O
1964 O
. O

the O
genus O
be O
native O
to O
china O
, O
the O
himalayas O
, O
and O
indochina O
( O
especially O
thailand O
) O
. O

morinda O
be O
a O
genus O
of O
flower O
plant O
in O
the O
madder O
family O
, O
rubiaceae O
. O

the O
generic O
name O
be O
derive O
from O
the O
latin O
word O
moru O
mulberry B-Plant
, O
from O
the O
appearance O
of O
the O
fruit O
, O
and O
indica O
, O
mean O
of O
india O
. O

kalmia O
be O
a O
genus O
of O
about O
ten O
specie O
of O
evergreen O
shrub O
from O
0.2ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“5 O

m O
tall O
, O
in O
the O
family O
ericaceae O
. O

-PRON- O
be O
native O
to O
north O
america O
( O
mainly O
in O
the O
eastern O
half O
of O
the O
continent O
) O
and O
cuba O
. O

-PRON- O
grow O
in O
acidic O
soil O
, O
with O
different O
specie O
in O
wet O
acid O
bog O
habitat O
( O
k. B-Plant
angustifolia I-Plant
, O
k. B-Plant
polifolia I-Plant
) O
and O
dry O
, O
sandy O
soil O
( O
k. B-Plant
ericoide I-Plant
, O
k. B-Plant
latifolia I-Plant
) O
. O

kalmia O
be O
name O
by O
linnaeus O
to O
honour O
-PRON- O
friend O
the O
botanist O
pehr O
kalm O
, O
who O
collect O
-PRON- O
in O
eastern O
north O
america O
during O
the O
mid-18th O
century O
. O

early O
mark O
catesby O
see O
-PRON- O
during O
-PRON- O
travel O
in O
carolina O
, O
and O
after O
-PRON- O
return O
to O
england O
in O
1726 O
, O
import O
seed O
. O

-PRON- O
describe O
-PRON- O
, O
a O
costly O
rarity O
, O
in O
-PRON- O
natural O
history O
of O
carolina O
, O
as O
chamaedaphne O
foliis O
tini O
, O
that O
be O
to O
say O
with O
leaf O
like O
the O
laurustinus B-Plant
the O
botanist O
and O
plant O
- O
collector O
peter O
collinson O
, O
who O
have O
beg O
some O
of O
the O
shrub O
from O
-PRON- O
correspondent O
john O
custis O
in O
virginia O
, O
write O
, O
when O
-PRON- O
plant O
flower O
, O
that O
-PRON- O
really O
think O
-PRON- O
exceed O
the O
laurus O
tinus O
. O

the O
leaf O
be O
2ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“12 O
cm O
long O
and O
simple O
lanceolate O
. O

the O
flower O
be O
white O
, O
pink O
or O
purple O
, O
in O
corymb O
of O
10 O
- O
50 O
, O
reminiscent O
of O
rhododendron O
flower O
but O
flat O
, O
with O
a O
star O
- O
like O
calyx O
of O
five O
conjoined O
petal O
each O
flower O
be O
1ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“3 O
cm O
diameter O
. O

the O
fruit O
be O
a O
five O
- O
lob O
capsule O
, O
which O
split O
to O
release O
the O
numerous O
small O
seed O
. O

the O
foliage O
be O
toxic O
if O
eat O
, O
with O
sheep O
be O
particularly O
prone O
to O
poisoning O
, O
hence O
the O
name O
lambkill B-Plant
use O
for O
some O
of O
the O
specie O
. O

other O
name O
for O
kalmia O
, O
particularly O
kalmia B-Plant
angustifolia I-Plant
, O
be O
sheep B-Plant
- I-Plant
laurel I-Plant
, O
lamb B-Plant
- I-Plant
kill I-Plant
, O
calf B-Plant
- I-Plant
kill I-Plant
, O
kill B-Plant
- I-Plant
kid I-Plant
, O
and O
sheep B-Plant
- I-Plant
poison I-Plant
, O
which O
may O
be O
write O
with O
or O
without O
the O
hyphen O
. O

( O
see O
specie O
list O
below O
. O

) O
kid O
here O
refer O
to O
a O
young O
goat O
, O
not O
a O
human O
child O
, O
but O
the O
foliage O
and O
twig O
be O
toxic O
to O
human O
as O
well O
. O

-PRON- O
have O
also O
be O
call O
spoonwood B-Plant
because O
kalm O
be O
tell O
by O
dutch O
settler O
of O
north O
america O
that O
native O
americans O
make O
spoon O
from O
the O
wood O
. O

give O
-PRON- O
toxicity O
, O
this O
may O
be O
folklore O
rather O
than O
scientific O
fact O
. O

kalmias O
be O
popular O
garden O
shrub O
, O
grow O
for O
-PRON- O
decorative O
flower O
. O

-PRON- O
should O
not O
be O
plant O
where O
-PRON- O
be O
accessible O
to O
livestock O
due O
to O
the O
toxicity O
. O

kalmia O
specie O
be O
use O
as O
food O
plant O
by O
the O
larvae O
of O
some O
lepidopteran O
specie O
include O
coleophora O
kalmiella O
which O
feed O
exclusively O
on O
kalmia O
. O

impatien B-Plant
noli I-Plant
- I-Plant
tangere I-Plant
( O
touch B-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
balsam I-Plant
latin O
impatiÃƒâ€žÃ¢â‚¬Å“ns O
impatient O
or O
not O
allow O
, O
and O
nÃƒâ€¦Ã‚ÂlÃƒâ€žÃ‚Â« O
tangere O
do O
not O
touch O
: O
literally O
be O
unwilling O
to O
touch O
) O
be O
an O
annual O
herbaceous O
plant O
in O
the O
family O
balsaminaceae O
find O
in O
damp O
place O
in O
europe O
, O
asia O
and O
north O
america O
. O

the O
yellow O
flower O
be O
follow O
by O
pod O
which O
forcefully O
explode O
when O
ripe O
, O
eject O
the O
seed O
for O
some O
distance O
. O

also O
call O
touch B-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
, O
yellow B-Plant
balsam I-Plant
, O
jewelwe B-Plant
, O
western B-Plant
touch I-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
or O
wild B-Plant
balsam I-Plant
. O

guthriea B-Plant
capensis I-Plant
be O
an O
acaulescent O
perennial O
herb O
endemic O
to O
south O
africa O
and O
occur O
in O
cool O
and O
damp O
site O
face O
south O
or O
east O
in O
the O
mountain O
of O
the O
cape O
province O
, O
lesotho O
and O
kwazulu O
- O
natal O
. O

guthriea O
be O
monotypic O
and O
be O
name O
after O
the O
botanist O
and O
mathematician O
francis O
guthrie O
by O
-PRON- O
friend O
the O
botanist O
harry O
bolus O
. O

this O
ground O
- O
hugging O
specie O
with O
a O
rhizome O
and O
fleshy O
root O
form O
a O
compact O
rosette O
of O
some O
20 O
- O
30 O
broadly O
elliptic O
or O
cordate O
discolorous O
leaf O
with O
crenate O
margin O
, O
measure O
about O
50 O
x O
75 O
mm O
, O
glossy O
above O
with O
deeply O
indented O
venation O
hide O
creamy O
- O
green O
flower O
which O
be O
solitary O
and O
stalk O
. O

guthriea O
belong O
to O
the O
family O
achariaceae O
, O
a O
family O
which O
now O
include O
various O
specie O
previously O
place O
in O
the O
flacourtiaceae O
, O
such O
as O
kiggelaria B-Plant
africana I-Plant
, O
rawsonia B-Plant
lucida I-Plant
and O
xylotheca B-Plant
kraussiana I-Plant
. O

bulbine O
be O
a O
genus O
of O
plant O
in O
the O
family O
asphodelaceae O
and O
subfamily O
asphodeloideae O
, O
name O
for O
the O
bulb O
- O
shape O
tuber O
of O
many O
specie O
. O

-PRON- O
be O
formerly O
place O
in O
the O
liliaceae O
. O

-PRON- O
be O
find O
chiefly O
in O
southern O
africa O
, O
with O
a O
few O
specie O
extend O
into O
tropical O
africa O
and O
a O
few O
other O
in O
australia O
and O
yemen O
. O

bulbine O
be O
a O
genus O
of O
succulent O
plant O
with O
flower O
bear O
in O
lax O
or O
compound O
raceme O
. O

the O
flower O
be O
usually O
yellow O
, O
with O
bearded O
stamen O
some O
specie O
have O
white O
, O
orange O
, O
or O
pink O
flower O
. O

several O
specie O
be O
grow O
in O
garden O
, O
especially O
b. B-Plant
frutescen I-Plant
. O

specie O
of O
bulbine O
resemble O
haworthia O
and O
aloe O
in O
appearance O
, O
but O
with O
soft O
, O
fleshy O
leaf O
and O
tuberous O
root O
or O
a O
caudex O
. O

-PRON- O
be O
shrub O
, O
weedy O
perennial O
, O
dwarf O
geophyte O
, O
and O
soft O
annual O
. O

many O
of O
the O
dwarf O
specie O
have O
small O
, O
dome O
- O
shape O
tuber O
. O

dormancy O
usually O
extend O
from O
late O
spring O
to O
autumn O
, O
but O
-PRON- O
vary O
among O
specie O
and O
in O
different O
condition O
. O

the O
leaf O
die O
and O
drop O
, O
the O
root O
contract O
into O
the O
caudex O
, O
and O
the O
aboveground O
part O
wither O
. O

propagation O
be O
mostly O
by O
seed O
, O
but O
some O
specie O
form O
multiple O
head O
or O
offset O
and O
can O
be O
propagate O
with O
cutting O
. O

origanum O
( O
) O
be O
a O
genus O
of O
herbaceous O
perennial O
and O
subshrub O
in O
the O
family O
lamiaceae O
, O
native O
to O
europe O
, O
north O
africa O
, O
and O
much O
of O
temperate O
asia O
, O
where O
-PRON- O
be O
find O
in O
open O
or O
mountainous O
habitat O
. O

a O
few O
specie O
also O
naturalize O
in O
scatter O
location O
in O
north O
america O
and O
other O
region O
. O

the O
plant O
have O
strongly O
aromatic O
leaf O
and O
abundant O
tubular O
flower O
with O
long O
- O
last O
coloured O
bract O
. O

the O
genus O
include O
the O
important O
group O
of O
culinary O
herb O
: O
marjoram B-Plant
( O
origanum B-Plant
majorana I-Plant
) O
and O
oregano B-Plant
( O
origanum O
vulgare).origanum O

specie O
be O
use O
as O
food O
plant O
by O
the O
larvae O
of O
some O
lepidoptera O
specie O
, O
include O
coleophora O
albitarsella O
. O

adenium O
be O
a O
genus O
of O
flower O
plant O
in O
the O
apocynum O
family O
, O
apocynaceae O
, O
first O
describe O
as O
a O
genus O
in O
1819 O
. O

-PRON- O
be O
native O
to O
africa O
and O
the O
arabian O
peninsula O
. O

filago O
be O
a O
genus O
of O
plant O
in O
the O
sunflower O
family O
, O
native O
to O
europe O
, O
asia O
, O
and O
north O
africa O
. O

-PRON- O
be O
sometimes O
call O
cottonros O
or O
cudweed B-Plant
. O

the O
name O
cudweed B-Plant
come O
from O
the O
fact O
that O
-PRON- O
be O
once O
use O
to O
feed O
cow O
that O
have O
lose O
the O
ability O
to O
chew O
the O
cud O
. O

several O
specie O
be O
sometimes O
treat O
as O
member O
of O
genus O
logfia O
. O

jensenia O
be O
a O
bryophyte O
plant O
genus O
in O
the O
liverwort B-Plant
family O
pallaviciniaceae O
. O

-PRON- O
have O
be O
treat O
as O
a O
subgenus O
of O
pallavicinia O
by O
several O
author O
, O
though O
a O
set O
of O
feature O
seem O
to O
set O
-PRON- O
apart O
as O
a O
genus O
. O

the O
six O
or O
seven O
specie O
of O
the O
genus O
belong O
to O
a O
southern O
, O
possibly O
gondwana O
element O
. O

catopsis O
be O
a O
genus O
in O
the O
botanical O
family O
bromeliaceae O
, O
subfamily O
tillandsioideae O
. O

the O
genus O
name O
be O
from O
the O
greek O
( O
hang O
down O
) O
and O
opsis O
( O
appearance O
) O
. O

catopsis O
be O
a O
genus O
of O
plant O
widespread O
across O
much O
of O
latin O
america O
from O
mexico O
to O
brazil O
, O
plus O
florida O
and O
the O
west O
indies O
. O

one O
of O
the O
specie O
, O
catopsis B-Plant
berteroniana I-Plant
, O
be O
think O
to O
be O
carnivorous O
. O

phlox B-Plant
hoodii I-Plant
, O
the O
spiny B-Plant
phlox I-Plant
or O
carpet B-Plant
phlox I-Plant
, O
be O
a O
species O
of O
phlox B-Plant
. O

-PRON- O
be O
a O
plant O
of O
western O
north O
america O
, O
where O
-PRON- O
be O
a O
common O
flower O
in O
sagebrush B-Plant
country O
. O

-PRON- O
be O
among O
the O
first O
plant O
to O
bloom O
in O
spring O
, O
after O
the O
snow O
have O
melt O
. O

-PRON- O
distribution O
extend O
from O
alaska O
to O
arizona O
. O

there O
be O
many O
subspecie O
. O

this O
perennial O
herb O
be O
variable O
in O
morphology O
, O
but O
usually O
form O
a O
tight O
mat O
or O
loose O
clump O
on O
the O
ground O
. O

the O
short O
stem O
emerge O
from O
a O
woody O
taproot O
and O
caudex O
unit O
and O
the O
plant O
form O
be O
no O
more O
than O
13 O
centimetre O
( O
5 O
in O
) O
tall O
. O

the O
abundant O
tiny O
, O
sharp O
- O
pointed O
leaf O
be O
oppositely O
arrange O
and O
barely O
exceed O
one O
centimetre O
( O
1ÃƒÂ¢Ã‚ÂÃ¢â‚¬Å¾3 O
in O
) O
long O
. O

the O
herbage O
be O
hairy O
in O
texture O
, O
the O
hair O
short O
to O
long O
, O
woolly O
to O
cobwebby O
. O

the O
appearance O
of O
the O
plant O
be O
almost O
mosslike O
until O
bloom O
. O

the O
inflorescence O
be O
a O
solitary O
flower O
in O
shade O
of O
white O
, O
pink O
, O
or O
blue O
. O

-PRON- O
have O
a O
tubular O
throat O
about O
one O
centimetre O
( O
1ÃƒÂ¢Ã‚ÂÃ¢â‚¬Å¾3 O
in O
) O
long O
spread O
into O
a O
flat O
five O
- O
lob O
corolla O
. O

gastrodia O
be O
a O
genus O
of O
achlorophyllous O
orchid B-Plant
with O
64 O
currently O
accept O
specie O
. O

-PRON- O
be O
native O
to O
asia O
( O
china O
, O
the O
russian O
far O
east O
, O
japan O
, O
korea O
, O
southeast O
asia O
, O
the O
indian O
subcontinent O
) O
, O
australia O
, O
new O
zealand O
, O
central O
africa O
, O
and O
various O
island O
of O
the O
indian O
and O
pacific O
oceans O
. O

gastrodia B-Plant
elata I-Plant
be O
a O
traditional O
chinese O
herb O
, O
tian O
ma O
( O
chinese O
: O
ÃƒÂ¥Ã‚Â¤Ã‚Â©ÃƒÂ©Ã‚ÂºÃ‚Â» O
) O
, O
and O
be O
commonly O
use O
in O
china O
to O
treat O
hypertension O
, O
improve O
circulation O
and O
resolve O
headache O
. O

anthoceros O
be O
a O
genus O
of O
hornwort B-Plant
in O
the O
family O
anthocerotaceae O
. O

the O
genus O
be O
global O
in O
-PRON- O
distribution O
. O

-PRON- O
name O
mean O
' O
flower O
horn O
' O
, O
and O
refer O
to O
the O
characteristic O
horn O
- O
shape O
sporophyte O
that O
all O
hornwort B-Plant
produce O
. O

rumex B-Plant
dentatus I-Plant
be O
a O
species O
of O
flower O
plant O
in O
the O
knotweed O
family O
know O
by O
the O
common O
name O
tooth B-Plant
dock I-Plant
and O
aegean O
dock O
. O

-PRON- O
be O
native O
to O
part O
of O
eurasia O
and O
north O
africa O
, O
and O
-PRON- O
be O
widely O
know O
elsewhere O
as O
an O
introduce O
specie O
. O

-PRON- O
grow O
in O
disturbed O
habitat O
, O
often O
in O
moist O
area O
, O
such O
as O
lakeshore O
and O
the O
edge O
of O
cultivate O
field O
. O

-PRON- O
be O
an O
annual O
or O
biennial O
herb O
produce O
a O
slender O
, O
erect O
stem O
up O
to O
70 O
or O
80 O
centimeter O
in O
maximum O
height O
. O

the O
leaf O
be O
lance O
- O
shape O
to O
oval O
with O
slightly O
wavy O
edge O
, O
grow O
to O
a O
maximum O
length O
around O
12 O
centimeter O
. O

the O
inflorescence O
be O
an O
interrupted O
series O
of O
cluster O
of O
flower O
, O
with O
10 O
to O
20 O
flower O
per O
cluster O
and O
each O
flower O
hang O
on O
a O
pedicel O
. O

each O
flower O
have O
usually O
six O
tepal O
, O
the O
3 O
inner O
of O
which O
be O
edge O
with O
spinelike O
tooth O
and O
have O
tubercle O
at O
-PRON- O
center O
. O

agavoideae O
be O
a O
subfamily O
of O
monocot O
flower O
plant O
in O
the O
family O
asparagaceae O
, O
order O
asparagales O
. O

-PRON- O
have O
previously O
be O
treat O
as O
a O
separate O
family O
, O
agavaceae O
. O

the O
group O
include O
many O
well O
- O
know O
desert O
and O
dry O
zone O
type O
such O
as O
the O
agave O
, O
yucca B-Plant
, O
and O
joshua B-Plant
tree I-Plant
. O

there O
be O
about O
640 O
specie O
in O
around O
23 O
genera O
, O
widespread O
in O
the O
tropical O
, O
subtropical O
and O
warm O
temperate O
region O
of O
the O
world O
. O

saururaceae O
be O
a O
plant O
family O
comprise O
four O
genera O
and O
seven O
specie O
of O
herbaceous O
flower O
plant O
native O
to O
eastern O
and O
southern O
asia O
and O
north O
america O
. O

the O
family O
have O
be O
recognise O
by O
most O
taxonomist O
, O
and O
be O
sometimes O
know O
as O
the O
lizard's O
- O
tail O
family O
. O

the O
apg O
iv O
system O
( O
2016 O
unchanged O
from O
the O
2009 O
apg O
iii O
system O
, O
the O
2003 O
apg O
ii O
system O
and O
the O
1998 O
apg O
system O
) O
assign O
-PRON- O
to O
the O
order O
piperales O
in O
the O
clade O
magnoliid O
. O

cryptocoryne B-Plant
beckettii I-Plant
( O
also O
know O
as O
beckett B-Plant
's I-Plant
water I-Plant
trumpet I-Plant
) O
be O
a O
plant O
specie O
belong O
to O
the O
aroid O
genus O
cryptocoryne O
. O

crataegus B-Plant
ÃƒÆ’Ã¢â‚¬â€ I-Plant
lavalleei O
, O
sometimes O
know O
as O
hybrid O
cockspurthorn B-Plant
or O
lavallÃƒÆ’Ã‚Â©e B-Plant
's I-Plant
hawthorn I-Plant
, O
be O
a O
hybrid O
that O
arise O
between O
cultivate O
specimen O
of O
two O
specie O
in O
the O
genus O
crataegus O
( O
hawthorn B-Plant
) O
. O

the O
female O
parent O
be O
c. B-Plant
mexicana I-Plant
( O
sometimes O
mistakenly O
call O
c. B-Plant
pubescen I-Plant
) O
, O
and O
the O
male O
parent O
be O
think O
to O
be O
c. B-Plant
calpodendron I-Plant
( O
which O
be O
sometimes O
mistakenly O
call O
c. O

crus O
- O
galli).carriÃƒÆ’Ã‚Â¨re O

's O
hawthorn B-Plant
, O
c. B-Plant
carrierei O
have O
the O
same O
parentage O
, O
and O
be O
therefore O
a O
synonym O
, O
i.e. O

the O
same O
specie O
. O

there O
be O
minor O
difference O
between O
lavallÃƒÆ’Ã‚Â©e B-Plant
's I-Plant
hawthorn I-Plant
and O
carriÃƒÆ’Ã‚Â¨re B-Plant
's I-Plant
hawthorn I-Plant
, O
and O
the O
latter O
be O
consider O
a O
separate O
cultivar O
, O
which O
be O
formally O
write O
as O
crataegus O
' O
carrierei O
' O
. O

crataegus B-Plant
ÃƒÆ’Ã¢â‚¬â€ I-Plant
lavalleei O
be O
an O
ornamental O
small O
tree O
with O
glossy O
dark O
green O
unlob O
leaf O
that O
be O
use O
horticulturally O
. O

the O
cultivar O
' O
carrierei O
' O
have O
gain O
the O
royal O
horticultural O
society O
's O
award O
of O
garden O
merit O
. O

cedronella O
be O
a O
genus O
of O
flower O
plant O
in O
the O
mentheae O
tribe O
of O
family O
lamiaceae O
, O
comprise O
a O
single O
specie O
, O
cedronella B-Plant
canariensis I-Plant
, O
native O
to O
the O
canary O
islands O
, O
the O
azores O
, O
and O
madeira O
. O

-PRON- O
be O
also O
naturalize O
in O
various O
place O
( O
south O
africa O
, O
st. O

helena O
, O
new O
zealand O
, O
california O
) O
. O

common O
name O
include O
canary B-Plant
islands I-Plant
- I-Plant
balm I-Plant
, O
canary B-Plant
balm I-Plant
, O
and O
balm B-Plant
- I-Plant
of I-Plant
- I-Plant
gilead I-Plant
. O

-PRON- O
be O
a O
perennial O
herbaceous O
plant O
grow O
to O
1 O
- O
1.5 O

m O
tall O
. O

the O
distinctive O
feature O
of O
these O
plant O
be O
the O
compound O
leave O
consist O
of O
3 O
leaflet O
, O
unusual O
in O
the O
lamiaceae O
, O
which O
usually O
have O
simple O
leaf O
. O

the O
leafy O
stem O
terminate O
in O
dense O
, O
short O
spike O
of O
flower O
with O
tubular O
2-lipp O
white O
or O
pink O
flower O
. O

the O
genus O
name O
be O
a O
diminutive O
of O
cedrus O
, O
though O
the O
only O
connection O
between O
this O
herb O
and O
the O
large O
conifer B-Plant
of O
cedrus O
be O
a O
vaguely O
similar O
resinous O
scent O
of O
the O
foliage O
. O

the O
genus O
platanthera O
belong O
to O
the O
subfamily O
orchidoideae O
of O
the O
family O
orchidaceae O
, O
and O
comprise O
about O
100 O
specie O
of O
orchid B-Plant
. O

the O
member O
of O
this O
genus O
, O
know O
as O
the O
butterfly B-Plant
orchid I-Plant
or O
fringed B-Plant
orchid I-Plant
, O
be O
previously O
include O
in O
the O
genus O
orchis O
, O
which O
be O
a O
close O
relative O
( O
along O
with O
the O
genus O
habenaria O
) O
. O

-PRON- O
be O
distribute O
throughout O
the O
temperate O
region O
of O
the O
northern O
hemisphere O
. O

-PRON- O
be O
terrestrial O
and O
have O
tubercule O
. O

pitcairnia O
be O
a O
genus O
of O
the O
botanical O
family O
bromeliaceae O
, O
subfamily O
pitcairnioideae O
. O

-PRON- O
be O
name O
for O
dr. O

william O
pitcairn O
, O
english O
physician O
and O
gardener O
( O
1711 O
- O
1791 O
) O
. O

the O
genus O
pitcairnia O
rank O
as O
the O
second O
most O
prolific O
of O
the O
bromeliad O
family O
( O
after O
tillandsia O
) O
. O

-PRON- O
be O
most O
abundant O
in O
colombia O
, O
peru O
and O
brazil O
, O
but O
can O
also O
be O
find O
in O
area O
from O
cuba O
and O
mexico O
south O
to O
argentina O
. O

one O
specie O
, O
pitcairnia B-Plant
feliciana I-Plant
be O
find O
in O
tropical O
west O
africa O
and O
be O
the O
only O
member O
of O
the O
bromeliaceae O
family O
not O
native O
to O
the O
western O
hemisphere O
. O

almost O
all O
pitcairnia O
be O
terrestrial O
or O
saxicolous O
, O
and O
prefer O
moist O
area O
. O

however O
, O
many O
be O
find O
grow O
epiphytically O
in O
tree O
. O

44 O
pitcairnia O
specie O
have O
be O
classify O
in O
the O
genus O
pepinia O
. O

pepinia O
be O
first O
establish O
as O
a O
subgenus O
by O
lyman O
smith O
and O
then O
elevate O
to O
a O
genus O
by O
varadarajan O
and O
gilmatin O
base O
on O
the O
absence O
of O
seed O
appendage O
. O

a O
molecular O
study O
support O
the O
view O
that O
the O
plant O
be O
best O
classify O
within O
pitcairnia O
. O

marchantiopsida O
be O
one O
of O
three O
class O
within O
the O
liverwort B-Plant
phylum O
marchantiophyta O
. O

quercus B-Plant
garryana I-Plant
, O
the O
garry B-Plant
oak I-Plant
, O
oregon B-Plant
white I-Plant
oak I-Plant
, O
oregon B-Plant
oak I-Plant
, O
or O
hu'dshnam O
, O
from O
the O
traditional O
klamath O
language O
, O
be O
a O
tree O
specie O
with O
a O
range O
stretch O
from O
southern O
california O
to O
southwestern O
british O
columbia O
. O

-PRON- O
grow O
from O
sea O
level O
to O
210 O
meter O
( O
690 O
ft O
) O
altitude O
in O
the O
northern O
part O
of O
-PRON- O
range O
, O
and O
at O
300 O
to O
1,800 O
meter O
( O
980 O
to O
5,910 O
ft O
) O
in O
the O
south O
of O
the O
range O
in O
california O
. O

the O
tree O
get O
one O
of O
-PRON- O
name O
from O
nicholas O
garry O
, O
deputy O
governor O
of O
the O
hudson B-Plant
's O
bay O
company O
, O
1822ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“35 O
. O

homoranthus O
be O
a O
genus O
of O
about O
thirty O
specie O
of O
plant O
in O
the O
myrtle O
family O
myrtaceae O
and O
all O
be O
endemic O
to O
australia O
. O

plant O
in O
this O
genus O
share O
similarity O
with O
those O
in O
both O
darwinia O
and O
verticordia O
. O

-PRON- O
be O
shrub O
with O
-PRON- O
leaf O
arrange O
in O
opposite O
pair O
and O
with O
flower O
appear O
either O
singly O
or O
in O
small O
group O
, O
usually O
in O
upper O
leaf O
axil O
. O

-PRON- O
be O
find O
in O
queensland O
, O
new O
south O
wales O
and O
south O
australia O
. O

the O
genus O
be O
first O
describe O
in O
1836 O
. O

none O
of O
the O
specie O
be O
common O
nor O
be O
-PRON- O
well O
- O
know O
in O
horticulture O
. O

thalia O
be O
a O
genus O
of O
six O
currently O
recognize O
specie O
find O
in O
aquatic O
or O
marshy O
habitat O
, O
range O
in O
africa O
from O
senegal O
to O
sudan O
to O
zimbabwe O
, O
and O
in O
the O
americas O
from O
illinois O
to O
argentina O
. O

alligator B-Plant
- I-Plant
flag I-Plant
be O
a O
common O
name O
for O
plant O
in O
this O
genus O
. O

the O
generic O
name O
be O
in O
honor O
of O
johannes O
thal O
( O
1542ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“1583 O
) O
, O
a O
german O
doctor O
who O
write O
a O
flora O
of O
the O
harz O
mountains O
. O

mucuna O
be O
a O
genus O
of O
around O
100 O
accept O
specie O
of O
climb O
liana O
( O
vine O
) O
and O
shrub O
of O
the O
family O
fabaceae O
: O
tribe O
phaseoleae O
and O
typically O
find O
in O
tropical O
forest O
. O

the O
name O
of O
the O
genus O
be O
derive O
from O
mucunÃƒÆ’Ã‚Â£ O
, O
a O
tupi O
ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“ O
guarani O
word O
for O
these O
specie O
. O

drosophyllum O
( O
, O
rarely O
) O
be O
a O
genus O
of O
carnivorous O
plant O
contain O
the O
single O
specie O
drosophyllum B-Plant
lusitanicum I-Plant
( O
portuguese O
sundew B-Plant
or O
dewy O
pine B-Plant
) O
. O

in O
appearance O
, O
-PRON- O
be O
similar O
to O
the O
related O
genus O
drosera O
( O
the O
sundew O
) O
, O
and O
to O
the O
much O
more O
distantly O
relate O
byblis O
( O
the O
rainbow O
plant O
) O
. O

drosophyllum B-Plant
lusitanicum I-Plant
bear O
bright O
- O
yellow O
flower O
, O
4 O
cm O
( O
1.6 O

in O
) O
in O
diameter O
, O
bear O
in O
group O
of O
3ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“15 O
between O
february O
and O
May O
the O
translucent O
seedpod O
bear O
3ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“10 O
opaque O
black O
, O
pear B-Plant
- O
shape O
seed O
, O
2.5 O

mm O
( O
98 O
in O
) O
in O
diameter O
. O

seed O
germination O
may O
be O
aid O
by O
scarification O
. O

the O
genus O
have O
always O
be O
assume O
to O
be O
closely O
ally O
to O
drosera O
, O
and O
be O
previously O
place O
in O
the O
droseraceae O
. O

recent O
molecular O
and O
biochemical O
study O
, O
however O
, O
place O
-PRON- O
in O
the O
monotypic O
drosophyllaceae O
, O
as O
recommend O
by O
the O
angiosperm O
phylogeny O
group O
, O
and O
ally O
with O
the O
dioncophyllaceae O
( O
triphyophyllum O
) O
and O
ancistrocladaceae O
. O

aeschynomene O
be O
a O
genus O
of O
flower O
plant O
in O
the O
family O
fabaceae O
, O
and O
be O
recently O
assign O
to O
the O
informal O
monophyletic O
dalbergia O
clade O
of O
the O
dalbergieae O
. O

-PRON- O
be O
know O
commonly O
as O
jointvetch O
. O

these O
legume O
be O
most O
common O
in O
warm O
region O
and O
many O
specie O
be O
aquatic O
. O

the O
genus O
as O
currently O
circumscribe O
be O
paraphyletic O
and O
-PRON- O
have O
be O
suggest O
that O
the O
subgenus O
ochopodium O
be O
elevate O
to O
a O
new O
genus O
within O
the O
dalbergieae O
, O
though O
other O
change O
will O
also O
be O
require O
to O
render O
the O
genus O
monophyletic O
. O

drosera B-Plant
paradoxa I-Plant
be O
a O
carnivorous O
plant O
in O
the O
genus O
drosera O
and O
be O
endemic O
to O
the O
northern O
territory O
and O
western O
australia O
. O

-PRON- O
be O
a O
perennial O
herb O
with O
a O
woody O
stem O
that O
can O
grow O
as O
tall O
as O
30 O
cm O
( O
12 O
in O
) O
. O

the O
leaf O
on O
the O
single O
terminal O
rosette O
be O
erect O
or O
horizontal O
( O
with O
age O
) O
and O
hold O
at O
the O
end O
of O
linear O
petiole O
, O
which O
be O
typically O
20ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“35 O
mm O
( O
approximately O
1 O
inch O
) O
long O
at O
flower O
time O
. O

the O
carnivorous O
leaf O
be O
sub O
- O
orbicular O
and O
small O
at O
2.5ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“3 O

mm O
( O
approximately O
1/10 O
inch O
) O
wide O
and O
2ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“3 O
mm O
( O
approximately O
1/10 O
inch O
) O
long O
. O

inflorescence O
be O
20ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“40 O
cm O
( O
8ÃƒÂ¢Ã¢â€šÂ¬Ã¢â‚¬Å“16 O
in O
) O
long O
with O
pink O
or O
white O
flower O
be O
produce O
on O
-50 O
to O
70-flowered O
crowded O
raceme O
from O
july O
to O
september O
during O
the O
dry O
season O
. O

drosera B-Plant
paradoxa I-Plant
be O
find O
in O
skeletal O
sandy O
soil O
over O
sandstone O
in O
or O
along O
the O
bank O
of O
seasonally O
dry O
creek O
or O
in O
sandstone O
crack O
. O

during O
the O
wet O
season O
from O
march O
to O
april O
, O
-PRON- O
habitat O
be O
typically O
flood O
with O
fast O
- O
flow O
water O
. O

drosera B-Plant
paradoxa I-Plant
be O
native O
to O
the O
west O
and O
north O
coast O
of O
the O
kimberley O
region O
inland O
to O
beverley O
springs O
, O
western O
australia O
and O
east O
to O
arnhem O
land O
and O
kakadu O
national O
park O
in O
the O
northern O
territory O
. O

-PRON- O
be O
first O
describe O
by O
australian O
botanist O
allen O
lowrie O
in O
a O
1997 O
issue O
of O
nuytsia O
, O
the O
journal O
of O
the O
western O
australian O
herbarium O
. O

early O
field O
observation O
of O
this O
specie O
be O
initially O
confusing O
, O
which O
be O
the O
source O
of O
this O
specie O
' O
specific O
epithet O
, O
paradoxa O
. O

some O
population  O
seem O
to O
be O
annual O
with O
new O
seedling O
replace O
the O
mature O
, O
woody O
plant O
that O
have O
exist O
there O
the O
previous O
year O
. O

other O
population O
have O
no O
woody O
stem O
, O
while O
other O
be O
tall O
and O
mature O
. O

several O
trip O
into O
the O
field O
from O
1993 O
to O
1997 O
be O
require O
to O
reveal O
these O
different O
form O
to O
be O
only O
stage O
in O
this O
specie O
' O
perennial O
growth O
cycle O
from O
seedl O
to O
pincushion B-Plant
basal O
rosette O
to O
erect O
woody O
- O
stemmed O
speciman O
. O

some O
50 O
species O
of O
orchid B-Plant
have O
been O
recorded O
here O
, O
including O
the O
evocatively O
named O
pink O
butterfly B-Plant
( O
orchis B-Plant
papilionacea I-Plant
) O
( O
plate O
64 O
) O
, O
lizard B-Plant
( O
himantoglossum B-Plant
hircinum I-Plant
) O
, O
man B-Plant
( O
aceras B-Plant
anthropophorum I-Plant
) O
, O
woodcock B-Plant
( O
ophrys B-Plant
scolopax I-Plant
) O
, O
fly B-Plant
( O
ophrys B-Plant
insectifera I-Plant
) O
and O
sawfly B-Plant
( O
ophrys B-Plant
tenthredinifera I-Plant
) O
orchids B-Plant
, O
to O
name O
but O
a O
few O
. O

92/27 O
parrots O
in O
peril O
, O
ecuador O
( O
march O
- O
july O
1992 O
) O
this O
team O
( O
4 O
british O
, O
4 O
ecuadorean O
) O
achieved O
their O
aim O
of O
surveying O
various O
sites O
up O
to O
3200 O
m O
in O
the O
podocarpus O
national O
park O
to O
assess O
the O
threat O
to O
three O
species O
of O
parrot O
, O
and O
also O
to O
assess O
the O
environmental O
impact O
of O
gold O
- O
mining O
and O
colonists O
on O
the O
park O
. O

september O
1994-january O
1995 O
the O
podocarpus O
national O
park O
includes O
the O
last O
substantial O
area O
of O
high O
- O
altitude O
montane O
forest O
left O
in O
the O
andes O
of O
southern O
ecuador O
, O
and O
as O
such O
contains O
a O
number O
of O
threatened O
species O
of O
flora O
and O
fauna O
. O

nine O
different O
kinds O
were O
found O
, O
one O
being O
a O
new O
species O
named O
primula B-Plant
jigmediana I-Plant
after O
jigme O
wangchuk O
, O
the O
king O
of O
bhutan O
. O

it O
appears O
that O
he O
went O
through O
the O
museum O
's O
gentiana O
holdings O
in O
1958 O
and O
' O
found O
what O
he O
considered O
to O
be O
a O
new O
species O
, O
which O
he O
called O
g. O
tilmanii O
. O

there O
are O
two O
dominant O
species O
of O
tree O
, O
lower O
down O
the O
evergreen O
nothofagus B-Plant
betuloides I-Plant
and O
higher O
up O
, O
the O
deciduous O
tv O
! O
veteran O
trees O
were O
of O
great O
girth O
, O
but O
i O
could O
not O
distinguish O
what O
they O
were O
except O
a O
species O
of O
oak B-Plant
, O
and O
another O
beautiful O
tree O
with O
large O
compound O
leaves O
which O
may O
have O
been O
either O
cedrela O
or O
alianthus O
. O

in O
wales O
, O
i O
can O
only O
remember O
, O
although O
there O
must O
have O
been O
others O
, O
the O
mysterious O
and O
unnecessary O
one O
on O
holly B-Plant
tree I-Plant
wall O
from O
which O
the O
piton O
route O
got O
its O
name O
; O
the O
holly B-Plant
tree I-Plant
wall O
on O
idwal O
slabs O
was O
worked O
out O
by O
him O
with O
c. O
f. O
holland O
. O

the O
tree O
- O
line O
is O
low O
, O
down O
at O
2800 O
m O
, O
and O
the O
forest O
151 O
bristling O
with O
mammals O
such O
as O
howler O
and O
spider O
monkeys O
, O
bears O
and O
a O
fierce O
blue O
carnivorous O
foxgives O
way O
to O
the O
' O
sabana O
rubia B-Plant
, O
a O
gently O
- O
sloping O
, O
marshy O
expanse O
of'pseudo O
- O
paramo O
' O
, O
leading O
up O
to O
the O
border O
. O

from O
april O
to O
august O
in O
1982 O
, O
i O
mounted O
a O
one O
- O
man O
expedition O
to O
kashmir O
to O
study O
fir B-Plant
trees I-Plant
( O
abies B-Plant
pindrow I-Plant
) O
. O

ewing O
and O
trees O
named O
their O
grade O
iii O
gully O
taxus O
, O
obviously O
having O
read O
the O
account O
by O
thomson O
of O
the O
1894 O
examination O
. O

he O
led O
six O
of O
us O
up O
the O
holly B-Plant
tree I-Plant
wall O
which O
in O
1931 O
was O
considered O
extremely O
difficult O
. O

in O
1917 O
and O
1918 O
with O
herbert O
carr O
, O
r O
a O
frazer O
, O
i O
a O
richards O
( O
and O
his O
spaniel O
sancho O
panza O
) O
, O
c O
f O
holland O
and O
others O
, O
she O
explored O
tryfan O
, O
lliwedd O
, O
the O
devil O
's O
kitchen O
, O
cwm O
idwal O
151 O
and O
was O
one O
of O
the O
first O
party O
up O
holly B-Plant
tree I-Plant
wall O
. O

the O
trees O
were O
the O
real O
enemy O
, O
old O
trees O
, O
young O
trees O
, O
rotten O
and O
burnt O
trees O
, O
douglas B-Plant
firs I-Plant
, O
jack O
pines B-Plant
, O
spruce B-Plant
, O
poplar B-Plant
and O
birch B-Plant
; O
the O
lower O
slopes O
between O
2700 O
and O
3000 O
metres O
are O
dominated O
by O
the O
yunnan B-Plant
pine I-Plant
pinus B-Plant
yunnanensis I-Plant
which O
is O
interspersed O
with O
hardwood O
trees O
such O
as O
poplar B-Plant
and O
lime B-Plant
as O
well O
as O
a O
very O
wide O
range O
of O
interesting O
shrubs O
. O

above O
the O
deciduous O
tree O
- O
line O
, O
pine B-Plant
forests O
compete O
with O
swashes O
of O
yellow B-Plant
azalea I-Plant
giving O
way O
to O
meadows O
bejewelled O
with O
alpine O
flowers O
swept O
by O
wave O
- O
tossed O
tracts O
of O
the O
white O
blossomed O
rhododendron B-Plant
caucasicum I-Plant
. O

wild B-Plant
jasmine I-Plant
( O
jasminum B-Plant
fruticans I-Plant
) O
and O
bar B-Plant
- I-Plant
berry I-Plant
( O
berberis B-Plant
vulgaris I-Plant
) O
bloom O
amidst O
the O
glossy O
evergreen O
foliage O
of O
straw B-Plant
- I-Plant
berry I-Plant
trees O
( O
arbutus O
unedd O
) O
and O
spanish B-Plant
laurel I-Plant
( O
laurus B-Plant
nobilis I-Plant
) O
, O
whilst O
the O
turpentine B-Plant
tree I-Plant
( O
pistacia B-Plant
terebinthus I-Plant
) O
, O
a O
close O
relative O
of O
the O
pistachio B-Plant
, O
spreads O
its O
leaves O
in O
the O
sunniest O
spots O
together O
with O
wild O
figs B-Plant
( O
ficus B-Plant
carica I-Plant
) O
, O
walnuts B-Plant
( O
juglans B-Plant
regia I-Plant
) O
and O
olives B-Plant
( O
olea B-Plant
europaea I-Plant
ssp. I-Plant
sylvestris I-Plant
) O
. O

its O
abun O
- O
dant O
forests O
, O
exploited O
by O
seafaring O
nations O
from O
the O
romans O
onwards O
, O
combine O
chestnut B-Plant
, O
oak B-Plant
, O
beech B-Plant
and O
, O
above O
all O
, O
the O
transcendental O
corsican B-Plant
pine I-Plant
, O
a O
monarch O
of O
european O
trees O
, O
which O
attains O
700 O
years O
of O
age O
and O
over O
50 O
m O
in O
height O
. O

from O
a O
distance O
the O
tree O
silhouettes O
could O
have O
been O
scots O
pines B-Plant
, O
but O
were O
actually O
evergreen O
beech B-Plant
nothofagus B-Plant
betuloides I-Plant
, O
intermingled O
with O
the O
autumn O
crimson O
and O
gold O
of O
deciduous O
southern B-Plant
beech I-Plant
nothofaguspumilla O
and O
antarctica O
. O

up O
in O
the O
fragile O
alpine O
zone O
, O
where O
even O
a O
small O
two O
- O
foot O
- O
diameter O
conifer B-Plant
( O
deodar B-Plant
or O
pine B-Plant
) O
will O
be O
some O
200 O
years O
old O
, O
we O
watched O
in O
horror O
as O
many O
of O
these O
trees O
were O
cut O
down O
merely O
to O
melt O
tar O
to O
put O
on O
the O
road O
. O

and O
, O
by O
the O
sacred O
lake O
of O
mabartsho O
, O
yellow O
tree O
paeonies O
, O
a O
variety O
of O
paeonia B-Plant
lutea I-Plant
. O

and O
on O
the O
walk O
- O
out O
next O
day O
there O
were O
fine O
tree B-Plant
ferns I-Plant
and O
bright O
blue O
iris B-Plant
decora I-Plant
. O

he O
pointed O
out O
a O
bequartodendron O
tree O
, O
enmeshed O
in O
a O
strangler O
fig B-Plant
which O
he O
had O
watched O
grow O
since O
he O
first O
came O
here O
in O
1962 O
. O

a O
pleasant O
scramble O
zigzags O
through O
boulders O
, O
prickly O
euphorbia O
and O
the O
surreal O
, O
fleshy O
kokerboom O
or O
' O
quiver O
' O
trees O
, O
whose O
pith B-Plant
was O
made O
into O
arrow O
quivers O
by O
the O
bushmen O
. O

13 O
we O
found O
a O
small O
group O
of O
mountain B-Plant
cabbage I-Plant
trees O
( O
cordyline B-Plant
indivisa I-Plant
) O
growing O
on O
the O
ridge O
above O
the O
tree O
line O
. O

not O
a O
sturdy O
english B-Plant
oak I-Plant
or O
anything O
of O
the O
kind O
, O
but O
a O
tree O
, O
a O
bush O
of O
a O
tree O
, O
of O
sorts O
. O

the O
section O
covering O
1926 O
- O
1950 O
is O
titled O
' O
canada O
drifts O
from O
the O
mainstream O
of O
world O
mountaineering O
' O
, O
but O
it O
contains O
such O
stories O
as O
that O
of O
the O
mundays O
, O
don O
and O
phyllis O
, O
who O
carried O
601b O
loads O
for O
13 O
days O
of O
bushwacking O
in O
search O
of O
mount O
waddington O
, O
felling O
trees O
to O
cross O
glacial O
torrents O
( O
photo O
page O
108 O
) O
. O

thick O
tangles O
of O
nothofagus B-Plant
antarctica I-Plant
had O
to O
be O
fought O
through O
, O
but O
on O
crossing O
the O
lapataia O
river O
we O
found O
guanaco O
trails O
, O
speeding O
progress O
through O
the O
forest O
and O
low O
tree O
scrub O
. O

run O
by O
mr O
conrad O
pinches O
, O
this O
school O
occupied O
one O
of O
the O
large O
terraced O
houses O
on O
the O
west O
side O
of O
the O
road O
running O
south O
from O
walnut B-Plant
tree O
walk O
. O

vol O
99 O
of O
the O
, O
4/(1994)contains O
an O
article O
by O
rosemary B-Plant
setting O
out O
the O
relationships O
and O
climbing O
achievements O
of O
her O
convoluted O
quaker O
family O
, O
together O
with O
a O
family O
tree O
. O

there O
was O
a O
small O
pink O
- O
headed O
onion B-Plant
here O
also O
( O
allium B-Plant
carolinianum I-Plant
) O
, O
collected O
by O
the O
kirghiz O
for O
food O
, O
as O
well O
as O
numerous O
aromatic O
herbs O
whose O
fragrance O
drifted O
across O
the O
slopes O
. O

herbs O
such O
as O
the O
beautiful O
george O
forrest O
's O
primrose B-Plant
primula B-Plant
forrestii I-Plant
with O
flowers O
of O
rich O
golden O
- O
yellow O
also O
flourish O
at O
this O
altitude O
, O
as O
does O
the O
rare O
and O
bizarre O
- O
looking O
slipper B-Plant
orchid I-Plant
cypripedium B-Plant
margaritaceum I-Plant
. O

the O
list O
of O
herbs O
which O
grow O
within O
this O
rich O
area O
of O
temperate O
forest O
is O
truly O
encyclopaedic O
, O
for O
here O
are O
to O
be O
found O
such O
treasures O
as O
primula B-Plant
bella I-Plant
, O
iris B-Plant
chrysographes I-Plant
, O
arisaema B-Plant
wilsonii I-Plant
and O
the O
yellow O
slipper B-Plant
orchid I-Plant
cypripedium B-Plant
flavum I-Plant
. O

in O
1957 O
sir O
wally O
herbert O
had O
led O
a O
dog O
- O
sled O
team O
down O
the O
spine O
of O
the O
antarctic O
peninsular O
from O
hope O
bay O
in O
the O
north O
, O
to O
the O
reclus O
peninsula O
where O
the O
team O
were O
picked O
up O
from O
portal O
point O
. O

until O
further O
work O
is O
done O
with O
the O
existing O
herbarium O
material O
it O
is O
doubtful O
whether O
we O
shall O
hear O
anything O
further O
of O
gentiana B-Plant
tilmanii I-Plant
. O

fruit O
and O
herbs O
that O
grew O
naturally O
in O
borrowdale O
rounded O
off O
an O
austere O
but O
healthy O
diet O
prepared O
over O
an O
open O
fire O
, O
a O
woodbine B-Plant
clasped O
between O
his O
toes B-Plant
to O
prevent O
ash O
falling O
into O
his O
food O
. O

and O
for O
its O
associations O
with O
the O
high O
places O
, O
the O
highland O
heather B-Plant
, O
so O
disagreeable O
to O
captain O
bun O
, O
was O
crowned O
by O
ruskin O
, O
with O
the O
blue O
gentian B-Plant
and O
the O
alpine B-Plant
rose I-Plant
, O
in O
uncontested O
queenliness O
, O
flowers O
wholly O
without O
similitude O
. O

even O
alpine O
flowers O
are O
at O
home O
here O
especially O
the O
' O
k'fcchenschelle O
' O
, O
the O
pasque B-Plant
flower I-Plant
( O
anemone O
pulsatilla O
) O
. O

a O
yellow O
starry O
- O
flowered O
clematis O
( O
c. B-Plant
hilariae I-Plant
) O
formed O
tumbled O
entanglements O
along O
field O
boundaries O
. O

along O
the O
rivers O
and O
streams O
there O
are O
the O
usual O
sedge B-Plant
pastures O
mixed O
with O
a O
few O
grasses O
but O
in O
the O
wet O
places O
, O
large O
drifts O
of O
deep O
blue O
primroses O
( O
primula B-Plant
macrophylla I-Plant
) O
and O
a O
small O
bright O
yellow O
buttercup B-Plant
( O
ranunculus B-Plant
pulchellus I-Plant
) O
were O
almost O
past O
flowering O
. O

this O
year O
has O
seen O
the O
first O
face O
route O
on O
the O
tower O
left O
of O
lotus O
flower O
; O
most O
memorable O
was O
the O
carpet O
of O
crocus O
sieberi O
that O
grew O
so O
thick O
amidst O
the O
tussock B-Plant
grass I-Plant
of O
the O
upper O
pastures O
that O
it O
was O
impossible O
to O
avoid O
treading O
its O
flowers O
underfoot O
. O

in O
june O
the O
meadows O
at O
this O
altitude O
are O
alight O
with O
the O
colour O
of O
flowers O
- O
rhododendron B-Plant
adenogynutn I-Plant
occurs O
in O
flowing O
masses O
of O
pale O
pink O
, O
the O
yellow B-Plant
bells I-Plant
of O
lilium O
lopophorum O
stud O
the O
slopes O
in O
association O
with O
the O
purple O
lloydia B-Plant
tibetica I-Plant
var. I-Plant
purpurescens I-Plant
( O
an O
asian O
counterpart O
of O
the O
snowdon O
lily B-Plant
) O
and O
the O
golden O
meconopsis B-Plant
integrifolia I-Plant
. O

on O
the O
cliffs O
cling O
cushions O
of O
androsace B-Plant
delavayi I-Plant
and O
the O
almost O
impossibly O
- O
named O
solmslaubachia B-Plant
pulcherrima I-Plant
, O
one O
of O
forrest O
's O
favourite O
alpines O
with O
cress B-Plant
- O
like O
ice O
- O
blue O
flowers O
. O

best O
of O
all O
is O
the O
exquisite O
dwarf O
alpine O
' O
blue B-Plant
poppy I-Plant
' O
meconopsis B-Plant
delavayi I-Plant
which O
kingdon O
- O
ward O
described O
as O
' O
a O
shimmering O
bluish O
- O
violet B-Plant
flower O
with O
the O
texture O
of O
japanese O
silk O
' O
. O

higher O
still O
in O
the O
north O
- O
facing O
base O
- O
rich O
wetter O
flushes O
the O
seemingly O
uncultivatable O
primula B-Plant
dryadifolia I-Plant
shows O
its O
mauve O
- O
pink O
flowers O
against O
broad O
prostrate O
mats O
of O
foliage O
( O
25 O
cm O
across O
) O
, O
accompanied O
by O
three O
' O
sisters O
' O
of O
the O
same O
genus O
, O
primula B-Plant
pinnatifida I-Plant
, O
p O
secundiflora O
and O
p O
pseudo O
- O
sikkimensis O
. O

montague O
's O
enthusiasm O
had O
amused O
him O
and O
he O
recalled O
, O
laughingly O
, O
how O
when O
he O
reached O
the O
top O
his O
leader O
had O
given O
a O
shout O
of O
pleasure O
and O
rushed O
to O
admire O
a O
carpet O
of O
lloydia O
in O
full O
flower O
. O

in O
the O
australian O
aboriginal O
samples O
, O
187 O
c O
- O
- O
> O
g O
was O
found O
to O
be O
associated O
with O
hla O
haplotypes O
common O
in O
caucasians O
, O
suggesting O
that O
it O
was O
introduced O
by O
recent O
admixture O
. O

in O
the O
chinese O
samples O
analyzed O
, O
187 O
c O
- O
- O
> O
g O
was O
present O
in O
association O
with O
a O
wide O
variety O
of O
hla O
haplotypes O
, O
showing O
this O
mutation O
to O
be O
widespread O
and O
likely O
to O
predate O
the O
more O
genetically O
restricted O
845 O
g O
- O
- O
> O
a O
mutation O
. O

genotype O
- O
phenotype O
correlations O
in O
attenuated B-Disease
adenomatous B-Disease
polyposis B-Disease
coli B-Disease
. O

germ O
- O
line O
mutations O
of O
the O
tumor B-Disease
suppressor O
apc O
are O
implicated O
in O
attenuated B-Disease
adenomatous B-Disease
polyposis B-Disease
coli B-Disease
( O
aapc B-Disease
) O
, O
a O
variant O
of O
familial B-Disease
adenomatous B-Disease
polyposis B-Disease
( O
fap B-Disease
) O
. O

aapc B-Disease
is O
recognized O
by O
the O
occurrence O
of O
< O
100 O
colonic B-Disease
adenomas B-Disease
and O
a O
later O
onset O
of O
colorectal B-Disease
cancer B-Disease
( O
age O
> O
40 O
years O
) O
. O

the O
aim O
of O
this O
study O
was O
to O
assess O
genotype O
- O
phenotype O
correlations O
in O
aapc B-Disease
families O
. O

by O
protein O
- O
truncation O
test O
( O
ptt O
) O
assay O
, O
the O
entire O
coding O
region O
of O
the O
apc B-Disease
gene O
was O
screened O
in O
affected O
individuals O
from O
11 O
aapc B-Disease
kindreds O
, O
and O
their O
phenotypic O
differences O
were O
examined O
. O

five O
novel O
germ O
- O
line O
apc B-Disease
mutations O
were O
identified O
in O
seven O
kindreds O
. O

mutations O
were O
located O
in O
three O
different O
regions O
of O
the O
apc B-Disease
gene O
( O
1 O
) O
at O
the O
5 O
end O
spanning O
exons O
4 O
and O
5 O
, O
( O
2 O
) O
within O
exon O
9 O
, O
and O
( O
3 O
) O
at O
the O
3 O
distal O
end O
of O
the O
gene O
. O

variability O
in O
the O
number O
of O
colorectal B-Disease
adenomas B-Disease
was O
most O
apparent O
in O
individuals O
with O
mutations O
in O
region O
1 O
, O
and O
upper O
- O
gastrointestinal O
manifestations O
were O
more O
severe O
in O
them O
. O

in O
individuals O
with O
mutations O
in O
either O
region O
2 O
or O
region O
3 O
, O
the O
average O
number O
of O
adenomas B-Disease
tended O
to O
be O
lower O
than O
those O
in O
individuals O
with O
mutations O
in O
region O
1 O
, O
although O
age O
at O
diagnosis O
was O
similar O
. O

in O
all O
aapc B-Disease
kindreds O
, O
a O
predominance O
of O
right O
- O
sided O
colorectal B-Disease
adenomas B-Disease
and O
rectal B-Disease
polyp B-Disease
sparing O
was O
observed O
. O

no O
desmoid B-Disease
tumors B-Disease
were O
found O
in O
these O
kindreds O
. O

our O
data O
suggest O
that O
, O
in O
aapc B-Disease
families O
, O
the O
location O
of O
the O
apc B-Disease
mutation O
may O
partially O
predict O
specific O
phenotypic O
expression O
. O

this O
should O
help O
in O
the O
design O
of O
tailored O
clinical O
- O
management O
protocols O
in O
this O
subset O
of O
fap B-Disease
patients O
. O

. O

wilms B-Disease
' B-Disease
tumor B-Disease
1 O
and O
dax O
- O
1 O
modulate O
the O
orphan O
nuclear O
receptor O
sf O
- O
1 O
in O
sex O
- O
specific O
gene O
expression O
. O

products O
of O
steroidogenic O
factor O
1 O
( O
sf O
- O
1 O
) O
and O
wilms B-Disease
tumor B-Disease
1 O
( O
wt1 O
) O
genes O
are O
essential O
for O
mammalian O
gonadogenesis O
prior O
to O
sexual O
differentiation O
. O

in O
males O
, O
sf O
- O
1 O
participates O
in O
sexual O
development O
by O
regulating O
expression O
of O
the O
polypeptide O
hormone O
mullerian O
inhibiting O
substance O
( O
mis O
) O
. O

here O
, O
we O
show O
that O
wt1 O
- O
kts O
isoforms O
associate O
and O
synergize O
with O
sf O
- O
1 O
to O
promote O
mis O
expression O
. O

in O
contrast O
, O
wt1 O
missense O
mutations O
, O
associated O
with O
male B-Disease
pseudohermaphroditism B-Disease
in O
denys B-Disease
- B-Disease
drash B-Disease
syndrome B-Disease
, O
fail O
to O
synergize O
with O
sf O
- O
1 O
. O

additionally O
, O
the O
x O
- O
linked O
, O
candidate O
dosage O
- O
sensitive O
sex O
- O
reversal O
gene O
, O
dax O
- O
1 O
, O
antagonizes O
synergy O
between O
sf O
- O
1 O
and O
wt1 O
, O
most O
likely O
through O
a O
direct O
interaction O
with O
sf O
- O
1 O
. O

we O
propose O
that O
wt1 O
and O
dax O
- O
1 O
functionally O
oppose O
each O
other O
in O
testis O
development O
by O
modulating O
sf O
- O
1 O
- O
mediated O
transactivation O
. O

. O

a O
mouse O
model O
for O
prader B-Disease
- B-Disease
willi B-Disease
syndrome B-Disease
imprinting O
- O
centre O
mutations O
. O

imprinting O
in O
the O
15q11 O
- O
q13 O
region O
involves O
an O
imprinting O
centre O
( O
ic O
) O
, O
mapping O
in O
part O
to O
the O
promoter O
and O
first O
exon O
of O
snrpn O
. O

deletion O
of O
this O
ic O
abolishes O
local O
paternally O
derived O
gene O
expression O
and O
results O
in O
prader B-Disease
- B-Disease
willi B-Disease
syndrome B-Disease
( O
pws B-Disease
) O
. O

we O
have O
created O
two O
deletion O
mutations O
in O
mice O
to O
understand O
pws B-Disease
and O
the O
mechanism O
of O
this O
ic O
. O

mice O
harbouring O
an O
intragenic O
deletion O
in O
snrpn O
are O
phenotypically O
normal O
, O
suggesting O
that O
mutations O
of O
snrpn O
are O
not O
sufficient O
to O
induce O
pws B-Disease
. O

mice O
with O
a O
larger O
deletion O
involving O
both O
snrpn O
and O
the O
putative O
pws O
- O
ic O
lack O
expression O
of O
the O
imprinted O
genes O
zfp127 O
( O
mouse O
homologue O
of O
znf127 O
) O
, O
ndn O
and O
ipw O
, O
and O
manifest O
several O
phenotypes O
common O
to O
pws B-Disease
infants O
. O

these O
data O
demonstrate O
that O
both O
the O
position O
of O
the O
ic O
and O
its O
role O
in O
the O
coordinate O
expression O
of O
genes O
is O
conserved O
between O
mouse O
and O
human O
, O
and O
indicate O
that O
the O
mouse O
is O
a O
suitable O
model O
system O
in O
which O
to O
investigate O
the O
molecular O
mechanisms O
of O
imprinting O
in O
this O
region O
of O
the O
genome O
. O

. O

mutations O
of O
the O
atm O
gene O
detected O
in O
japanese O
ataxia B-Disease
- B-Disease
telangiectasia B-Disease
patients O
: O
possible O
preponderance O
of O
the O
two O
founder O
mutations O
4612del165 O
and O
7883del5 O
. O

the O
atm O
( O
a O
- O
t O
, O
mutated O
) O
gene O
on O
human O
chromosome O
11q22 O
. O

3 O
has O
recently O
been O
identified O
as O
the O
gene O
responsible O
for O
the O
human O
recessive B-Disease
disease B-Disease
ataxia B-Disease
- B-Disease
telangiectasia B-Disease
( O
a B-Disease
- B-Disease
t B-Disease
) O
. O

in O
order O
to O
define O
the O
types O
of O
disease O
- O
causing O
atm O
mutations O
in O
japanese O
a B-Disease
- B-Disease
t B-Disease
patients O
as O
well O
as O
to O
look O
for O
possible O
mutational O
hotspots O
, O
reverse O
- O
transcribed O
rna O
derived O
from O
ten O
patients O
belonging O
to O
eight O
unrelated O
japanese O
a B-Disease
- B-Disease
t B-Disease
families O
was O
analyzed O
for O
mutations O
by O
the O
restriction O
endonuclease O
fingerprinting O
method O
. O

as O
has O
been O
reported O
by O
others O
, O
mutations O
that O
lead O
to O
exon O
skipping O
or O
premature O
protein O
truncation O
were O
also O
predominant O
in O
our O
mutants O
. O

six O
different O
mutations O
were O
identified O
on O
12 O
of O
the O
16 O
alleles O
examined O
. O

four O
were O
deletions O
involving O
a O
loss O
of O
a O
single O
exon O
exon O
7 O
, O
exon O
16 O
, O
exon O
33 O
or O
exon O
35 O
. O

the O
others O
were O
minute O
deletions O
, O
4649dela O
in O
exon O
33 O
and O
7883del5 O
in O
exon O
55 O
. O

the O
mutations O
4612del165 O
and O
7883del5 O
were O
found O
in O
more O
than O
two O
unrelated O
families O
; O
44 O
% O
( O
7 O
of O
16 O
) O
of O
the O
mutant O
alleles O
had O
one O
of O
the O
two O
mutations O
. O

the O
4612del165 O
mutations O
in O
three O
different O
families O
were O
all O
ascribed O
to O
the O
same O
t O
- O
- O
> O
a O
substitution O
at O
the O
splice O
donor O
site O
in O
intron O
33 O
. O

microsatellite O
genotyping O
around O
the O
atm O
locus O
also O
indicated O
that O
a O
common O
haplotype O
was O
shared O
by O
the O
mutant O
alleles O
in O
both O
mutations O
. O

this O
suggests O
that O
these O
two O
founder O
mutations O
may O
be O
predominant O
among O
japanese O
atm O
mutant O
alleles O
. O

w474c O
amino O
acid O
substitution O
affects O
early O
processing O
of O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
a O
and O
is O
associated O
with O
subacute O
g B-Disease
( B-Disease
m2 B-Disease
) B-Disease
gangliosidosis B-Disease
. O

mutations O
in O
the O
hexa O
gene O
, O
encoding O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
a O
( O
hex O
a O
) O
, O
that O
abolish O
hex O
a O
enzyme O
activity O
cause O
tay B-Disease
- B-Disease
sachs B-Disease
disease B-Disease
( O
tsd B-Disease
) O
, O
the O
fatal O
infantile B-Disease
form B-Disease
of B-Disease
g B-Disease
( B-Disease
m2 B-Disease
) B-Disease
gangliosidosis B-Disease
, B-Disease
type B-Disease
1 B-Disease
. O

less O
severe O
, O
subacute O
( O
juvenile O
- O
onset O
) O
and O
chronic O
( O
adult O
- O
onset O
) O
variants O
are O
characterized O
by O
a O
broad O
spectrum O
of O
clinical O
manifestations O
and O
are O
associated O
with O
residual O
levels O
of O
hex O
a O
enzyme O
activity O
. O

we O
identified O
a O
1422 O
g O
- O
- O
> O
c O
( O
amino O
acid O
w474c O
) O
substitution O
in O
the O
first O
position O
of O
exon O
13 O
of O
hexa O
of O
a O
non O
- O
jewish O
proband O
who O
manifested O
a O
subacute O
variant O
of O
g B-Disease
( B-Disease
m2 B-Disease
) B-Disease
gangliosidosis B-Disease
. O

on O
the O
second O
maternally O
inherited O
allele O
, O
we O
identified O
the O
common O
infantile O
disease O
- O
causing O
4 O
- O
bp O
insertion O
, O
+ O
tatc O
1278 O
, O
in O
exon O
11 O
. O

pulse O
- O
chase O
analysis O
using O
proband O
fibroblasts O
revealed O
that O
the O
w474c O
- O
containing O
alpha O
- O
subunit O
precursor O
was O
normally O
synthesized O
, O
but O
not O
phosphorylated O
or O
secreted O
, O
and O
the O
mature O
lysosomal O
alpha O
- O
subunit O
was O
not O
detected O
. O

when O
the O
w474c O
- O
containing O
alpha O
- O
subunit O
was O
transiently O
co O
- O
expressed O
with O
the O
beta O
- O
subunit O
to O
produce O
hex O
a O
( O
alphabeta O
) O
in O
cos O
- O
7 O
cells O
, O
the O
mature O
alpha O
- O
subunit O
was O
present O
, O
but O
its O
level O
was O
much O
lower O
than O
that O
from O
normal O
alpha O
- O
subunit O
transfections O
, O
although O
higher O
than O
in O
those O
cells O
transfected O
with O
an O
alpha O
- O
subunit O
associated O
with O
infantile O
tsd B-Disease
. O

furthermore O
, O
the O
precursor O
level O
of O
the O
w474c O
alpha O
- O
subunit O
was O
found O
to O
accumulate O
in O
comparison O
to O
the O
normal O
alpha O
- O
subunit O
precursor O
levels O
. O

we O
conclude O
that O
the O
1422 O
g O
- O
- O
> O
c O
mutation O
is O
the O
cause O
of O
hex B-Disease
a B-Disease
enzyme B-Disease
deficiency B-Disease
in O
the O
proband O
. O

the O
resulting O
w474c O
substitution O
clearly O
interferes O
with O
alpha O
- O
subunit O
processing O
, O
but O
because O
the O
base O
substitution O
falls O
at O
the O
first O
position O
of O
exon O
13 O
, O
aberrant O
splicing O
may O
also O
contribute O
to O
hex B-Disease
a B-Disease
deficiency B-Disease
in O
this O
proband O
. O

. O

two O
frequent O
missense O
mutations O
in O
pendred B-Disease
syndrome B-Disease
. O

pendred B-Disease
syndrome B-Disease
is O
an O
autosomal B-Disease
recessive B-Disease
disorder B-Disease
characterized O
by O
early O
childhood O
deafness B-Disease
and O
goiter B-Disease
. O

a O
century O
after O
its O
recognition O
as O
a O
syndrome O
by O
vaughan O
pendred O
, O
the O
disease O
gene O
( O
pds O
) O
was O
mapped O
to O
chromosome O
7q22 O
- O
q31 O
. O

1 O
and O
, O
recently O
, O
found O
to O
encode O
a O
putative O
sulfate O
transporter O
. O

we O
performed O
mutation O
analysis O
of O
the O
pds B-Disease
gene O
in O
patients O
from O
14 O
pendred B-Disease
families O
originating O
from O
seven O
countries O
and O
identified O
all O
mutations O
. O

the O
mutations O
include O
three O
single O
base O
deletions O
, O
one O
splice O
site O
mutation O
and O
10 O
missense O
mutations O
. O

one O
missense O
mutation O
( O
l236p O
) O
was O
found O
in O
a O
homozygous O
state O
in O
two O
consanguineous O
families O
and O
in O
a O
heterozygous O
state O
in O
five O
additional O
non O
- O
consanguineous O
families O
. O

another O
missense O
mutation O
( O
t416p O
) O
was O
found O
in O
a O
homozygous O
state O
in O
one O
family O
and O
in O
a O
heterozygous O
state O
in O
four O
families O
. O

pendred B-Disease
patients O
in O
three O
non O
- O
consanguineous O
families O
were O
shown O
to O
be O
compound O
heterozygotes O
for O
l236p O
and O
t416p O
. O

in O
total O
, O
one O
or O
both O
of O
these O
mutations O
were O
found O
in O
nine O
of O
the O
14 O
families O
analyzed O
. O

the O
identification O
of O
two O
frequent O
pds B-Disease
mutations O
will O
facilitate O
the O
molecular O
diagnosis O
of O
pendred B-Disease
syndrome B-Disease
. O

insertional O
mutation O
by O
transposable O
element O
, O
l1 O
, O
in O
the O
dmd B-Disease
gene O
results O
in O
x B-Disease
- B-Disease
linked B-Disease
dilated B-Disease
cardiomyopathy B-Disease
. O

x B-Disease
- B-Disease
linked B-Disease
dilated B-Disease
cardiomyopathy B-Disease
( O
xldcm B-Disease
) O
is O
a O
clinical O
phenotype O
of O
dystrophinopathy B-Disease
which O
is O
characterized O
by O
preferential O
myocardial B-Disease
involvement B-Disease
without O
any O
overt O
clinical O
signs O
of O
skeletal B-Disease
myopathy B-Disease
. O

to O
date O
, O
several O
mutations O
in O
the O
duchenne B-Disease
muscular B-Disease
dystrophy B-Disease
gene O
, O
dmd O
, O
have O
been O
identified O
in O
patients O
with O
xldcm B-Disease
, O
but O
a O
pathogenic O
correlation O
of O
these O
cardiospecific O
mutations O
in O
dmd O
with O
the O
xldcm B-Disease
phenotype O
has O
remained O
to O
be O
elucidated O
. O

we O
report O
here O
the O
identification O
of O
a O
unique O
de O
novo O
l1 O
insertion O
in O
the O
muscle O
exon O
1 O
in O
dmd O
in O
three O
xldcm B-Disease
patients O
from O
two O
unrelated O
japanese O
families O
. O

the O
insertion O
was O
a O
5 O
- O
truncated O
form O
of O
human O
l1 O
inversely O
integrated O
in O
the O
5 O
- O
untranslated O
region O
in O
the O
muscle O
exon O
1 O
, O
which O
affected O
the O
transcription O
or O
the O
stability O
of O
the O
muscle O
form O
of O
dystrophin O
transcripts O
but O
not O
that O
of O
the O
brain O
or O
purkinje O
cell O
form O
, O
probably O
due O
to O
its O
unique O
site O
of O
integration O
. O

we O
speculate O
that O
this O
insertion O
of O
an O
l1 O
sequence O
in O
dmd O
is O
responsible O
for O
some O
of O
the O
population O
of O
japanese O
patients O
with O
xldcm B-Disease
. O

. O

severe O
early O
- O
onset O
obesity B-Disease
, O
adrenal B-Disease
insufficiency B-Disease
and O
red O
hair O
pigmentation O
caused O
by O
pomc O
mutations O
in O
humans O
. O

sequential O
cleavage O
of O
the O
precursor O
protein O
pre O
- O
pro O
- O
opiomelanocortin O
( O
pomc O
) O
generates O
the O
melanocortin O
peptides O
adrenocorticotrophin O
( O
acth O
) O
, O
melanocyte O
- O
stimulating O
hormones O
( O
msh O
) O
alpha O
, O
beta O
and O
gamma O
as O
well O
as O
the O
opioid O
- O
receptor O
ligand O
beta O
- O
endorphin O
. O

while O
a O
few O
cases O
of O
isolated O
acth B-Disease
deficiency B-Disease
have O
been O
reported O
( O
omim O
201400 O
) O
, O
an O
inherited O
pomc O
defect O
has O
not O
been O
described O
so O
far O
. O

recent O
studies O
in O
animal O
models O
elucidated O
a O
central O
role O
of O
alpha O
- O
msh O
in O
the O
regulation O
of O
food O
intake O
by O
activation O
of O
the O
brain O
melanocortin O
- O
4 O
- O
receptor O
( O
mc4 O
- O
r O
; O
refs O
3 O
- O
5 O
) O
and O
the O
linkage O
of O
human O
obesity B-Disease
to O
chromosome O
2 O
in O
close O
proximity O
to O
the O
pomc O
locus O
, O
led O
to O
the O
proposal O
of O
an O
association O
of O
pomc O
with O
human O
obesity B-Disease
. O

the O
dual O
role O
of O
alpha O
- O
msh O
in O
regulating O
food O
intake O
and O
influencing O
hair O
pigmentation O
predicts O
that O
the O
phenotype O
associated O
with O
a O
defect O
in O
pomc O
function O
would O
include O
obesity B-Disease
, O
alteration O
in O
pigmentation O
and O
acth B-Disease
deficiency B-Disease
. O

the O
observation O
of O
these O
symptoms O
in O
two O
probands O
prompted O
us O
to O
search O
for O
mutations O
within O
their O
pomc O
genes O
. O

patient O
1 O
was O
found O
to O
be O
a O
compound O
heterozygote O
for O
two O
mutations O
in O
exon O
3 O
( O
g7013t O
, O
c7133delta O
) O
which O
interfere O
with O
appropriate O
synthesis O
of O
acth O
and O
alpha O
- O
msh O
. O

patient O
2 O
was O
homozygous O
for O
a O
mutation O
in O
exon O
2 O
( O
c3804a O
) O
which O
abolishes O
pomc O
translation O
. O

these O
findings O
represent O
the O
first O
examples O
of O
a O
genetic B-Disease
defect B-Disease
within O
the O
pomc O
gene O
and O
define O
a O
new O
monogenic B-Disease
endocrine B-Disease
disorder B-Disease
resulting O
in O
early O
- O
onset O
obesity B-Disease
, O
adrenal B-Disease
insufficiency B-Disease
and O
red O
hair O
pigmentation O
. O

. O

a O
european O
multicenter O
study O
of O
phenylalanine B-Disease
hydroxylase B-Disease
deficiency B-Disease
: O
classification O
of O
105 O
mutations O
and O
a O
general O
system O
for O
genotype O
- O
based O
prediction O
of O
metabolic O
phenotype O
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
and O
mild B-Disease
hyperphenylalaninemia B-Disease
( O
mhp B-Disease
) O
are O
allelic B-Disease
disorders B-Disease
caused O
by O
mutations O
in O
the O
gene O
encoding O
phenylalanine O
hydroxylase O
( O
pah O
) O
. O

previous O
studies O
have O
suggested O
that O
the O
highly O
variable O
metabolic O
phenotypes O
of O
pah B-Disease
deficiency B-Disease
correlate O
with O
pah O
genotypes O
. O

we O
identified O
both O
causative O
mutations O
in O
686 O
patients O
from O
seven O
european O
centers O
. O

on O
the O
basis O
of O
the O
phenotypic O
characteristics O
of O
297 O
functionally O
hemizygous O
patients O
, O
105 O
of O
the O
mutations O
were O
assigned O
to O
one O
of O
four O
arbitrary O
phenotype O
categories O
. O

we O
proposed O
and O
tested O
a O
simple O
model O
for O
correlation O
between O
genotype O
and O
phenotypic O
outcome O
. O

the O
observed O
phenotype O
matched O
the O
predicted O
phenotype O
in O
79 O
% O
of O
the O
cases O
, O
and O
in O
only O
5 O
of O
184 O
patients O
was O
the O
observed O
phenotype O
more O
than O
one O
category O
away O
from O
that O
expected O
. O

among O
the O
seven O
contributing O
centers O
, O
the O
proportion O
of O
patients O
for O
whom O
the O
observed O
phenotype O
did O
not O
match O
the O
predicted O
phenotype O
was O
4 O
% O
- O
23 O
% O
( O
p O
< O
. O

0001 O
) O
, O
suggesting O
that O
differences O
in O
methods O
used O
for O
mutation O
detection O
or O
phenotype O
classification O
may O
account O
for O
a O
considerable O
proportion O
of O
genotype O
- O
phenotype O
inconsistencies O
. O

our O
data O
indicate O
that O
the O
pah O
- O
mutation O
genotype O
is O
the O
main O
determinant O
of O
metabolic O
phenotype O
in O
most O
patients O
with O
pah B-Disease
deficiency B-Disease
. O

in O
the O
present O
study O
, O
the O
classification O
of O
105 O
pah O
mutations O
may O
allow O
the O
prediction O
of O
the O
biochemical O
phenotype O
in O
> O
10 O
, O
000 O
genotypes O
, O
which O
may O
be O
useful O
for O
the O
management O
of O
hyperphenylalaninemia B-Disease
in O
newborns O
. O

somatic O
instability O
of O
the O
ctg O
repeat O
in O
mice O
transgenic O
for O
the O
myotonic B-Disease
dystrophy B-Disease
region O
is O
age O
dependent O
but O
not O
correlated O
to O
the O
relative O
intertissue O
transcription O
levels O
and O
proliferative O
capacities O
. O

a O
( O
ctg O
) O
nexpansion O
in O
the O
3 O
- O
untranslated O
region O
( O
utr O
) O
of O
the O
dm O
protein O
kinase O
gene O
( O
dmpk O
) O
is O
responsible O
for O
causing O
myotonic B-Disease
dystrophy B-Disease
( O
dm B-Disease
) O
. O

major O
instability O
, O
with O
very O
large O
expansions O
between O
generations O
and O
high O
levels O
of O
somatic O
mosaicism O
, O
is O
observed O
in O
patients O
. O

there O
is O
a O
good O
correlation O
between O
repeat O
size O
( O
at O
least O
in O
leucocytes O
) O
, O
clinical O
severity O
and O
age O
of O
onset O
. O

the O
trinucleotide O
repeat O
instability O
mechanisms O
involved O
in O
dm B-Disease
and O
other O
human O
genetic B-Disease
diseases B-Disease
are O
unknown O
. O

we O
studied O
somatic O
instability O
by O
measuring O
the O
ctg O
repeat O
length O
at O
several O
ages O
in O
various O
tissues O
of O
transgenic O
mice O
carrying O
a O
( O
ctg O
) O
55expansion O
surrounded O
by O
45 O
kb O
of O
the O
human O
dm B-Disease
region O
, O
using O
small O
- O
pool O
pcr O
. O

these O
mice O
have O
been O
shown O
to O
reproduce O
the O
intergenerational O
and O
somatic O
instability O
of O
the O
55 O
ctg O
repeat O
suggesting O
that O
surrounding O
sequences O
and O
the O
chromatin O
environment O
are O
involved O
in O
instability O
mechanisms O
. O

as O
observed O
in O
some O
of O
the O
tissues O
of O
dm B-Disease
patients O
, O
there O
is O
a O
tendency O
for O
repeat O
length O
and O
somatic O
mosaicism O
to O
increase O
with O
the O
age O
of O
the O
mouse O
. O

furthermore O
, O
we O
observed O
no O
correlation O
between O
the O
somatic O
mutation O
rate O
and O
tissue O
proliferation O
capacity O
. O

the O
somatic O
mutation O
rates O
in O
different O
tissues O
were O
also O
not O
correlated O
to O
the O
relative O
inter O
- O
tissue O
difference O
in O
transcriptional O
levels O
of O
the O
three O
genes O
( O
dmahp O
, O
dmpk O
and O
59 O
) O
surrounding O
the O
repeat O
. O

. O

a O
novel O
missense O
mutation O
in O
patients O
from O
a O
retinoblastoma B-Disease
pedigree O
showing O
only O
mild O
expression O
of O
the O
tumor B-Disease
phenotype O
. O

we O
have O
used O
single O
strand O
conformation O
polymorphism O
analysis O
to O
study O
the O
27 O
exons O
of O
the O
rb1 O
gene O
in O
individuals O
from O
a O
family O
showing O
mild O
expression O
of O
the O
retinoblastoma B-Disease
phenotype O
. O

in O
this O
family O
affected O
individuals O
developed O
unilateral B-Disease
tumors B-Disease
and O
, O
as O
a O
result O
of O
linkage O
analysis O
, O
unaffected O
mutation O
carriers O
were O
also O
identified O
within O
the O
pedigree O
. O

a O
single O
band O
shift O
using O
sscp O
was O
identified O
in O
exon O
21 O
which O
resulted O
in O
a O
missense O
mutation O
converting O
a O
cys O
- O
- O
> O
arg O
at O
nucleotide O
position O
28 O
in O
the O
exon O
. O

the O
mutation O
destroyed O
an O
ndei O
restriction O
enzyme O
site O
. O

analysis O
of O
all O
family O
members O
demonstrated O
that O
the O
missense O
mutation O
co O
- O
segregated O
with O
patients O
with O
tumors B-Disease
or O
who O
, O
as O
a O
result O
of O
linkage O
analysis O
had O
been O
predicted O
to O
carry O
the O
predisposing O
mutation O
. O

these O
observations O
point O
to O
another O
region O
of O
the O
rb1 O
gene O
where O
mutations O
only O
modify O
the O
function O
of O
the O
gene O
and O
raise O
important O
questions O
for O
genetic O
counseling O
in O
families O
with O
these O
distinctive O
phenotypes O
. O

. O

maternal B-Disease
disomy B-Disease
and O
prader B-Disease
- B-Disease
willi B-Disease
syndrome B-Disease
consistent O
with O
gamete O
complementation O
in O
a O
case O
of O
familial O
translocation O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O

2 O
) O
. O

maternal B-Disease
uniparental B-Disease
disomy B-Disease
( B-Disease
upd B-Disease
) B-Disease
for B-Disease
chromosome B-Disease
15 B-Disease
is O
responsible O
for O
an O
estimated O
30 O
% O
of O
cases O
of O
prader B-Disease
- B-Disease
willi B-Disease
syndrome B-Disease
( O
pws B-Disease
) O
. O

we O
report O
on O
an O
unusual O
case O
of O
maternal B-Disease
disomy B-Disease
15 B-Disease
in O
pws B-Disease
that O
is O
most O
consistent O
with O
adjacent O
- O
1 O
segregation O
of O
a O
paternal O
t O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O

2 O
) O
with O
simultaneous O
maternal O
meiotic O
nondisjunction O
for O
chromosome O
15 O
. O

the O
patient O
( O
j O
. O

b O
. O

) O
, O
a O
17 O
- O
year O
- O
old O
white O
male O
with O
pws B-Disease
, O
was O
found O
to O
have O
47 O
chromosomes O
with O
a O
supernumerary O
, O
paternal O
der O
( O
15 O
) O
consisting O
of O
the O
short O
arm O
and O
the O
proximal O
long O
arm O
of O
chromosome O
15 O
, O
and O
distal O
chromosome O
arm O
3p O
. O

the O
t O
( O
3 O
; O
15 O
) O
was O
present O
in O
the O
balanced O
state O
in O
the O
patients O
father O
and O
a O
sister O
. O

fluorescent O
in O
situ O
hybridization O
analysis O
demonstrated O
that O
the O
pws B-Disease
critical O
region O
resided O
on O
the O
derivative O
chromosome O
3 O
and O
that O
there O
was O
no O
deletion O
of O
the O
pws B-Disease
region O
on O
the O
normal O
pair O
of O
15s O
present O
in O
j O
. O

b O
. O

methylation O
analysis O
at O
exon O
alpha O
of O
the O
small O
nuclear O
ribonucleoprotein O
- O
associated O
polypeptide O
n O
( O
snrpn O
) O
gene O
showed O
a O
pattern O
characteristic O
of O
only O
the O
maternal O
chromosome O
15 O
in O
j O
. O

b O
. O

maternal B-Disease
disomy B-Disease
was O
confirmed O
by O
polymerase O
chain O
reaction O
analysis O
of O
microsatellite O
repeats O
at O
the O
gamma O
- O
aminobutyric O
acid O
receptor O
beta3 O
subunit O
( O
gabrb3 O
) O
locus O
. O

a O
niece O
( O
b O
. O

b O
. O

) O
with O
45 O
chromosomes O
and O
the O
derivative O
3 O
but O
without O
the O
der O
( O
15 O
) O
demonstrated O
a O
phenotype O
consistent O
with O
that O
reported O
for O
haploinsufficiency O
of O
distal O
3 O
p O
. O

uniparental B-Disease
disomy B-Disease
associated O
with O
unbalanced O
segregation O
of O
non O
- O
robertsonian O
translocations O
has O
been O
reported O
previously O
but O
has O
not O
, O
to O
our O
knowledge O
, O
been O
observed O
in O
a O
case O
of O
pws B-Disease
. O

furthermore O
, O
our O
findings O
are O
best O
interpreted O
as O
true O
gamete O
complementation O
resulting O
in O
maternal B-Disease
upd B-Disease
15 B-Disease
and O
pws B-Disease
schwartz B-Disease
- B-Disease
jampel B-Disease
syndrome B-Disease
type B-Disease
2 B-Disease
and O
stuve B-Disease
- B-Disease
wiedemann B-Disease
syndrome B-Disease
: O
a O
case O
for O
lumping O
. O

recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
schwartz B-Disease
- B-Disease
jampel B-Disease
syndrome B-Disease
( O
sjs B-Disease
) O
of O
myotonia B-Disease
and O
skeletal B-Disease
dysplasia B-Disease
, O
which O
we O
called O
sjs B-Disease
type B-Disease
2 B-Disease
. O

this O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
stuve B-Disease
- B-Disease
wiedemann B-Disease
syndrome B-Disease
( O
sws B-Disease
) O
, O
which O
comprises O
campomelia B-Disease
at O
birth O
with O
skeletal B-Disease
dysplasia B-Disease
, O
contractures B-Disease
, O
and O
early B-Disease
death B-Disease
. O

to O
test O
for O
possible O
nosologic O
identity O
between O
these O
disorders O
, O
we O
reviewed O
the O
literature O
and O
obtained O
a O
follow O
- O
up O
of O
the O
only O
two O
surviving O
patients O
, O
one O
with O
sjs B-Disease
type B-Disease
2 B-Disease
at O
age O
10 O
years O
and O
another O
with O
sws B-Disease
at O
age O
7 O
years O
. O

patients O
reported O
as O
having O
either O
neonatal O
sjs B-Disease
or O
sws B-Disease
presented O
a O
combination O
of O
a O
severe O
, O
prenatal O
- O
onset O
neuromuscular B-Disease
disorder B-Disease
( O
with O
congenital B-Disease
joint B-Disease
contractures B-Disease
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
hyperthermia B-Disease
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
campomelic B-Disease
- B-Disease
metaphyseal B-Disease
skeletal B-Disease
dysplasia B-Disease
. O

the O
similarity O
of O
the O
clinical O
and O
radiographic O
findings O
is O
so O
extensive O
that O
these O
disorders O
appear O
to O
be O
a O
single O
entity O
. O

the O
follow O
- O
up O
observation O
of O
an O
identical O
and O
unique O
pattern O
of O
progressive O
bone B-Disease
dysplasia B-Disease
in O
the O
two O
patients O
( O
one O
with O
sjs B-Disease
type B-Disease
2 B-Disease
, O
one O
with O
sws B-Disease
) O
surviving O
beyond O
infancy O
adds O
to O
the O
evidence O
in O
favor O
of O
identity O
. O

the O
hypothesis O
that O
sws B-Disease
and O
sjs B-Disease
type B-Disease
2 B-Disease
are O
the O
same O
disorder O
should O
be O
testable O
by O
molecular O
methods O
. O

. O

a O
mouse O
model O
of O
severe O
von B-Disease
willebrand B-Disease
disease B-Disease
: O
defects O
in O
hemostasis O
and O
thrombosis B-Disease
. O

von B-Disease
willebrand B-Disease
factor B-Disease
( B-Disease
vwf B-Disease
) B-Disease
deficiency B-Disease
causes O
severe O
von B-Disease
willebrand B-Disease
disease B-Disease
in O
humans O
. O

we O
generated O
a O
mouse O
model O
for O
this O
disease O
by O
using O
gene O
targeting O
. O

vwf B-Disease
- B-Disease
deficient B-Disease
mice O
appeared O
normal O
at O
birth O
; O
they O
were O
viable O
and O
fertile O
. O

neither O
vwf O
nor O
vwf O
propolypeptide O
( O
von B-Disease
willebrand B-Disease
antigen O
ii O
) O
were O
detectable O
in O
plasma O
, O
platelets O
, O
or O
endothelial O
cells O
of O
the O
homozygous O
mutant O
mice O
. O

the O
mutant O
mice O
exhibited O
defects O
in O
hemostasis O
with O
a O
highly O
prolonged O
bleeding O
time O
and O
spontaneous O
bleeding O
events O
in O
approximately O
10 O
% O
of O
neonates O
. O

as O
in O
the O
human O
disease O
, O
the O
factor O
viii O
level O
in O
these O
mice O
was O
reduced O
strongly O
as O
a O
result O
of O
the O
lack O
of O
protection O
provided O
by O
vwf O
. O

defective O
thrombosis B-Disease
in O
mutant O
mice O
was O
also O
evident O
in O
an O
in O
vivo O
model O
of O
vascular B-Disease
injury B-Disease
. O

in O
this O
model O
, O
the O
exteriorized O
mesentery O
was O
superfused O
with O
ferric O
chloride O
and O
the O
accumulation O
of O
fluorescently O
labeled O
platelets O
was O
observed O
by O
intravital O
microscopy O
. O

we O
conclude O
that O
these O
mice O
very O
closely O
mimic O
severe O
human O
von B-Disease
willebrand B-Disease
disease B-Disease
and O
will O
be O
very O
useful O
for O
investigating O
the O
role O
of O
vwf O
in O
normal O
physiology O
and O
in O
disease O
models O
. O

. O

oral O
contraceptives O
and O
the O
risk O
of O
hereditary B-Disease
ovarian B-Disease
cancer B-Disease
. O

hereditary B-Disease
ovarian B-Disease
cancer B-Disease
clinical O
study O
group O
. O

background O
women O
with O
mutations O
in O
either O
the O
brca1 O
or O
the O
brca2 O
gene O
have O
a O
high O
lifetime O
risk O
of O
ovarian B-Disease
cancer B-Disease
. O

oral O
contraceptives O
protect O
against O
ovarian B-Disease
cancer B-Disease
in O
general O
, O
but O
it O
is O
not O
known O
whether O
they O
also O
protect O
against O
hereditary B-Disease
forms B-Disease
of B-Disease
ovarian B-Disease
cancer B-Disease
. O

methods O
we O
enrolled O
207 O
women O
with O
hereditary B-Disease
ovarian B-Disease
cancer B-Disease
and O
161 O
of O
their O
sisters O
as O
controls O
in O
a O
case O
- O
control O
study O
. O

all O
the O
patients O
carried O
a O
pathogenic O
mutation O
in O
either O
brca1 O
( O
179 O
women O
) O
or O
brca2 O
( O
28 O
women O
) O
. O

the O
control O
women O
were O
enrolled O
regardless O
of O
whether O
or O
not O
they O
had O
either O
mutation O
. O

lifetime O
histories O
of O
oral O
- O
contraceptive O
use O
were O
obtained O
by O
interview O
or O
by O
written O
questionnaire O
and O
were O
compared O
between O
patients O
and O
control O
women O
, O
after O
adjustment O
for O
year O
of O
birth O
and O
parity O
. O

results O
the O
adjusted O
odds O
ratio O
for O
ovarian B-Disease
cancer B-Disease
associated O
with O
any O
past O
use O
of O
oral O
contraceptives O
was O
0 O
. O

5 O
( O
95 O
percent O
confidence O
interval O
, O
0 O
. O

3 O
to O
0 O
. O

8 O
) O
. O

the O
risk O
decreased O
with O
increasing O
duration O
of O
use O
( O
p O
for O
trend O
, O
< O
0 O
. O

001 O
) O
; O
use O
for O
six O
or O
more O
years O
was O
associated O
with O
a O
60 O
percent O
reduction O
in O
risk O
. O

oral O
- O
contraceptive O
use O
protected O
against O
ovarian B-Disease
cancer B-Disease
both O
for O
carriers O
of O
the O
brca1 O
mutation O
( O
odds O
ratio O
, O
0 O
. O

5 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O

3 O
to O
0 O
. O

9 O
) O
and O
for O
carriers O
of O
the O
brca2 O
mutation O
( O
odds O
ratio O
, O
0 O
. O

4 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O

2 O
to O
1 O
. O

1 O
) O
. O

conclusions O
oral O
- O
contraceptive O
use O
may O
reduce O
the O
risk O
of O
ovarian B-Disease
cancer B-Disease
in O
women O
with O
pathogenic O
mutations O
in O
the O
brca1 O
or O
brca2 O
gene O
a O
japanese O
family O
with O
adrenoleukodystrophy B-Disease
with O
a O
codon O
291 O
deletion O
: O
a O
clinical O
, O
biochemical O
, O
pathological O
, O
and O
genetic O
report O
. O

we O
report O
a O
japanese O
family O
with O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
with O
a O
three O
base O
pair O
deletion O
( O
delgag O
291 O
) O
in O
the O
ald B-Disease
gene O
. O

a O
variety O
of O
phenotypes O
were O
observed O
within O
this O
family O
. O

while O
the O
proband O
( O
patient O
1 O
) O
was O
classified O
as O
having O
a O
rare O
intermediate O
type O
of O
adult O
cerebral O
and O
cerebello O
- O
brain O
stem O
forms O
, O
his O
younger O
brother O
( O
patient O
2 O
) O
and O
nephew O
( O
patient O
3 O
) O
had O
a O
childhood O
ald B-Disease
type O
. O

another O
nephew O
( O
patient O
4 O
) O
of O
patient O
1 O
was O
classified O
as O
having O
an O
adolescent O
form O
. O

the O
tau O
level O
in O
the O
cerebrospinal O
fluid O
( O
csf O
) O
in O
patient O
1 O
was O
as O
high O
as O
that O
of O
patients O
with O
alzheimers B-Disease
disease B-Disease
( O
ad B-Disease
) O
. O

his O
brain O
magnetic O
resonance O
image O
( O
mri O
) O
showed O
abnormalities B-Disease
in B-Disease
the B-Disease
bilateral B-Disease
cerebellar B-Disease
hemispheres B-Disease
and O
brain O
stem O
, O
but O
not O
in O
the O
cerebral O
white O
matter O
, O
where O
marked O
reductions O
of O
the O
cerebral O
blood O
flow O
and O
oxygen O
metabolism O
were O
clearly O
demonstrated O
by O
positron O
emission O
tomography O
( O
pet O
) O
. O

in O
patients O
2 O
and O
3 O
, O
the O
autopsy O
findings O
showed O
massive O
demyelination B-Disease
of B-Disease
the B-Disease
cerebral B-Disease
white B-Disease
matter B-Disease
with O
sparing O
of O
the O
u O
- O
fibers O
, O
compatible O
with O
the O
findings O
of O
childhood O
ald B-Disease
. O

oleic O
and O
erucic O
acids O
( O
lorenzos O
oil O
) O
were O
administered O
to O
patients O
1 O
and O
4 O
, O
but O
sufficient O
effectiveness O
was O
not O
obtained O
. O

the O
findings O
in O
this O
family O
suggest O
that O
delgag291 O
is O
part O
of O
the O
cause O
of O
japanese O
ald B-Disease
with O
phenotypic O
variations O
. O

moreover O
, O
although O
the O
scale O
of O
the O
study O
is O
limited O
, O
there O
is O
a O
possibility O
that O
pet O
can O
detect O
an O
insidious B-Disease
lesion B-Disease
which O
is O
undetectable O
by O
computed O
tomogram O
( O
ct O
) O
or O
mri O
analysis O
, O
and O
that O
the O
higher O
level O
of O
tau O
reflects O
the O
process O
of O
neuronal B-Disease
degeneration B-Disease
in O
ald B-Disease
. O

lorenzos O
oil O
should O
be O
given O
in O
the O
early O
stage O
. O

. O

nonsense O
mutation O
in O
exon O
4 O
of O
human O
complement O
c9 O
gene O
is O
the O
major O
cause O
of O
japanese O
complement B-Disease
c9 B-Disease
deficiency B-Disease
. O

deficiency B-Disease
of B-Disease
the B-Disease
ninth B-Disease
component B-Disease
of B-Disease
human B-Disease
complement B-Disease
( O
c9 O
) O
is O
the O
most O
common O
complement B-Disease
deficiency B-Disease
in O
japan O
but O
is O
rare O
in O
other O
countries O
. O

we O
studied O
the O
molecular O
basis O
of O
c9 B-Disease
deficiency B-Disease
in O
four O
japanese O
c9 B-Disease
- B-Disease
deficient B-Disease
patients O
who O
had O
suffered O
from O
meningococcal B-Disease
meningitis B-Disease
. O

direct O
sequencing O
of O
amplified O
c9 O
cdna O
and O
dna O
revealed O
a O
nonsense O
substitution O
( O
cga O
- O
- O
> O
tga O
) O
at O
codon O
95 O
in O
exon O
4 O
in O
the O
four O
c9 B-Disease
- B-Disease
deficient B-Disease
individuals O
. O

an O
allele O
- O
specific O
polymerase O
chain O
reaction O
system O
designed O
to O
detect O
exclusively O
only O
one O
of O
the O
normal O
and O
mutant O
alleles O
indicated O
that O
all O
the O
four O
patients O
were O
homozygous O
for O
the O
mutation O
in O
exon O
4 O
and O
that O
the O
parents O
of O
patient O
2 O
were O
heterozygous O
. O

the O
common O
mutation O
at O
codon O
95 O
in O
exon O
4 O
might O
be O
responsible O
for O
most O
japanese O
c9 B-Disease
deficiency B-Disease
. O

. O

brca1 O
required O
for O
transcription O
- O
coupled O
repair O
of O
oxidative O
dna O
damage O
. O

the O
breast B-Disease
and B-Disease
ovarian B-Disease
cancer B-Disease
susceptibility O
gene O
brca1 O
encodes O
a O
zinc O
finger O
protein O
of O
unknown O
function O
. O

association O
of O
the O
brca1 O
protein O
with O
the O
dna O
repair O
protein O
rad51 O
and O
changes O
in O
the O
phosphorylation O
and O
cellular O
localization O
of O
the O
protein O
after O
exposure O
to O
dna O
- O
damaging O
agents O
are O
consistent O
with O
a O
role O
for O
brca1 O
in O
dna O
repair O
. O

here O
, O
it O
is O
shown O
that O
mouse O
embryonic O
stem O
cells O
deficient B-Disease
in B-Disease
brca1 B-Disease
are O
defective O
in O
the O
ability O
to O
carry O
out O
transcription O
- O
coupled O
repair O
of O
oxidative O
dna O
damage O
, O
and O
are O
hypersensitive O
to O
ionizing O
radiation O
and O
hydrogen O
peroxide O
. O

these O
results O
suggest O
that O
brca1 O
participates O
, O
directly O
or O
indirectly O
, O
in O
transcription O
- O
coupled O
repair O
of O
oxidative O
dna O
damage O
. O

. O

truncation O
mutations O
in O
the O
transactivation O
region O
of O
pax6 O
result O
in O
dominant O
- O
negative O
mutants O
. O

pax6 O
is O
a O
transcription O
factor O
with O
two O
dna O
- O
binding O
domains O
( O
paired O
box O
and O
homeobox O
) O
and O
a O
proline O
- O
serine O
- O
threonine O
( O
pst O
) O
- O
rich O
transactivation O
domain O
. O

pax6 O
regulates O
eye O
development O
in O
animals O
ranging O
from O
jellyfish O
to O
drosophila O
to O
humans O
. O

heterozygous O
mutations O
in O
the O
human O
pax6 O
gene O
result O
in O
various O
phenotypes O
, O
including O
aniridia B-Disease
, O
peters B-Disease
anomaly B-Disease
, O
autosomal B-Disease
dominant B-Disease
keratitis B-Disease
, O
and O
familial B-Disease
foveal B-Disease
dysplasia B-Disease
. O

it O
is O
believed O
that O
the O
mutated O
allele O
of O
pax6 O
produces O
an O
inactive O
protein O
and O
aniridia B-Disease
is O
caused O
due O
to O
genetic O
haploinsufficiency O
. O

however O
, O
several O
truncation O
mutations O
have O
been O
found O
to O
occur O
in O
the O
c O
- O
terminal O
half O
of O
pax6 O
in O
patients O
with O
aniridia B-Disease
resulting O
in O
mutant O
proteins O
that O
retain O
the O
dna O
- O
binding O
domains O
but O
have O
lost O
most O
of O
the O
transactivation O
domain O
. O

it O
is O
not O
clear O
whether O
such O
mutants O
really O
behave O
as O
loss O
- O
of O
- O
function O
mutants O
as O
predicted O
by O
haploinsufficiency O
. O

contrary O
to O
this O
theory O
, O
our O
data O
showed O
that O
these O
mutants O
are O
dominant O
- O
negative O
in O
transient O
transfection O
assays O
when O
they O
are O
coexpressed O
with O
wild O
- O
type O
pax6 O
. O

we O
found O
that O
the O
dominant O
- O
negative O
effects O
result O
from O
the O
enhanced O
dna O
binding O
ability O
of O
these O
mutants O
. O

kinetic O
studies O
of O
binding O
and O
dissociation O
revealed O
that O
various O
truncation O
mutants O
have O
3 O
- O
5 O
- O
fold O
higher O
affinity O
to O
various O
dna O
- O
binding O
sites O
when O
compared O
with O
the O
wild O
- O
type O
pax6 O
. O

these O
results O
provide O
a O
new O
insight O
into O
the O
role O
of O
mutant O
pax6 O
in O
causing O
aniridia B-Disease
. O

. O

reversal O
of O
severe O
hypertrophic B-Disease
cardiomyopathy B-Disease
and O
excellent O
neuropsychologic O
outcome O
in O
very B-Disease
- B-Disease
long B-Disease
- B-Disease
chain B-Disease
acyl B-Disease
- B-Disease
coenzyme B-Disease
a B-Disease
dehydrogenase B-Disease
deficiency B-Disease
. O

very B-Disease
- B-Disease
long B-Disease
- B-Disease
chain B-Disease
acyl B-Disease
- B-Disease
coenzyme B-Disease
a B-Disease
dehydrogenase B-Disease
( B-Disease
vlcad B-Disease
) B-Disease
deficiency B-Disease
is O
a O
disorder O
of O
fatty O
acid O
beta O
oxidation O
that O
reportedly O
has O
high O
rates O
of O
morbidity O
and O
mortality O
. O

we O
describe O
the O
outcome O
of O
a O
5 O
- O
year O
- O
old O
girl O
with O
vlcad B-Disease
deficiency B-Disease
who O
was O
first O
seen O
at O
5 O
months O
of O
age O
with O
severe O
hypertrophic B-Disease
cardiomyopathy B-Disease
, O
hepatomegaly B-Disease
, O
encephalopathy B-Disease
, O
and O
hypotonia B-Disease
. O

biochemical O
studies O
indicated O
vlcad B-Disease
deficiency B-Disease
caused O
by O
a O
stable O
yet O
inactive O
enzyme O
. O

molecular O
genetic O
analysis O
of O
her O
vlcad O
gene O
revealed O
a O
t1372c O
( O
f458l O
) O
missense O
mutation O
and O
a O
1668 O
acag O
1669 O
splice O
site O
mutation O
. O

after O
initial O
treatment O
with O
intravenous O
glucose O
and O
carnitine O
, O
the O
patient O
has O
thrived O
on O
a O
low O
- O
fat O
diet O
supplemented O
with O
medium O
- O
chain O
triglyceride O
oil O
and O
carnitine O
and O
avoidance O
of O
fasting O
. O

her O
ventricular O
hypertrophy O
resolved O
significantly O
over O
1 O
year O
, O
and O
cognitively O
, O
she O
is O
in O
the O
superior O
range O
for O
age O
. O

clinical O
recognition O
of O
vlcad B-Disease
deficiency B-Disease
is O
important O
because O
it O
is O
one O
of O
the O
few O
directly O
treatable O
causes O
of O
cardiomyopathy B-Disease
in O
children O
. O

. O

cloning O
of O
a O
novel O
member O
of O
the O
low O
- O
density O
lipoprotein O
receptor O
family O
. O

a O
gene O
encoding O
a O
novel O
transmembrane O
protein O
was O
identified O
by O
dna O
sequence O
analysis O
within O
the O
insulin B-Disease
- B-Disease
dependent B-Disease
diabetes B-Disease
mellitus B-Disease
( O
iddm B-Disease
) O
locus O
iddm4 O
on O
chromosome O
11q13 O
. O

based O
on O
its O
chromosomal O
position O
, O
this O
gene O
is O
a O
candidate O
for O
conferring O
susceptibility O
to O
diabetes B-Disease
. O

the O
gene O
, O
termed O
low O
- O
density O
lipoprotein O
receptor O
related O
protein O
5 O
( O
lrp5 O
) O
, O
encodes O
a O
protein O
of O
1615 O
amino O
acids O
that O
contains O
conserved O
modules O
which O
are O
characteristic O
of O
the O
low O
- O
density O
lipoprotein O
( O
ldl O
) O
receptor O
family O
. O

these O
modules O
include O
a O
putative O
signal O
peptide O
for O
protein O
export O
, O
four O
epidermal O
growth O
factor O
( O
egf O
) O
repeats O
with O
associated O
spacer O
domains O
, O
three O
ldl O
- O
receptor O
( O
ldlr O
) O
repeats O
, O
a O
single O
transmembrane O
spanning O
domain O
, O
and O
a O
cytoplasmic O
domain O
. O

the O
encoded O
protein O
has O
a O
unique O
organization O
of O
egf O
and O
ldlr O
repeats O
; O
therefore O
, O
lrp5 O
likely O
represents O
a O
new O
category O
of O
the O
ldlr O
family O
. O

both O
human O
and O
mouse O
lrp5 O
cdnas O
have O
been O
isolated O
and O
the O
encoded O
mature O
proteins O
are O
95 O
% O
identical O
, O
indicating O
a O
high O
degree O
of O
evolutionary O
conservation O
. O

. O

the O
apc B-Disease
variants O
i1307k O
and O
e1317q O
are O
associated O
with O
colorectal B-Disease
tumors B-Disease
, O
but O
not O
always O
with O
a O
family O
history O
. O

classical O
familial B-Disease
adenomatous B-Disease
polyposis B-Disease
( O
fap B-Disease
) O
is O
a O
high O
- O
penetrance O
autosomal B-Disease
dominant B-Disease
disease B-Disease
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B-Disease
adenomas B-Disease
and B-Disease
carcinoma B-Disease
and O
that O
results O
from O
truncating O
mutations O
in O
the O
apc B-Disease
gene O
. O

a O
variant O
of O
fap B-Disease
is O
attenuated B-Disease
adenomatous B-Disease
polyposis B-Disease
coli B-Disease
, O
which O
results O
from O
germ O
- O
line O
mutations O
in O
the O
5 O
and O
3 O
regions O
of O
the O
apc B-Disease
gene O
. O

attenuated B-Disease
adenomatous B-Disease
polyposis B-Disease
coli B-Disease
patients O
have O
multiple O
colorectal B-Disease
adenomas B-Disease
( O
typically O
fewer O
than O
100 O
) O
without O
the O
florid O
phenotype O
of O
classical O
fap B-Disease
. O

another O
group O
of O
patients O
with O
multiple O
adenomas B-Disease
has O
no O
mutations O
in O
the O
apc B-Disease
gene O
, O
and O
their O
phenotype O
probably O
results O
from O
variation O
at O
a O
locus O
, O
or O
loci O
, O
elsewhere O
in O
the O
genome O
. O

recently O
, O
however O
, O
a O
missense O
variant O
of O
apc B-Disease
( O
i1307k O
) O
was O
described O
that O
confers O
an O
increased O
risk O
of O
colorectal B-Disease
tumors B-Disease
, O
including O
multiple O
adenomas B-Disease
, O
in O
ashkenazim O
. O

we O
have O
studied O
a O
set O
of O
164 O
patients O
with O
multiple O
colorectal B-Disease
adenomas B-Disease
and B-Disease
/ B-Disease
or B-Disease
carcinoma B-Disease
and O
analyzed O
codons O
1263 O
- O
1377 O
( O
exon O
15g O
) O
of O
the O
apc B-Disease
gene O
for O
germ O
- O
line O
variants O
. O

three O
patients O
with O
the O
i1307k O
allele O
were O
detected O
, O
each O
of O
ashkenazi O
descent O
. O

four O
patients O
had O
a O
germ O
- O
line O
e1317q O
missense O
variant O
of O
apc O
that O
was O
not O
present O
in O
controls O
; O
one O
of O
these O
individuals O
had O
an O
unusually O
large O
number O
of O
metaplastic B-Disease
polyps B-Disease
of B-Disease
the B-Disease
colorectum B-Disease
. O

there O
is O
increasing O
evidence O
that O
there O
exist O
germ O
- O
line O
variants O
of O
the O
apc B-Disease
gene O
that O
predispose O
to O
the O
development O
of O
multiple O
colorectal B-Disease
adenomas B-Disease
and B-Disease
carcinoma B-Disease
, O
but O
without O
the O
florid O
phenotype O
of O
classical O
fap B-Disease
, O
and O
possibly O
with O
importance O
for O
colorectal B-Disease
cancer B-Disease
risk O
in O
the O
general O
population O
. O

. O

genomic O
structure O
of O
the O
human O
congenital B-Disease
chloride B-Disease
diarrhea B-Disease
( O
cld B-Disease
) O
gene O
. O

congenital B-Disease
chloride B-Disease
diarrhea B-Disease
( O
cld B-Disease
) O
is O
caused O
by O
mutations O
in O
a O
gene O
which O
encodes O
an O
intestinal O
anion O
transporter O
. O

we O
report O
here O
the O
complete O
genomic O
organization O
of O
the O
human O
cld B-Disease
gene O
which O
spans O
approximately O
39kb O
, O
and O
comprises O
21 O
exons O
. O

all O
exon O
/ O
intron O
boundaries O
conform O
to O
the O
gt O
/ O
ag O
rule O
. O

an O
analysis O
of O
the O
putative O
promoter O
region O
sequence O
shows O
a O
putative O
tata O
box O
and O
predicts O
multiple O
transcription O
factor O
binding O
sites O
. O

the O
genomic O
structure O
was O
determined O
using O
dna O
from O
several O
sources O
including O
multiple O
large O
- O
insert O
libaries O
and O
genomic O
dna O
from O
finnish O
cld B-Disease
patients O
and O
controls O
. O

exon O
- O
specific O
primers O
developed O
in O
this O
study O
will O
facilitate O
mutation O
screening O
studies O
of O
patients O
with O
the O
disease O
. O

genomic O
sequencing O
of O
a O
bac O
clone O
h O
_ O
rg364p16 O
revealed O
the O
presence O
of O
another O
, O
highly O
homologous O
gene O
3 O
of O
the O
cld B-Disease
gene O
, O
with O
a O
similar O
genomic O
structure O
, O
recently O
identified O
as O
the O
pendred B-Disease
syndrome B-Disease
gene O
( O
pds B-Disease
) O
. O

. O

the O
apci1307k O
allele O
and O
cancer B-Disease
risk O
in O
a O
community O
- O
based O
study O
of O
ashkenazi O
jews O
. O

mutations O
in O
apc O
are O
classically O
associated O
with O
familial B-Disease
adenomatous B-Disease
polyposis B-Disease
( O
fap B-Disease
) O
, O
a O
highly O
penetrant O
autosomal B-Disease
dominant B-Disease
disorder B-Disease
characterized O
by O
multiple O
intestinal O
polyps B-Disease
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B-Disease
cancer B-Disease
( O
crc B-Disease
) O
. O

apc B-Disease
is O
a O
tumour O
- O
suppressor O
gene O
, O
and O
somatic O
loss O
occurs O
in O
tumours B-Disease
. O

the O
germline O
t O
- O
to O
- O
a O
transversion O
responsible O
for O
the O
apc O
i1307k O
allele O
converts O
the O
wild O
- O
type O
sequence O
to O
a O
homopolymer O
tract O
( O
a8 O
) O
that O
is O
genetically O
unstable O
and O
prone O
to O
somatic O
mutation O
. O

the O
i1307k O
allele O
was O
found O
in O
6 O
. O

1 O
% O
of O
unselected O
ashkenazi O
jews O
and O
higher O
proportions O
of O
ashkenazim O
with O
family O
or O
personal O
histories O
of O
crc B-Disease
( O
ref O
. O

2 O
) O
. O

to O
evaluate O
the O
role O
of O
i1307k O
in O
cancer B-Disease
, O
we O
genotyped O
5 O
, O
081 O
ashkenazi O
volunteers O
in O
a O
community O
survey O
. O

risk O
of O
developing O
colorectal B-Disease
, B-Disease
breast B-Disease
and B-Disease
other B-Disease
cancers B-Disease
were O
compared O
between O
genotyped O
i1307k O
carriers O
and O
non O
- O
carriers O
and O
their O
first O
- O
degree O
relatives O
. O

sperm O
dna O
analysis O
in O
a O
friedreich B-Disease
ataxia B-Disease
premutation O
carrier O
suggests O
both O
meiotic O
and O
mitotic O
expansion O
in O
the O
frda B-Disease
gene O
. O

friedreich B-Disease
ataxia B-Disease
is O
usually O
caused O
by O
an O
expansion O
of O
a O
gaa O
trinucleotide O
repeat O
in O
intron O
1 O
of O
the O
frda B-Disease
gene O
. O

occasionally O
, O
a O
fully O
expanded O
allele O
has O
been O
found O
to O
arise O
from O
a O
premutation O
of O
100 O
or O
less O
triplet O
repeats O
. O

we O
have O
examined O
the O
sperm O
dna O
of O
a O
premutation O
carrier O
. O

this O
mans O
leucocyte O
dna O
showed O
one O
normal O
allele O
and O
one O
allele O
of O
approximately O
100 O
repeats O
. O

his O
sperm O
showed O
an O
expanded O
allele O
in O
a O
tight O
range O
centering O
on O
a O
size O
of O
approximately O
320 O
trinucleotide O
repeats O
. O

his O
affected O
son O
has O
repeat O
sizes O
of O
1040 O
and O
540 O
. O

these O
data O
suggest O
that O
expansion O
occurs O
in O
two O
stages O
, O
the O
first O
during O
meiosis O
followed O
by O
a O
second O
mitotic O
expansion O
. O

we O
also O
show O
that O
in O
all O
informative O
carrier O
father O
to O
affected O
child O
transmissions O
, O
with O
the O
notable O
exception O
of O
the O
premutation O
carrier O
, O
the O
expansion O
size O
decreases O
. O

. O

the O
r496h O
mutation O
of O
arylsulfatase O
a O
does O
not O
cause O
metachromatic B-Disease
leukodystrophy B-Disease
. O

deficiency B-Disease
of B-Disease
arylsulfatase B-Disease
a B-Disease
( O
arsa O
) O
enzyme O
activity O
causes O
metachromatic B-Disease
leukodystrophy B-Disease
( O
mld B-Disease
) O
. O

a O
number O
of O
arsa O
gene O
mutations O
responsible O
for O
mld B-Disease
have O
been O
identified O
. O

recently O
, O
the O
r496h O
mutation O
of O
arsa O
was O
proposed O
to O
be O
a O
cause O
of O
mld B-Disease
( O
draghia O
et O
al O
. O

, O
1997 O
) O
. O

we O
have O
investigated O
the O
r496h O
mutation O
and O
found O
this O
mutation O
at O
a O
relatively O
high O
frequency O
in O
an O
african O
american O
population O
( O
f O
= O
0 O
. O

09 O
, O
n O
= O
61 O
subjects O
) O
. O

the O
arsa O
enzyme O
activity O
in O
subjects O
with O
and O
without O
the O
r496h O
mutation O
was O
determined O
and O
found O
to O
be O
normal O
. O

it O
is O
therefore O
concluded O
that O
the O
r496h O
mutation O
of O
arsa O
does O
not O
negatively O
influence O
the O
activity O
of O
arsa O
and O
is O
not O
a O
cause O
of O
mld B-Disease
down O
- O
regulation O
of O
transmembrane O
carbonic O
anhydrases O
in O
renal B-Disease
cell B-Disease
carcinoma B-Disease
cell O
lines O
by O
wild O
- O
type O
von B-Disease
hippel B-Disease
- B-Disease
lindau B-Disease
transgenes O
. O

to O
discover O
genes O
involved O
in O
von B-Disease
hippel B-Disease
- B-Disease
lindau B-Disease
( O
vhl B-Disease
) O
- O
mediated O
carcinogenesis O
, O
we O
used O
renal B-Disease
cell B-Disease
carcinoma B-Disease
cell O
lines O
stably O
transfected O
with O
wild O
- O
type O
vhl O
- O
expressing O
transgenes O
. O

large O
- O
scale O
rna O
differential O
display O
technology O
applied O
to O
these O
cell O
lines O
identified O
several O
differentially O
expressed O
genes O
, O
including O
an O
alpha O
carbonic O
anhydrase O
gene O
, O
termed O
ca12 O
. O

the O
deduced O
protein O
sequence O
was O
classified O
as O
a O
one O
- O
pass O
transmembrane O
ca O
possessing O
an O
apparently O
intact O
catalytic O
domain O
in O
the O
extracellular O
ca O
module O
. O

reintroduced O
wild O
- O
type O
vhl B-Disease
strongly O
inhibited O
the O
overexpression O
of O
the O
ca12 O
gene O
in O
the O
parental O
renal B-Disease
cell B-Disease
carcinoma B-Disease
cell O
lines O
. O

similar O
results O
were O
obtained O
with O
ca9 O
, O
encoding O
another O
transmembrane O
ca O
with O
an O
intact O
catalytic O
domain O
. O

although O
both O
domains O
of O
the O
vhl B-Disease
protein O
contribute O
to O
regulation O
of O
ca12 O
expression O
, O
the O
elongin O
binding O
domain O
alone O
could O
effectively O
regulate O
ca9 O
expression O
. O

we O
mapped O
ca12 O
and O
ca9 O
loci O
to O
chromosome O
bands O
15q22 O
and O
17q21 O
. O

2 O
respectively O
, O
regions O
prone O
to O
amplification O
in O
some O
human O
cancers B-Disease
. O

additional O
experiments O
are O
needed O
to O
define O
the O
role O
of O
ca O
ix O
and O
ca O
xii O
enzymes O
in O
the O
regulation O
of O
ph O
in O
the O
extracellular O
microenvironment O
and O
its O
potential O
impact O
on O
cancer B-Disease
cell O
growth O
. O

a O
gene O
encoding O
a O
transmembrane O
protein O
is O
mutated O
in O
patients O
with O
diabetes B-Disease
mellitus B-Disease
and O
optic B-Disease
atrophy B-Disease
( O
wolfram B-Disease
syndrome B-Disease
) O
. O

wolfram B-Disease
syndrome B-Disease
( O
wfs B-Disease
; O
omim O
222300 O
) O
is O
an O
autosomal B-Disease
recessive B-Disease
neurodegenerative B-Disease
disorder B-Disease
defined O
by O
young O
- O
onset O
non O
- O
immune O
insulin B-Disease
- B-Disease
dependent B-Disease
diabetes B-Disease
mellitus B-Disease
and O
progressive O
optic B-Disease
atrophy B-Disease
. O

linkage O
to O
markers O
on O
chromosome O
4p O
was O
confirmed O
in O
five O
families O
. O

on O
the O
basis O
of O
meiotic O
recombinants O
and O
disease O
- O
associated O
haplotypes O
, O
the O
wfs B-Disease
gene O
was O
localized O
to O
a O
bac O
/ O
p1 O
contig O
of O
less O
than O
250 O
kb O
. O

mutations O
in O
a O
novel O
gene O
( O
wfs1 O
) O
encoding O
a O
putative O
transmembrane O
protein O
were O
found O
in O
all O
affected O
individuals O
in O
six O
wfs B-Disease
families O
, O
and O
these O
mutations O
were O
associated O
with O
the O
disease O
phenotype O
. O

wfs1 O
appears O
to O
function O
in O
survival O
of O
islet O
beta O
- O
cells O
and O
neurons O
. O

. O

stable O
interaction O
between O
the O
products O
of O
the O
brca1 O
and O
brca2 O
tumor B-Disease
suppressor O
genes O
in O
mitotic O
and O
meiotic O
cells O
. O

brca1 O
and O
brca2 O
account O
for O
most O
cases O
of O
familial O
, O
early O
onset O
breast B-Disease
and B-Disease
/ B-Disease
or B-Disease
ovarian B-Disease
cancer B-Disease
and O
encode O
products O
that O
each O
interact O
with O
hrad51 O
. O

results O
presented O
here O
show O
that O
brca1 O
and O
brca2 O
coexist O
in O
a O
biochemical O
complex O
and O
colocalize O
in O
subnuclear O
foci O
in O
somatic O
cells O
and O
on O
the O
axial O
elements O
of O
developing O
synaptonemal O
complexes O
. O

like O
brca1 O
and O
rad51 O
, O
brca2 O
relocates O
to O
pcna O
+ O
replication O
sites O
following O
exposure O
of O
s O
phase O
cells O
to O
hydroxyurea O
or O
uv O
irradiation O
. O

thus O
, O
brca1 O
and O
brca2 O
participate O
, O
together O
, O
in O
a O
pathway O
( O
s O
) O
associated O
with O
the O
activation O
of O
double O
- O
strand O
break O
repair O
and O
/ O
or O
homologous O
recombination O
. O

dysfunction O
of O
this O
pathway O
may O
be O
a O
general O
phenomenon O
in O
the O
majority O
of O
cases O
of O
hereditary B-Disease
breast B-Disease
and B-Disease
/ B-Disease
or B-Disease
ovarian B-Disease
cancer B-Disease
. O

. O

a O
novel O
arg362ser O
mutation O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
cyp27 O
) O
: O
its O
effects O
on O
pre O
- O
mrna O
splicing O
and O
enzyme O
activity O
. O

a O
novel O
c O
to O
a O
mutation O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
cyp27 O
) O
was O
identified O
by O
sequencing O
amplified O
cyp27 O
gene O
products O
from O
a O
patient O
with O
cerebrotendinous B-Disease
xanthomatosis B-Disease
( O
ctx B-Disease
) O
. O

the O
mutation O
changed O
the O
adrenodoxin O
cofactor O
binding O
residue O
362arg O
to O
362ser O
( O
cgt O
362arg O
to O
agt O
362ser O
) O
, O
and O
was O
responsible O
for O
deficiency O
in O
the O
sterol O
27 O
- O
hydroxylase O
activity O
, O
as O
confirmed O
by O
expression O
of O
mutant O
cdna O
into O
cos O
- O
1 O
cells O
. O

quantitative O
analysis O
showed O
that O
the O
expression O
of O
cyp27 O
gene O
mrna O
in O
the O
patient O
represented O
52 O
. O

5 O
% O
of O
the O
normal O
level O
. O

as O
the O
mutation O
occurred O
at O
the O
penultimate O
nucleotide O
of O
exon O
6 O
( O
- O
2 O
position O
of O
exon O
6 O
- O
intron O
6 O
splice O
site O
) O
of O
the O
gene O
, O
we O
hypothesized O
that O
the O
mutation O
may O
partially O
affect O
the O
normal O
splicing O
efficiency O
in O
exon O
6 O
and O
cause O
alternative O
splicing O
elsewhere O
, O
which O
resulted O
in O
decreased O
transcript O
in O
the O
patient O
. O

transfection O
of O
constructed O
minigenes O
, O
with O
or O
without O
the O
mutation O
, O
into O
cos O
- O
1 O
cells O
confirmed O
that O
the O
mutant O
minigene O
was O
responsible O
for O
a O
mrna O
species O
alternatively O
spliced O
at O
an O
activated O
cryptic O
5 O
splice O
site O
88 O
bp O
upstream O
from O
the O
3 O
end O
of O
exon O
6 O
. O

our O
data O
suggest O
that O
the O
c O
to O
a O
mutation O
at O
the O
penultimate O
nucleotide O
of O
exon O
6 O
of O
the O
cyp27 O
gene O
not O
only O
causes O
the O
deficiency B-Disease
in B-Disease
the B-Disease
sterol B-Disease
27 B-Disease
- B-Disease
hydroxylase B-Disease
activity B-Disease
, O
but O
also O
partially O
leads O
to O
alternative O
pre O
- O
mrna O
splicing O
of O
the O
gene O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
regarding O
effects O
on O
pre O
- O
mrna O
splicing O
of O
a O
mutation O
at O
the O
- O
2 O
position O
of O
a O
5 O
splice O
site O
. O

atm O
germline O
mutations O
in O
classical O
ataxia B-Disease
- B-Disease
telangiectasia B-Disease
patients O
in O
the O
dutch O
population O
. O

germline O
mutations O
in O
the O
atm O
gene O
are O
responsible O
for O
the O
autosomal B-Disease
recessive B-Disease
disorder B-Disease
ataxia B-Disease
- B-Disease
telangiectasia B-Disease
( O
a B-Disease
- B-Disease
t B-Disease
) O
. O

in O
our O
study O
, O
we O
have O
determined O
the O
atm O
mutation O
spectrum O
in O
19 O
classical O
a B-Disease
- B-Disease
t B-Disease
patients O
, O
including O
some O
immigrant O
populations O
, O
as O
well O
as O
12 O
of O
dutch O
ethnic O
origin O
. O

both O
the O
protein O
truncation O
test O
( O
ptt O
) O
and O
the O
restriction O
endonuclease O
fingerprinting O
( O
ref O
) O
method O
were O
used O
and O
compared O
for O
their O
detection O
efficiency O
, O
identifying O
76 O
% O
and O
60 O
% O
of O
the O
mutations O
, O
respectively O
. O

most O
patients O
were O
found O
to O
be O
compound O
heterozygote O
. O

seventeen O
mutations O
were O
distinct O
, O
of O
which O
10 O
were O
not O
reported O
previously O
. O

mutations O
are O
small O
deletions O
or O
point O
mutations O
frequently O
affecting O
splice O
sites O
. O

moreover O
, O
a O
16 O
. O

7 O
- O
kb O
genomic O
deletion O
of O
the O
3 O
end O
of O
the O
gene O
, O
most O
likely O
a O
result O
of O
recombination O
between O
two O
line O
elements O
, O
was O
identified O
. O

the O
most O
frequently O
found O
mutation O
, O
identified O
in O
three O
unrelated O
turkish O
a B-Disease
- B-Disease
t B-Disease
individuals O
, O
was O
previously O
described O
to O
be O
a O
turkish O
a B-Disease
- B-Disease
t B-Disease
founder O
mutation O
. O

the O
presence O
of O
a O
founder O
mutation O
among O
relatively O
small O
ethnic O
population O
groups O
in O
western O
europe O
could O
indicate O
a O
high O
carrier O
frequency O
in O
such O
communities O
. O

in O
patients O
of O
dutch O
ethnic O
origin O
, O
however O
, O
no O
significant O
founder O
effect O
could O
be O
identified O
. O

the O
observed O
genetic O
heterogeneity O
including O
the O
relative O
high O
percentage O
of O
splice O
- O
site O
mutations O
had O
no O
reflection O
on O
the O
phenotype O
. O

all O
patients O
manifested O
classical O
a B-Disease
- B-Disease
t B-Disease
and O
increased O
cellular O
radioresistant O
dna O
synthesis O
. O

determination O
of O
the O
genomic O
structure O
of O
the O
col4a4 O
gene O
and O
of O
novel O
mutations O
causing O
autosomal B-Disease
recessive B-Disease
alport B-Disease
syndrome B-Disease
. O

autosomal B-Disease
recessive B-Disease
alport B-Disease
syndrome B-Disease
is O
a O
progressive O
hematuric B-Disease
glomerulonephritis B-Disease
characterized O
by O
glomerular B-Disease
basement B-Disease
membrane B-Disease
abnormalities B-Disease
and O
associated O
with O
mutations O
in O
either O
the O
col4a3 O
or O
the O
col4a4 O
gene O
, O
which O
encode O
the O
alpha3 O
and O
alpha4 O
type O
iv O
collagen O
chains O
, O
respectively O
. O

to O
date O
, O
mutation O
screening O
in O
the O
two O
genes O
has O
been O
hampered O
by O
the O
lack O
of O
genomic O
structure O
information O
. O

we O
report O
here O
the O
complete O
characterization O
of O
the O
48 O
exons O
of O
the O
col4a4 O
gene O
, O
a O
comprehensive O
gene O
screen O
, O
and O
the O
subsequent O
detection O
of O
10 O
novel O
mutations O
in O
eight O
patients O
diagnosed O
with O
autosomal B-Disease
recessive B-Disease
alport B-Disease
syndrome B-Disease
. O

furthermore O
, O
we O
identified O
a O
glycine O
to O
alanine O
substitution O
in O
the O
collagenous O
domain O
that O
is O
apparently O
silent O
in O
the O
heterozygous O
carriers O
, O
in O
11 O
. O

5 O
% O
of O
all O
control O
individuals O
, O
and O
in O
one O
control O
individual O
homozygous O
for O
this O
glycine O
substitution O
. O

there O
has O
been O
no O
previous O
finding O
of O
a O
glycine O
substitution O
that O
is O
not O
associated O
with O
any O
obvious O
phenotype O
in O
homozygous O
individuals O
. O

founder O
brca1 O
and O
brca2 O
mutations O
in O
french O
canadian O
breast B-Disease
and B-Disease
ovarian B-Disease
cancer B-Disease
families O
. O

we O
have O
identified O
four O
mutations O
in O
each O
of O
the O
breast B-Disease
cancer B-Disease
- O
susceptibility O
genes O
, O
brca1 O
and O
brca2 O
, O
in O
french O
canadian O
breast B-Disease
cancer B-Disease
and O
breast B-Disease
/ B-Disease
ovarian B-Disease
cancer B-Disease
families O
from O
quebec O
. O

to O
identify O
founder O
effects O
, O
we O
examined O
independently O
ascertained O
french O
canadian O
cancer B-Disease
families O
for O
the O
distribution O
of O
these O
eight O
mutations O
. O

mutations O
were O
found O
in O
41 O
of O
97 O
families O
. O

six O
of O
eight O
mutations O
were O
observed O
at O
least O
twice O
. O

the O
brca1 O
c4446t O
mutation O
was O
the O
most O
common O
mutation O
found O
, O
followed O
by O
the O
brca2 O
8765delag O
mutation O
. O

together O
, O
these O
mutations O
were O
found O
in O
28 O
of O
41 O
families O
identified O
to O
have O
a O
mutation O
. O

the O
odds O
of O
detection O
of O
any O
of O
the O
four O
brca1 O
mutations O
was O
18 O
. O

7x O
greater O
if O
one O
or O
more O
cases O
of O
ovarian B-Disease
cancer B-Disease
were O
also O
present O
in O
the O
family O
. O

the O
odds O
of O
detection O
of O
any O
of O
the O
four O
brca2 O
mutations O
was O
5 O
. O

3x O
greater O
if O
there O
were O
at O
least O
five O
cases O
of O
breast B-Disease
cancer B-Disease
in O
the O
family O
. O

interestingly O
, O
the O
presence O
of O
a O
breast B-Disease
cancer B-Disease
case O
< O
36 O
years O
of O
age O
was O
strongly O
predictive O
of O
the O
presence O
of O
any O
of O
the O
eight O
mutations O
screened O
. O

carriers O
of O
the O
same O
mutation O
, O
from O
different O
families O
, O
shared O
similar O
haplotypes O
, O
indicating O
that O
the O
mutant O
alleles O
were O
likely O
to O
be O
identical O
by O
descent O
for O
a O
mutation O
in O
the O
founder O
population O
. O

the O
identification O
of O
common O
brca1 O
and O
brca2 O
mutations O
will O
facilitate O
carrier O
detection O
in O
french O
canadian O
breast B-Disease
cancer B-Disease
and O
breast B-Disease
/ B-Disease
ovarian B-Disease
cancer B-Disease
families O
. O

are O
dp71 O
and O
dp140 O
brain O
dystrophin O
isoforms O
related O
to O
cognitive B-Disease
impairment B-Disease
in O
duchenne B-Disease
muscular B-Disease
dystrophy B-Disease
? O
molecular O
study O
and O
neuropsychological O
analysis O
were O
performed O
concurrently O
on O
49 O
patients O
with O
duchenne B-Disease
muscular B-Disease
dystrophy B-Disease
( O
dmd B-Disease
) O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B-Disease
impairment B-Disease
observed O
in O
most O
dmd B-Disease
patients O
. O

complete O
analysis O
of O
the O
dystrophin O
gene O
was O
performed O
to O
define O
the O
localization O
of O
deletions O
and O
duplications O
in O
relation O
to O
the O
different O
dmd B-Disease
promoters O
. O

qualitative O
analysis O
of O
the O
dp71 O
transcript O
and O
testing O
for O
the O
specific O
first O
exon O
of O
dp140 O
were O
also O
carried O
out O
. O

neuropsychological O
analysis O
assessed O
verbal O
and O
visuospatial O
intelligence O
, O
verbal O
memory O
, O
and O
reading O
skills O
. O

comparison O
of O
molecular O
and O
psychometric O
findings O
demonstrated O
that O
deletions O
and O
duplications O
that O
were O
localized O
in O
the O
distal O
part O
of O
the O
gene O
seemed O
to O
be O
preferentially O
associated O
with O
cognitive B-Disease
impairment B-Disease
. O

two O
altered O
dp71 O
transcripts O
and O
two O
deleted O
dp140 O
dna O
sequences O
were O
found O
in O
four O
patients O
with O
severe O
cerebral B-Disease
dysfunction B-Disease
. O

these O
findings O
suggest O
that O
some O
sequences O
located O
in O
the O
distal O
part O
of O
the O
gene O
and O
, O
in O
particular O
, O
some O
dmd B-Disease
isoforms O
expressed O
in O
the O
brain O
may O
be O
related O
to O
the O
cognitive B-Disease
impairment B-Disease
associated O
with O
dmd B-Disease
. O

. O

i1307k O
apc O
and O
hmlh1 O
mutations O
in O
a O
non O
- O
jewish O
family O
with O
hereditary B-Disease
non B-Disease
- B-Disease
polyposis B-Disease
colorectal B-Disease
cancer B-Disease
. O

we O
describe O
a O
french O
canadian O
hereditary B-Disease
non B-Disease
- B-Disease
polyposis B-Disease
colorectal B-Disease
cancer B-Disease
( O
hnpcc B-Disease
) O
kindred O
which O
carries O
a O
novel O
truncating O
mutation O
in O
hmlh1 O
. O

interestingly O
, O
the O
i1307k O
apc O
polymorphism O
, O
associated O
with O
an O
increased O
risk O
of O
colorectal B-Disease
cancer B-Disease
, O
is O
also O
present O
in O
this O
family O
. O

the O
i1307k O
polymorphism O
has O
previously O
only O
been O
identified O
in O
individuals O
of O
self O
- O
reported O
ashkenazi O
jewish O
origins O
. O

in O
addition O
, O
in O
this O
family O
, O
there O
appears O
to O
be O
no O
relationship O
between O
the O
i1307k O
polymorphism O
and O
the O
presence O
or O
absence O
of O
cancer B-Disease
. O

. O

identification O
of O
a O
novel O
mutation O
of O
the O
cpo O
gene O
in O
a O
japanese O
hereditary B-Disease
coproporphyria B-Disease
family O
. O

hereditary B-Disease
coproporphyria B-Disease
( O
hcp B-Disease
) O
is O
an O
autosomal B-Disease
dominant B-Disease
disease B-Disease
characterized O
by O
a O
deficiency B-Disease
of B-Disease
coproporphyrinogen B-Disease
oxidase B-Disease
( O
cpo O
) O
caused O
by O
a O
mutation O
in O
the O
cpo O
gene O
. O

only O
11 O
mutations O
of O
the O
gene O
have O
been O
reported O
in O
hcp B-Disease
patients O
. O

we O
report O
another O
mutation O
in O
a O
japanese O
family O
. O

polymerase O
chain O
reaction O
- O
single O
strand O
conformational O
polymorphism O
and O
direct O
sequence O
analyses O
demonstrated O
a O
c O
to O
t O
substitution O
in O
exon O
1 O
of O
the O
cpo O
gene O
at O
nucleotide O
position O
85 O
, O
which O
lies O
in O
the O
putative O
presequence O
for O
targeting O
to O
mitochondria O
. O

this O
mutation O
changes O
the O
codon O
for O
glutamine O
to O
a O
termination O
codon O
at O
amino O
acid O
position O
29 O
. O

maei O
restriction O
analysis O
showed O
two O
other O
carriers O
in O
the O
family O
. O

the O
c O
- O
t O
mutation O
is O
located O
within O
a O
recently O
proposed O
putative O
alternative O
translation O
initiation O
codon O
( O
tic O
- O
1 O
) O
, O
supporting O
that O
tic O
- O
1 O
is O
the O
real O
tic O
rather O
than O
tic O
- O
2 O
. O

. O

human B-Disease
complement B-Disease
factor B-Disease
h B-Disease
deficiency B-Disease
associated O
with O
hemolytic B-Disease
uremic B-Disease
syndrome B-Disease
. O

this O
study O
reports O
on O
six O
cases O
of O
deficiency B-Disease
in B-Disease
the B-Disease
human B-Disease
complement B-Disease
regulatory B-Disease
protein B-Disease
factor B-Disease
h B-Disease
( O
fh O
) O
in O
the O
context O
of O
an O
acute B-Disease
renal B-Disease
disease B-Disease
. O

five O
of O
the O
cases O
were O
observed O
in O
children O
presenting O
with O
idiopathic O
hemolytic B-Disease
uremic B-Disease
syndrome B-Disease
( O
hus B-Disease
) O
. O

two O
of O
the O
children O
exhibited O
a O
homozygous O
deficiency O
characterized O
by O
the O
absence O
of O
the O
150 O
- O
kd O
form O
of O
factor O
h O
and O
the O
presence O
, O
upon O
immunoblotting O
, O
of O
the O
42 O
- O
kd O
factor O
h O
- O
like O
protein O
1 O
( O
fhl O
- O
1 O
) O
and O
other O
fh O
- O
related O
protein O
( O
fhr O
) O
bands O
. O

southern O
blot O
and O
pcr O
analysis O
of O
dna O
of O
one O
patient O
with O
homozygous O
deficiency O
ruled O
out O
the O
presence O
of O
a O
large O
deletion O
of O
the O
fh O
gene O
as O
the O
underlying O
defect O
for O
the O
deficiency O
. O

the O
other O
four O
children O
presented O
with O
heterozygous O
deficiency O
and O
exhibited O
a O
normal O
immunoblotting O
pattern O
of O
proteins O
of O
the O
fh O
family O
. O

factor B-Disease
h B-Disease
deficiency B-Disease
is O
the O
only O
complement B-Disease
deficiency B-Disease
associated O
with O
hus B-Disease
. O

these O
observations O
suggest O
a O
role O
for O
fh O
and O
/ O
or O
fh O
receptors O
in O
the O
pathogenesis O
of O
idiopathic O
hus B-Disease
. O

. O

further O
evidence O
for O
a O
major O
ancient O
mutation O
underlying O
myotonic B-Disease
dystrophy B-Disease
from O
linkage O
disequilibrium O
studies O
in O
the O
japanese O
population O
. O

the O
myotonic B-Disease
dystrophy B-Disease
( O
dm B-Disease
) O
mutation O
is O
an O
unstable O
( O
ctg O
) O
n O
repeat O
, O
present O
at O
a O
copy O
number O
of O
5 O
- O
37 O
repeats O
on O
normal O
chromosomes O
but O
amplified O
to O
50 O
- O
3000 O
copies O
on O
dm B-Disease
chromosomes O
. O

previous O
findings O
in O
caucasian O
populations O
of O
a O
dm B-Disease
founder O
chromosome O
raise O
a O
question O
about O
the O
molecular O
events O
involved O
in O
the O
expansion O
mutation O
. O

to O
investigate O
whether O
a O
founder O
chromosome O
for O
the O
dm B-Disease
mutation O
exists O
in O
the O
japanese O
population O
, O
we O
genotyped O
families O
using O
polymorphic O
markers O
near O
the O
( O
ctg O
) O
n O
repeat O
region O
and O
constructed O
haplotypes O
. O

six O
different O
haplotypes O
were O
found O
and O
dm B-Disease
alleles O
were O
always O
haplotype O
a O
. O

to O
find O
an O
origin O
of O
the O
( O
ctg O
) O
n O
repeat O
mutation O
and O
to O
investigate O
the O
mechanism O
of O
the O
expansion O
mutation O
in O
the O
japanese O
population O
we O
have O
studied O
90 O
japanese O
dm B-Disease
families O
comprising O
190 O
affected O
and O
130 O
unaffected O
members O
. O

the O
results O
suggest O
that O
a O
few O
common O
ancestral O
mutations O
in O
both O
caucasian O
and O
japanese O
populations O
have O
originated O
by O
expansion O
of O
an O
ancestral O
n O
= O
5 O
repeat O
to O
n O
= O
19 O
- O
37 O
copies O
. O

these O
data O
support O
multistep O
models O
of O
triplet O
repeat O
expansion O
that O
have O
been O
proposed O
for O
both O
dm B-Disease
and O
friedreichs B-Disease
ataxia B-Disease
. O

. O

the O
molecular O
basis O
of O
c6 B-Disease
deficiency B-Disease
in O
the O
western O
cape O
, O
south O
africa O
. O

deficiency B-Disease
of B-Disease
the B-Disease
sixth B-Disease
component B-Disease
of B-Disease
human B-Disease
complement B-Disease
( O
c6 O
) O
has O
been O
reported O
in O
a O
number O
of O
families O
from O
the O
western O
cape O
, O
south O
africa O
. O

meningococcal B-Disease
disease B-Disease
is O
endemic O
in O
the O
cape O
and O
almost O
all O
pedigrees O
of O
total O
c6 B-Disease
deficiency B-Disease
( O
c6q0 O
) O
have O
been O
ascertained O
because O
of O
recurrent O
disease O
. O

we O
have O
sequenced O
the O
expressed O
exons O
of O
the O
c6 O
gene O
from O
selected O
cases O
and O
have O
found O
three O
molecular O
defects O
leading O
to O
total O
deficiency O
879delg O
, O
which O
is O
the O
common O
defect O
in O
the O
cape O
and O
hitherto O
unreported O
, O
and O
1195delc O
and O
1936delg O
, O
which O
have O
been O
previously O
reported O
in O
african O
- O
americans O
. O

we O
also O
show O
that O
the O
879delg O
and O
1195delc O
defects O
are O
associated O
with O
characteristic O
c6 O
/ O
c7 O
region O
dna O
marker O
haplotypes O
, O
although O
small O
variations O
were O
observed O
. O

the O
1936delg O
defect O
was O
observed O
only O
once O
in O
the O
cape O
, O
but O
its O
associated O
haplotype O
could O
be O
deduced O
. O

the O
data O
from O
the O
haplotypes O
indicate O
that O
these O
three O
molecular O
defects O
account O
for O
the O
defects O
in O
all O
the O
38 O
unrelated O
c6q0 O
individuals O
we O
have O
studied O
from O
the O
cape O
. O

we O
have O
also O
observed O
the O
879delg O
defect O
in O
two O
dutch O
c6 B-Disease
- B-Disease
deficient B-Disease
kindreds O
, O
but O
the O
879delg O
defect O
in O
the O
cape O
probably O
did O
not O
come O
from O
the O
netherlands O
. O

. O

complement B-Disease
c7 B-Disease
deficiency B-Disease
: O
seven O
further O
molecular O
defects O
and O
their O
associated O
marker O
haplotypes O
. O

seven O
further O
molecular O
bases O
of O
c7 B-Disease
deficiency B-Disease
are O
described O
. O

all O
these O
new O
molecular O
defects O
involve O
single O
- O
nucleotide O
events O
, O
deletions O
and O
substitutions O
, O
some O
of O
which O
alter O
splice O
sites O
, O
and O
others O
codons O
. O

they O
are O
distributed O
along O
the O
c7 O
gene O
, O
but O
predominantly O
towards O
the O
3 O
end O
. O

all O
were O
found O
in O
compound O
heterozygous O
individuals O
. O

the O
c6 O
/ O
c7 O
marker O
haplotypes O
associated O
with O
most O
c7 B-Disease
defects B-Disease
are O
tabulated O
. O

. O

a O
genome O
- O
wide O
search O
for O
chromosomal O
loci O
linked O
to O
mental O
health O
wellness O
in O
relatives O
at O
high O
risk O
for O
bipolar B-Disease
affective B-Disease
disorder B-Disease
among O
the O
old O
order O
amish O
. O

bipolar B-Disease
affective B-Disease
disorder B-Disease
( O
bpad B-Disease
; O
manic B-Disease
- B-Disease
depressive B-Disease
illness B-Disease
) O
is O
characterized O
by O
episodes O
of O
mania B-Disease
and O
/ O
or O
hypomania B-Disease
interspersed O
with O
periods O
of O
depression B-Disease
. O

compelling O
evidence O
supports O
a O
significant O
genetic O
component O
in O
the O
susceptibility O
to O
develop O
bpad B-Disease
. O

to O
date O
, O
however O
, O
linkage O
studies O
have O
attempted O
only O
to O
identify O
chromosomal O
loci O
that O
cause O
or O
increase O
the O
risk O
of O
developing O
bpad B-Disease
. O

to O
determine O
whether O
there O
could O
be O
protective O
alleles O
that O
prevent O
or O
reduce O
the O
risk O
of O
developing O
bpad B-Disease
, O
similar O
to O
what O
is O
observed O
in O
other O
genetic B-Disease
disorders B-Disease
, O
we O
used O
mental O
health O
wellness O
( O
absence O
of O
any O
psychiatric B-Disease
disorder B-Disease
) O
as O
the O
phenotype O
in O
our O
genome O
- O
wide O
linkage O
scan O
of O
several O
large O
multigeneration O
old O
order O
amish O
pedigrees O
exhibiting O
an O
extremely O
high O
incidence O
of O
bpad B-Disease
. O

we O
have O
found O
strong O
evidence O
for O
a O
locus O
on O
chromosome O
4p O
at O
d4s2949 O
( O
maximum O
genehunter O
- O
plus O
nonparametric O
linkage O
score O
= O
4 O
. O

05 O
, O
p O
= O
5 O
. O

22 O
x O
10 O
( O
- O
4 O
) O
; O
sibpal O
pempirical O
value O
< O
3 O
x O
10 O
( O
- O
5 O
) O
) O
and O
suggestive O
evidence O
for O
a O
locus O
on O
chromosome O
4q O
at O
d4s397 O
( O
maximum O
genehunter O
- O
plus O
nonparametric O
linkage O
score O
= O
3 O
. O

29 O
, O
p O
= O
2 O
. O

57 O
x O
10 O
( O
- O
3 O
) O
; O
sibpal O
pempirical O
value O
< O
1 O
x O
10 O
( O
- O
3 O
) O
) O
that O
are O
linked O
to O
mental O
health O
wellness O
. O

these O
findings O
are O
consistent O
with O
the O
hypothesis O
that O
certain O
alleles O
could O
prevent O
or O
modify O
the O
clinical O
manifestations O
of O
bpad B-Disease
and O
perhaps O
other O
related O
affective B-Disease
disorders B-Disease
. O

segregation O
distortion O
in O
myotonic B-Disease
dystrophy B-Disease
. O

myotonic B-Disease
dystrophy B-Disease
( O
dm B-Disease
) O
is O
an O
autosomal B-Disease
dominant B-Disease
disease B-Disease
which O
, O
in O
the O
typical O
pedigree O
, O
shows O
a O
three O
generation O
anticipation O
cascade O
. O

this O
results O
in O
infertility B-Disease
and O
congenital B-Disease
myotonic B-Disease
dystrophy B-Disease
( O
cdm B-Disease
) O
with O
the O
disappearance O
of O
dm B-Disease
in O
that O
pedigree O
. O

the O
concept O
of O
segregation O
distortion O
, O
where O
there O
is O
preferential O
transmission O
of O
the O
larger O
allele O
at O
the O
dm B-Disease
locus O
, O
has O
been O
put O
forward O
to O
explain O
partially O
the O
maintenance O
of O
dm B-Disease
in O
the O
population O
. O

in O
a O
survey O
of O
dm B-Disease
in O
northern O
ireland O
, O
59 O
pedigrees O
were O
ascertained O
. O

sibships O
where O
the O
status O
of O
all O
the O
members O
had O
been O
identified O
were O
examined O
to O
determine O
the O
transmission O
of O
the O
dm B-Disease
expansion O
from O
affected O
parents O
to O
their O
offspring O
. O

where O
the O
transmitting O
parent O
was O
male O
, O
58 O
. O

3 O
% O
of O
the O
offspring O
were O
affected O
, O
and O
in O
the O
case O
of O
a O
female O
transmitting O
parent O
, O
68 O
. O

7 O
% O
were O
affected O
. O

studies O
on O
meiotic O
drive O
in O
dm B-Disease
have O
shown O
increased O
transmission O
of O
the O
larger O
allele O
at O
the O
dm B-Disease
locus O
in O
non O
- O
dm O
heterozygotes O
for O
ctgn O
. O

this O
study O
provides O
further O
evidence O
that O
the O
dm B-Disease
expansion O
tends O
to O
be O
transmitted O
preferentially O
. O

diagnosis O
of O
hemochromatosis B-Disease
. O

if O
untreated O
, O
hemochromatosis B-Disease
can O
cause O
serious O
illness O
and O
early B-Disease
death B-Disease
, O
but O
the O
disease O
is O
still O
substantially O
under O
- O
diagnosed O
. O

the O
cornerstone O
of O
screening O
and O
case O
detection O
is O
the O
measurement O
of O
serum O
transferrin O
saturation O
and O
the O
serum O
ferritin O
level O
. O

once O
the O
diagnosis O
is O
suspected O
, O
physicians O
must O
use O
serum O
ferritin O
levels O
and O
hepatic O
iron O
stores O
on O
liver O
biopsy O
specimens O
to O
assess O
patients O
for O
the O
presence O
of O
iron B-Disease
overload B-Disease
. O

liver O
biopsy O
is O
also O
used O
to O
establish O
the O
presence O
or O
absence O
of O
cirrhosis B-Disease
, O
which O
can O
affect O
prognosis O
and O
management O
. O

a O
dna O
- O
based O
test O
for O
the O
hfe O
gene O
is O
commercially O
available O
, O
but O
its O
place O
in O
the O
diagnosis O
of O
hemochromatosis B-Disease
is O
still O
being O
evaluated O
. O

currently O
, O
the O
most O
useful O
role O
for O
this O
test O
is O
in O
the O
detection O
of O
hemochromatosis B-Disease
in O
the O
family O
members O
of O
patients O
with O
a O
proven O
case O
of O
the O
disease O
. O

it O
is O
crucial O
to O
diagnose O
hemochromatosis B-Disease
before O
hepatic B-Disease
cirrhosis B-Disease
develops O
because O
phlebotomy O
therapy O
can O
avert O
serious O
chronic O
disease O
and O
can O
even O
lead O
to O
normal O
life O
expectancy O
. O

. O

prevalence O
of O
the O
i1307k O
apc B-Disease
gene O
variant O
in O
israeli O
jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B-Disease
cancer B-Disease
. O

background O
& O
aims O
israeli O
jews O
of O
european O
birth O
, O
i O
. O

e O
. O

, O
ashkenazim O
, O
have O
the O
highest O
colorectal B-Disease
cancer B-Disease
incidence O
of O
any O
israeli O
ethnic O
group O
. O

the O
i1307k O
apc B-Disease
gene O
variant O
was O
found O
in O
6 O
. O

1 O
% O
of O
american O
jews O
, O
28 O
% O
of O
their O
familial O
colorectal B-Disease
cancer B-Disease
cases O
, O
but O
not O
in O
non O
- O
jews O
. O

we O
assessed O
the O
i1307k O
prevalence O
in O
israeli O
jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B-Disease
cancer B-Disease
. O

methods O
dna O
samples O
from O
500 O
unrelated O
jews O
of O
european O
or O
non O
- O
european O
origin O
, O
with O
or O
without O
a O
personal O
and O
/ O
or O
family O
history O
of O
neoplasia B-Disease
, O
were O
examined O
for O
the O
i1307k O
variant O
by O
the O
allele O
- O
specific O
oligonucleotide O
( O
aso O
) O
method O
. O

results O
in O
persons O
at O
average O
risk O
for O
colorectal B-Disease
cancer B-Disease
, O
i1307k O
was O
found O
in O
5 O
. O

0 O
% O
of O
120 O
european O
and O
1 O
. O

6 O
% O
of O
188 O
non O
- O
european O
jews O
( O
p O
= O
0 O
. O

08 O
) O
. O

it O
occurred O
in O
15 O
. O

4 O
% O
of O
52 O
ashkenazi O
israelis O
with O
familial O
cancer B-Disease
( O
p O
= O
0 O
. O

02 O
) O
and O
was O
not O
detected O
in O
51 O
non O
- O
european O
jews O
at O
increased O
cancer B-Disease
risk O
. O

colorectal B-Disease
neoplasia B-Disease
occurred O
personally O
or O
in O
the O
families O
of O
13 O
of O
20 O
ashkenazi O
i1307k O
carriers O
, O
8 O
of O
whom O
also O
had O
a O
personal O
or O
family O
history O
of O
noncolonic O
neoplasia B-Disease
. O

conclusions O
the O
i1307k O
apc O
variant O
may O
represent O
a O
susceptibility O
gene O
for O
colorectal B-Disease
, B-Disease
or B-Disease
other B-Disease
, B-Disease
cancers B-Disease
in O
ashkenazi O
jews O
, O
and O
partially O
explains O
the O
higher O
incidence O
of O
colorectal B-Disease
cancer B-Disease
in O
european O
israelis O
. O

systematic O
analysis O
of O
coproporphyrinogen O
oxidase O
gene O
defects O
in O
hereditary B-Disease
coproporphyria B-Disease
and O
mutation O
update O
. O

hereditary B-Disease
coproporphyria B-Disease
( O
hc B-Disease
) O
is O
an O
acute O
hepatic B-Disease
porphyria B-Disease
with O
autosomal O
dominant O
inheritance O
caused O
by O
deficient B-Disease
activity B-Disease
of B-Disease
coproporphyrinogen B-Disease
iii B-Disease
oxidase B-Disease
( O
cpo O
) O
. O

clinical O
manifestations O
of O
the O
disease O
are O
characterized O
by O
acute O
attacks O
of O
neurological B-Disease
dysfunction B-Disease
often O
precipitated O
by O
drugs O
, O
fasting O
, O
cyclical O
hormonal O
changes O
, O
or O
infectious B-Disease
diseases B-Disease
. O

skin O
photosensitivity O
may O
also O
be O
present O
. O

the O
seven O
exons O
, O
the O
exon O
/ O
intron O
boundaries O
and O
part O
of O
3 O
noncoding O
sequence O
of O
the O
cpo O
gene O
were O
systematically O
analyzed O
by O
an O
exon O
- O
by O
- O
exon O
denaturing O
gradient O
gel O
electrophoresis O
( O
dgge O
) O
strategy O
followed O
by O
direct O
sequencing O
in O
seven O
unrelated O
heterozygous O
hc B-Disease
patients O
from O
france O
, O
holland O
, O
and O
czech O
republic O
. O

seven O
novel O
mutations O
and O
two O
new O
polymorphisms O
were O
detected O
. O

among O
these O
mutations O
two O
are O
missense O
( O
g197w O
, O
w427r O
) O
, O
two O
are O
nonsense O
( O
q306x O
, O
q385x O
) O
, O
two O
are O
small O
deletions O
( O
662de14bp O
; O
1168del3bp O
removing O
a O
glycine O
at O
position O
390 O
) O
, O
and O
one O
is O
a O
splicing O
mutation O
( O
ivs1 O
- O
15c O
- O
- O
> O
g O
) O
which O
creates O
a O
new O
acceptor O
splice O
site O
. O

the O
pathological O
significance O
of O
the O
point O
mutations O
g197w O
, O
w427r O
, O
and O
the O
in O
- O
frame O
deletion O
390delgly O
were O
assessed O
by O
their O
respective O
expression O
in O
a O
prokaryotic O
system O
using O
site O
- O
directed O
mutagenesis O
. O

these O
mutations O
resulted O
in O
the O
absence O
or O
a O
dramatic O
decrease O
of O
cpo O
activity O
. O

the O
two O
polymorphisms O
were O
localized O
in O
noncoding O
part O
of O
the O
gene O
1 O
) O
a O
c O
/ O
g O
polymorphism O
in O
the O
promotor O
region O
, O
142 O
bp O
upstream O
from O
the O
transcriptional O
initiation O
site O
( O
- O
142c O
/ O
g O
) O
, O
and O
2 O
) O
a O
6 O
bp O
deletion O
polymorphism O
in O
the O
3 O
noncoding O
part O
of O
the O
cpo O
gene O
, O
574 O
bp O
downstream O
of O
the O
last O
base O
of O
the O
normal O
termination O
codon O
( O
+ O
574 O
delattctt O
) O
. O

five O
intragenic O
dimorphisms O
are O
now O
well O
characterized O
and O
the O
high O
degree O
of O
allelic O
heterogeneity O
in O
hc B-Disease
is O
demonstrated O
with O
seven O
new O
different O
mutations O
making O
a O
total O
of O
nineteen O
cpo O
gene B-Disease
defects B-Disease
reported O
so O
far O
. O

. O

coincidence O
of O
two O
novel O
arylsulfatase O
a O
alleles O
and O
mutation O
459 O
+ O
1g O
> O
a O
within O
a O
family O
with O
metachromatic B-Disease
leukodystrophy B-Disease
: O
molecular O
basis O
of O
phenotypic O
heterogeneity O
. O

in O
a O
family O
with O
three O
siblings O
, O
one O
developed O
classical O
late O
infantile O
metachromatic B-Disease
leukodystrophy B-Disease
( O
mld B-Disease
) O
, O
fatal O
at O
age O
5 O
years O
, O
with O
deficient O
arylsulfatase O
a O
( O
arsa O
) O
activity O
and O
increased O
galactosylsulfatide O
( O
gs O
) O
excretion O
. O

the O
two O
other O
siblings O
, O
apparently O
healthy O
at O
12 O
( O
1 O
/ O
2 O
) O
and O
15 O
years O
, O
respectively O
, O
and O
their O
father O
, O
apparently O
healthy O
as O
well O
, O
presented O
arsa O
and O
gs O
values O
within O
the O
range O
of O
mld B-Disease
patients O
. O

mutation O
screening O
and O
sequence O
analysis O
disclosed O
the O
involvement O
of O
three O
different O
arsa O
mutations O
being O
the O
molecular O
basis O
of O
intrafamilial O
phenotypic O
heterogeneity O
. O

the O
late O
infantile O
patient O
inherited O
from O
his O
mother O
the O
frequent O
0 O
- O
type O
mutation O
459 O
+ O
1g O
> O
a O
, O
and O
from O
his O
father O
a O
novel O
, O
single O
basepair O
microdeletion O
of O
guanine O
at O
nucleotide O
7 O
in O
exon O
1 O
( O
7delg O
) O
. O

the O
two O
clinically O
unaffected O
siblings O
carried O
the O
maternal O
mutation O
459 O
+ O
1g O
> O
a O
and O
, O
on O
their O
paternal O
allele O
, O
a O
novel O
cytosine O
to O
thymidine O
transition O
at O
nucleotide O
2435 O
in O
exon O
8 O
, O
resulting O
in O
substitution O
of O
alanine O
464 O
by O
valine O
( O
a464v O
) O
. O

the O
fathers O
genotype O
thus O
was O
7delg O
/ O
a464v O
. O

mutation O
a464v O
was O
not O
found O
in O
18 O
unrelated O
mld B-Disease
patients O
and O
50 O
controls O
. O

a464v O
, O
although O
clearly O
modifying O
arsa O
and O
gs O
levels O
, O
apparently O
bears O
little O
significance O
for O
clinical O
manifestation O
of O
mld B-Disease
, O
mimicking O
the O
frequent O
arsa O
pseudodeficiency O
allele O
. O

our O
results O
demonstrate O
that O
in O
certain O
genetic O
conditions O
mld B-Disease
- O
like O
arsa O
and O
gs O
values O
need O
not O
be O
paralleled O
by O
clinical O
disease O
, O
a O
finding O
with O
serious O
diagnostic O
and O
prognostic O
implications O
. O

moreover O
, O
further O
arsa O
alleles O
functionally O
similar O
to O
a464v O
might O
exist O
which O
, O
together O
with O
0 O
- O
type O
mutations O
, O
may O
cause O
pathological O
arsa O
and O
gs O
levels O
, O
but O
not O
clinical O
outbreak O
of O
the O
disease O
. O

. O

human O
mlh1 O
deficiency O
predisposes O
to O
hematological B-Disease
malignancy B-Disease
and O
neurofibromatosis B-Disease
type B-Disease
1 B-Disease
. O

heterozygous O
germ O
- O
line O
mutations O
in O
the O
dna O
mismatch O
repair O
genes O
lead O
to O
hereditary B-Disease
nonpolyposis B-Disease
colorectal B-Disease
cancer B-Disease
. O

the O
disease O
susceptibility O
of O
individuals O
who O
constitutionally O
lack O
both O
wild O
- O
type O
alleles O
is O
unknown O
. O

we O
have O
identified O
three O
offspring O
in O
a O
hereditary B-Disease
nonpolyposis B-Disease
colorectal B-Disease
cancer B-Disease
family O
who O
developed O
hematological B-Disease
malignancy B-Disease
at O
a O
very O
early O
age O
, O
and O
at O
least O
two O
of O
them O
displayed O
signs O
of O
neurofibromatosis B-Disease
type B-Disease
1 B-Disease
( O
nf1 B-Disease
) O
. O

dna O
sequence O
analysis O
and O
allele O
- O
specific O
amplification O
in O
two O
siblings O
revealed O
a O
homozygous O
mlh1 O
mutation O
( O
c676t O
- O
- O
> O
arg226stop O
) O
. O

thus O
, O
a O
homozygous O
germ O
- O
line O
mlh1 O
mutation O
and O
consequent O
mismatch O
repair O
deficiency O
results O
in O
a O
mutator O
phenotype O
characterized O
by O
leukemia B-Disease
and O
/ O
or O
lymphoma B-Disease
associated O
with O
neurofibromatosis B-Disease
type B-Disease
1 B-Disease
. O

. O

missense O
mutations O
in O
the O
most O
ancient O
residues O
of O
the O
pax6 O
paired O
domain O
underlie O
a O
spectrum O
of O
human O
congenital B-Disease
eye B-Disease
malformations B-Disease
. O

mutations O
of O
the O
human O
pax6 O
gene O
underlie O
aniridia B-Disease
( O
congenital B-Disease
absence B-Disease
of B-Disease
the B-Disease
iris B-Disease
) O
, O
a O
rare O
dominant O
malformation B-Disease
of B-Disease
the B-Disease
eye B-Disease
. O

the O
spectrum O
of O
pax6 O
mutations O
in O
aniridia B-Disease
patients O
is O
highly O
biased O
, O
with O
92 O
% O
of O
all O
reported O
mutations O
leading O
to O
premature O
truncation O
of O
the O
protein O
( O
nonsense O
, O
splicing O
, O
insertions O
and O
deletions O
) O
and O
just O
2 O
% O
leading O
to O
substitution O
of O
one O
amino O
acid O
by O
another O
( O
missense O
) O
. O

the O
extraordinary O
conservation O
of O
the O
pax6 O
protein O
at O
the O
amino O
acid O
level O
amongst O
vertebrates O
predicts O
that O
pathological O
missense O
mutations O
should O
in O
fact O
be O
common O
even O
though O
they O
are O
hardly O
ever O
seen O
in O
aniridia B-Disease
patients O
. O

this O
indicates O
that O
there O
is O
a O
heavy O
ascertainment O
bias O
in O
the O
selection O
of O
patients O
for O
pax6 O
mutation O
analysis O
and O
that O
the O
missing O
pax6 O
missense O
mutations O
frequently O
may O
underlie O
phenotypes O
distinct O
from O
textbook O
aniridia B-Disease
. O

here O
we O
present O
four O
novel O
pax6 O
missense O
mutations O
, O
two O
in O
association O
with O
atypical O
phenotypes O
ectopia B-Disease
pupillae B-Disease
( O
displaced B-Disease
pupils B-Disease
) O
and O
congenital B-Disease
nystagmus B-Disease
( O
searching B-Disease
gaze B-Disease
) O
, O
and O
two O
in O
association O
with O
more O
recognizable O
aniridia B-Disease
phenotypes O
. O

strikingly O
, O
all O
four O
mutations O
are O
located O
within O
the O
pax6 O
paired O
domain O
and O
affect O
amino O
acids O
which O
are O
highly O
conserved O
in O
all O
known O
paired O
domain O
proteins O
. O

our O
results O
support O
the O
hypothesis O
that O
the O
under O
- O
representation O
of O
missense O
mutations O
is O
caused O
by O
ascertainment O
bias O
and O
suggest O
that O
a O
substantial O
burden O
of O
pax6 B-Disease
- B-Disease
related B-Disease
disease B-Disease
remains O
to O
be O
uncovered O
. O

. O

the O
chromosomal O
order O
of O
genes O
controlling O
the O
major O
histocompatibility O
complex O
, O
properdin O
factor O
b O
, O
and O
deficiency B-Disease
of B-Disease
the B-Disease
second B-Disease
component B-Disease
of B-Disease
complement B-Disease
. O

the O
relationship O
of O
the O
genes O
coding O
for O
hla O
to O
those O
coding O
for O
properdin O
factor O
b O
allotypes O
and O
for O
deficiency B-Disease
of B-Disease
the B-Disease
second B-Disease
component B-Disease
of B-Disease
complement B-Disease
( O
c2 O
) O
was O
studied O
in O
families O
of O
patients O
with O
connective O
tissue O
disorders O
. O

patients O
were O
selected O
because O
they O
were O
heterozygous O
or O
homozygous O
for O
c2 B-Disease
deficiency B-Disease
. O

12 O
families O
with O
15 O
matings O
informative O
for O
c2 B-Disease
deficiency B-Disease
were O
found O
. O

of O
57 O
informative O
meioses O
, O
two O
crossovers O
were O
noted O
between O
the O
c2 B-Disease
deficiency B-Disease
gene O
and O
the O
hla O
- O
b O
gene O
, O
with O
a O
recombinant O
fraction O
of O
0 O
. O

035 O
. O

a O
lod O
score O
of O
13 O
was O
calculated O
for O
linkage O
between O
c2 B-Disease
deficiency B-Disease
and O
hla O
- O
b O
at O
a O
maximum O
likelihood O
value O
of O
the O
recombinant O
fraction O
of O
0 O
. O

04 O
. O

18 O
families O
with O
21 O
informative O
matings O
for O
both O
properdin O
factor O
b O
allotype O
and O
hla O
- O
b O
were O
found O
. O

of O
72 O
informative O
meioses O
, O
three O
recombinants O
were O
found O
, O
giving O
a O
recombinant O
fraction O
of O
0 O
. O

042 O
. O

a O
lod O
score O
of O
16 O
between O
hla O
- O
b O
and O
factor O
b O
allotypes O
was O
calculated O
at O
a O
maximum O
likelihood O
value O
of O
the O
recombinant O
fraction O
of O
0 O
. O

04 O
. O

a O
crossover O
was O
shown O
to O
have O
occurred O
between O
genes O
for O
factor O
b O
and O
hla O
- O
d O
, O
in O
which O
hla O
- O
d O
segregared O
with O
hla O
- O
a O
and O
b O
. O

these O
studies O
suggest O
that O
the O
genes O
for O
factor O
b O
and O
c2 B-Disease
deficiency B-Disease
are O
located O
outside O
those O
for O
hla O
, O
that O
the O
order O
of O
genese O
is O
hla O
- O
a O
, O
- O
b O
, O
- O
d O
, O
factor O
b O
allotype O
, O
c2 B-Disease
deficiency B-Disease
, O
that O
the O
genes O
coding O
for O
c2 B-Disease
deficiency B-Disease
and O
factor O
b O
allotypes O
are O
approximately O
3 O
- O
- O
5 O
centimorgans O
from O
the O
hla O
- O
a O
and O
hla O
- O
b O
loci O
, O
and O
that O
the O
apparent O
lack O
of O
recombinants O
between O
the O
factor O
b O
gene O
and O
c2 B-Disease
deficiency B-Disease
gene O
suggests O
that O
these O
two O
genes O
lie O
in O
close O
proximity O
to O
one O
another O
. O

distribution O
of O
emerin O
and O
lamins O
in O
the O
heart O
and O
implications O
for O
emery B-Disease
- B-Disease
dreifuss B-Disease
muscular B-Disease
dystrophy B-Disease
. O

emerin O
is O
a O
nuclear O
membrane O
protein O
which O
is O
missing O
or O
defective O
in O
emery B-Disease
- B-Disease
dreifuss B-Disease
muscular B-Disease
dystrophy B-Disease
( O
edmd B-Disease
) O
. O

it O
is O
one O
member O
of O
a O
family O
of O
lamina O
- O
associated O
proteins O
which O
includes O
lap1 O
, O
lap2 O
and O
lamin O
b O
receptor O
( O
lbr O
) O
. O

a O
panel O
of O
16 O
monoclonal O
antibodies O
( O
mabs O
) O
has O
been O
mapped O
to O
six O
specific O
sites O
throughout O
the O
emerin O
molecule O
using O
phage O
- O
displayed O
peptide O
libraries O
and O
has O
been O
used O
to O
localize O
emerin O
in O
human O
and O
rabbit O
heart O
. O

several O
mabs O
against O
different O
emerin O
epitopes O
did O
not O
recognize O
intercalated O
discs O
in O
the O
heart O
, O
though O
they O
recognized O
cardiomyocyte O
nuclei O
strongly O
, O
both O
at O
the O
rim O
and O
in O
intranuclear O
spots O
or O
channels O
. O

a O
polyclonal O
rabbit O
antiserum O
against O
emerin O
did O
recognize O
both O
nuclear O
membrane O
and O
intercalated O
discs O
but O
, O
after O
affinity O
purification O
against O
a O
pure O
- O
emerin O
band O
on O
a O
western O
blot O
, O
it O
stained O
only O
the O
nuclear O
membrane O
. O

these O
results O
would O
not O
be O
expected O
if O
immunostaining O
at O
intercalated O
discs O
were O
due O
to O
a O
product O
of O
the O
emerin O
gene O
and O
, O
therefore O
, O
cast O
some O
doubt O
upon O
the O
hypothesis O
that O
cardiac B-Disease
defects B-Disease
in O
edmd B-Disease
are O
caused O
by O
absence O
of O
emerin O
from O
intercalated O
discs O
. O

although O
emerin O
was O
abundant O
in O
the O
membranes O
of O
cardiomyocyte O
nuclei O
, O
it O
was O
absent O
from O
many O
non O
- O
myocyte O
cells O
in O
the O
heart O
. O

this O
distribution O
of O
emerin O
was O
similar O
to O
that O
of O
lamin O
a O
, O
a O
candidate O
gene O
for O
an O
autosomal O
form O
of O
edmd B-Disease
. O

in O
contrast O
, O
lamin O
b1 O
was O
absent O
from O
cardiomyocyte O
nuclei O
, O
showing O
that O
lamin O
b1 O
is O
not O
essential O
for O
localization O
of O
emerin O
to O
the O
nuclear O
lamina O
. O

lamin O
b1 O
is O
also O
almost O
completely O
absent O
from O
skeletal O
muscle O
nuclei O
. O

in O
edmd B-Disease
, O
the O
additional O
absence O
of O
lamin O
b1 O
from O
heart O
and O
skeletal O
muscle O
nuclei O
which O
already O
lack O
emerin O
may O
offer O
an O
alternative O
explanation O
of O
why O
these O
tissues O
are O
particularly O
affected O
. O

. O

genetic O
mapping O
of O
the O
copper B-Disease
toxicosis B-Disease
locus O
in O
bedlington O
terriers O
to O
dog O
chromosome O
10 O
, O
in O
a O
region O
syntenic O
to O
human O
chromosome O
region O
2p13 O
- O
p16 O
. O

abnormal O
hepatic B-Disease
copper B-Disease
accumulation B-Disease
is O
recognized O
as O
an O
inherited B-Disease
disorder B-Disease
in O
man O
, O
mouse O
, O
rat O
and O
dog O
. O

the O
major O
cause O
of O
hepatic B-Disease
copper B-Disease
accumulation B-Disease
in O
man O
is O
a O
dysfunctional O
atp7b O
gene O
, O
causing O
wilson B-Disease
disease B-Disease
( O
wd B-Disease
) O
. O

mutations O
in O
the O
atp7b O
genes O
have O
also O
been O
demonstrated O
in O
mouse O
and O
rat O
. O

the O
atp7b O
gene O
has O
been O
excluded O
in O
the O
much O
rarer O
human O
copper B-Disease
overload B-Disease
disease O
non B-Disease
- B-Disease
indian B-Disease
childhood B-Disease
cirrhosis B-Disease
, O
indicating O
genetic O
heterogeneity O
. O

by O
investigating O
the O
common O
autosomal O
recessive O
copper B-Disease
toxicosis B-Disease
( O
ct B-Disease
) O
in O
bedlington O
terriers O
, O
we O
have O
identified O
a O
new O
locus O
involved O
in O
progressive O
liver B-Disease
disease B-Disease
. O

we O
examined O
whether O
the O
wd B-Disease
gene O
atp7b O
was O
also O
causative O
for O
ct B-Disease
by O
investigating O
the O
chromosomal O
co O
- O
localization O
of O
atp7b O
and O
c04107 O
, O
using O
fluorescence O
in O
situ O
hybridization O
( O
fish O
) O
. O

c04107 O
is O
an O
anonymous O
microsatellite O
marker O
closely O
linked O
to O
ct B-Disease
. O

however O
, O
bac O
clones O
containing O
atp7b O
and O
c04107 O
mapped O
to O
the O
canine O
chromosome O
regions O
cfa22q11 O
and O
cfa10q26 O
, O
respectively O
, O
demonstrating O
that O
wd B-Disease
cannot O
be O
homologous O
to O
ct B-Disease
. O

the O
copper O
transport O
genes O
ctr1 O
and O
ctr2 O
were O
also O
excluded O
as O
candidate O
genes O
for O
ct B-Disease
since O
they O
both O
mapped O
to O
canine O
chromosome O
region O
cfa11q22 O
. O

2 O
- O
22 O
. O

5 O
. O

a O
transcribed O
sequence O
identified O
from O
the O
c04107 O
- O
containing O
bac O
was O
found O
to O
be O
homologous O
to O
a O
gene O
expressed O
from O
human O
chromosome O
2p13 O
- O
p16 O
, O
a O
region O
devoid O
of O
any O
positional O
candidate O
genes O
. O

molecular O
analysis O
of O
the O
apc B-Disease
gene O
in O
205 O
families O
: O
extended O
genotype O
- O
phenotype O
correlations O
in O
fap B-Disease
and O
evidence O
for O
the O
role O
of O
apc B-Disease
amino O
acid O
changes O
in O
colorectal B-Disease
cancer B-Disease
predisposition O
. O

background O
/ O
aims O
the O
development O
of O
colorectal B-Disease
cancer B-Disease
and O
a O
variable O
range O
of O
extracolonic O
manifestations O
in O
familial B-Disease
adenomatous B-Disease
polyposis B-Disease
( O
fap B-Disease
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
adenomatous B-Disease
polyposis B-Disease
coli B-Disease
( O
apc B-Disease
) O
gene O
mutations O
. O

in O
this O
study O
, O
direct O
mutation O
analysis O
of O
the O
apc B-Disease
gene O
was O
performed O
to O
determine O
genotype O
- O
phenotype O
correlations O
for O
nine O
extracolonic O
manifestations O
and O
to O
investigate O
the O
incidence O
of O
apc B-Disease
mutations O
in O
non O
- O
fap O
colorectal B-Disease
cancer B-Disease
. O

methods O
the O
apc B-Disease
gene O
was O
analysed O
in O
190 O
unrelated O
fap B-Disease
and O
15 O
non O
- O
fap O
colorectal B-Disease
cancer B-Disease
patients O
using O
denaturing O
gradient O
gel O
electrophoresis O
, O
the O
protein O
truncation O
test O
, O
and O
direct O
sequencing O
. O

results O
chain O
terminating O
signals O
were O
only O
identified O
in O
patients O
belonging O
to O
the O
fap B-Disease
group O
( O
105 O
patients O
) O
. O

amino O
acid O
changes O
were O
identified O
in O
four O
patients O
, O
three O
of O
whom O
belonged O
to O
the O
non O
- O
fap O
group O
of O
colorectal B-Disease
cancer B-Disease
patients O
. O

genotype O
- O
phenotype O
correlations O
identified O
significant O
differences O
in O
the O
nature O
of O
certain O
extracolonic O
manifestations O
in O
fap B-Disease
patients O
belonging O
to O
three O
mutation O
subgroups O
. O

conclusions O
extended O
genotype O
- O
phenotype O
correlations O
made O
in O
this O
study O
may O
have O
the O
potential O
to O
determine O
the O
most O
appropriate O
surveillance O
and O
prophylactic O
treatment O
regimens O
for O
those O
patients O
with O
mutations O
associated O
with O
life O
threatening O
conditions O
. O

this O
study O
also O
provided O
evidence O
for O
the O
pathological O
nature O
of O
amino O
acid O
changes O
in O
apc O
associated O
with O
both O
fap B-Disease
and O
non O
- O
fap O
colorectal B-Disease
cancer B-Disease
patients O
. O

. O

inherited B-Disease
colorectal B-Disease
polyposis B-Disease
and O
cancer B-Disease
risk O
of O
the O
apc O
i1307k O
polymorphism O
. O

germ O
- O
line O
and O
somatic O
truncating O
mutations O
of O
the O
apc B-Disease
gene O
are O
thought O
to O
initiate O
colorectal B-Disease
tumor B-Disease
formation O
in O
familial B-Disease
adenomatous B-Disease
polyposis B-Disease
syndrome B-Disease
and O
sporadic O
colorectal O
carcinogenesis O
, O
respectively O
. O

recently O
, O
an O
isoleucine O
- O
- O
> O
lysine O
polymorphism O
at O
codon O
1307 O
( O
i1307k O
) O
of O
the O
apc B-Disease
gene O
has O
been O
identified O
in O
6 O
% O
- O
7 O
% O
of O
the O
ashkenazi O
jewish O
population O
. O

to O
assess O
the O
risk O
of O
this O
common O
apc B-Disease
allelic O
variant O
in O
colorectal O
carcinogenesis O
, O
we O
have O
analyzed O
a O
large O
cohort O
of O
unselected O
ashkenazi O
jewish O
subjects O
with O
adenomatous B-Disease
polyps B-Disease
and O
. O

or O
colorectal B-Disease
cancer B-Disease
, B-Disease
for O
the O
apc O
i1307k O
polymorphism O
. O

the O
apc O
i1307k O
allele O
was O
identified O
in O
48 O
( O
10 O
. O

1 O
% O
) O
of O
476 O
patients O
. O

compared O
with O
the O
frequency O
in O
two O
separate O
population O
control O
groups O
, O
the O
apc O
i1307k O
allele O
is O
associated O
with O
an O
estimated O
relative O
risk O
of O
1 O
. O

5 O
- O
1 O
. O

7 O
for O
colorectal B-Disease
neoplasia B-Disease
( O
both O
p O
= O
. O

01 O
) O
. O

furthermore O
, O
compared O
with O
noncarriers O
, O
apc O
i1307k O
carriers O
had O
increased O
numbers O
of O
adenomas B-Disease
and O
colorectal B-Disease
cancers B-Disease
per O
patient O
( O
p O
= O
. O

03 O
) O
, O
as O
well O
as O
a O
younger O
age O
at O
diagnosis O
. O

we O
conclude O
that O
the O
apc O
i1307k O
variant O
leads O
to O
increased O
adenoma B-Disease
formation O
and O
directly O
contributes O
to O
3 O
% O
- O
4 O
% O
of O
all O
ashkenazi O
jewish O
colorectal B-Disease
cancer B-Disease
. O

the O
estimated O
relative O
risk O
for O
carriers O
may O
justify O
specific O
clinical O
screening O
for O
the O
360 O
, O
000 O
americans O
expected O
to O
harbor O
this O
allele O
, O
and O
genetic O
testing O
in O
the O
setting O
of O
long O
- O
term O
- O
outcome O
studies O
may O
impact O
significantly O
on O
colorectal B-Disease
cancer B-Disease
prevention O
in O
this O
population O
. O

localization O
of O
human O
brca1 O
and O
its O
loss O
in O
high O
- O
grade O
, O
non B-Disease
- B-Disease
inherited B-Disease
breast B-Disease
carcinomas B-Disease
. O

although O
the O
link O
between O
the O
brca1 O
tumour B-Disease
- O
suppressor O
gene O
and O
hereditary B-Disease
breast B-Disease
and B-Disease
ovarian B-Disease
cancer B-Disease
is O
established O
, O
the O
role O
, O
if O
any O
, O
of O
brca1 O
in O
non B-Disease
- B-Disease
familial B-Disease
cancers B-Disease
is O
unclear O
. O

brca1 O
mutations O
are O
rare O
in O
sporadic B-Disease
cancers B-Disease
, O
but O
loss O
of O
brca1 O
resulting O
from O
reduced O
expression O
or O
incorrect O
subcellular O
localization O
is O
postulated O
to O
be O
important O
in O
non B-Disease
- B-Disease
familial B-Disease
breast B-Disease
and B-Disease
ovarian B-Disease
cancers B-Disease
. O

epigenetic O
loss O
, O
however O
, O
has O
not O
received O
general O
acceptance O
due O
to O
controversy O
regarding O
the O
subcellular O
localization O
of O
brca1 O
proteins O
, O
reports O
of O
which O
have O
ranged O
from O
exclusively O
nuclear O
, O
to O
conditionally O
nuclear O
, O
to O
the O
er O
/ O
golgi O
, O
to O
cytoplasmic O
invaginations O
into O
the O
nucleus O
. O

in O
an O
attempt O
to O
resolve O
this O
issue O
, O
we O
have O
comprehensively O
characterized O
19 O
anti O
- O
brca1 O
antibodies O
. O

these O
reagents O
detect O
a O
220 O
- O
kd O
protein O
localized O
in O
discrete O
nuclear O
foci O
in O
all O
epithelial O
cell O
lines O
, O
including O
those O
derived O
from O
breast B-Disease
malignancies B-Disease
. O

immunohistochemical O
staining O
of O
human O
breast O
specimens O
also O
revealed O
brca1 O
nuclear O
foci O
in O
benign O
breast O
, O
invasive B-Disease
lobular B-Disease
cancers B-Disease
and O
low B-Disease
- B-Disease
grade B-Disease
ductal B-Disease
carcinomas B-Disease
. O

conversely O
, O
brca1 O
expression O
was O
reduced O
or O
undetectable O
in O
the O
majority O
of O
high O
- O
grade O
, O
ductal B-Disease
carcinomas B-Disease
, O
suggesting O
that O
absence O
of O
brca1 O
may O
contribute O
to O
the O
pathogenesis O
of O
a O
significant O
percentage O
of O
sporadic B-Disease
breast B-Disease
cancers B-Disease
. O

brca1 O
is O
secreted O
and O
exhibits O
properties O
of O
a O
granin O
. O

germline O
mutations O
in O
brca1 O
are O
responsible O
for O
most O
cases O
of O
inherited B-Disease
breast B-Disease
and B-Disease
ovarian B-Disease
cancer B-Disease
. O

however O
, O
the O
function O
of O
the O
brca1 O
protein O
has O
remained O
elusive O
. O

we O
now O
show O
that O
brca1 O
encodes O
a O
190 O
- O
kd O
protein O
with O
sequence O
homology O
and O
biochemical O
analogy O
to O
the O
granin O
protein O
family O
. O

interestingly O
, O
brca2 O
also O
includes O
a O
motif O
similar O
to O
the O
granin O
consensus O
at O
the O
c O
terminus O
of O
the O
protein O
. O

both O
brca1 O
and O
the O
granins O
localize O
to O
secretory O
vesicles O
, O
are O
secreted O
by O
a O
regulated O
pathway O
, O
are O
post O
- O
translationally O
glycosylated O
and O
are O
responsive O
to O
hormones O
. O

as O
a O
regulated O
secretory O
protein O
, O
brca1 O
appears O
to O
function O
by O
a O
mechanism O
not O
previously O
described O
for O
tumour B-Disease
suppressor O
gene O
products O
. O

. O

ovarian B-Disease
cancer B-Disease
risk O
in O
brca1 O
carriers O
is O
modified O
by O
the O
hras1 O
variable O
number O
of O
tandem O
repeat O
( O
vntr O
) O
locus O
. O

women O
who O
carry O
a O
mutation O
in O
the O
brca1 O
gene O
( O
on O
chromosome O
17q21 O
) O
, O
have O
an O
80 O
% O
risk O
of O
breast B-Disease
cancer B-Disease
and O
a O
40 O
% O
risk O
of O
ovarian B-Disease
cancer B-Disease
by O
the O
age O
of O
70 O
( O
ref O
. O

1 O
) O
. O

the O
variable O
penetrance O
of O
brca1 O
suggests O
that O
other O
genetic O
and O
non O
- O
genetic O
factors O
play O
a O
role O
in O
tumourigenesis O
in O
these O
individuals O
. O

the O
hras1 O
variable O
number O
of O
tandem O
repeats O
( O
vntr O
) O
polymorphism O
, O
located O
1 O
kilobase O
( O
kb O
) O
downstream O
of O
the O
hras1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O

5 O
) O
is O
one O
possible O
genetic O
modifier O
of O
cancer B-Disease
penetrance O
. O

individuals O
who O
have O
rare O
alleles O
of O
the O
vntr O
have O
an O
increased O
risk O
of O
certain O
types O
of O
cancers B-Disease
, O
including O
breast B-Disease
cancer B-Disease
( O
2 O
- O
4 O
) O
. O

to O
investigate O
whether O
the O
presence O
of O
rare O
hras1 O
alleles O
increases O
susceptibility O
to O
hereditary B-Disease
breast B-Disease
and B-Disease
ovarian B-Disease
cancer B-Disease
, O
we O
have O
typed O
a O
panel O
of O
307 O
female O
brca1 O
carriers O
at O
this O
locus O
using O
a O
pcr O
- O
based O
technique O
. O

the O
risk O
for O
ovarian B-Disease
cancer B-Disease
was O
2 O
. O

11 O
times O
greater O
for O
brca1 O
carriers O
harbouring O
one O
or O
two O
rare O
hras1 O
alleles O
, O
compared O
to O
carriers O
with O
only O
common O
alleles O
( O
p O
= O
0 O
. O

015 O
) O
. O

the O
magnitude O
of O
the O
relative O
risk O
associated O
with O
a O
rare O
hras1 O
allele O
was O
not O
altered O
by O
adjusting O
for O
the O
other O
known O
risk O
factors O
for O
hereditary B-Disease
ovarian B-Disease
cancer B-Disease
( O
5 O
) O
. O

susceptibility O
to O
breast B-Disease
cancer B-Disease
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
rare O
hras1 O
alleles O
. O

this O
study O
is O
the O
first O
to O
show O
the O
effect O
of O
a O
modifying O
gene O
on O
the O
penetrance O
of O
an O
inherited B-Disease
cancer B-Disease
syndrome B-Disease
a O
novel O
homeodomain O
- O
encoding O
gene O
is O
associated O
with O
a O
large O
cpg O
island O
interrupted O
by O
the O
myotonic B-Disease
dystrophy B-Disease
unstable O
( O
ctg O
) O
n O
repeat O
. O

myotonic B-Disease
dystrophy B-Disease
( O
dm B-Disease
) O
is O
associated O
with O
a O
( O
ctg O
) O
n O
trinucleotide O
repeat O
expansion O
in O
the O
3 O
- O
untranslated O
region O
of O
a O
protein O
kinase O
- O
encoding O
gene O
, O
dmpk O
, O
which O
maps O
to O
chromosome O
19q13 O
. O

3 O
. O

characterisation O
of O
the O
expression O
of O
this O
gene O
in O
patient O
tissues O
has O
thus O
far O
generated O
conflicting O
data O
on O
alterations O
in O
the O
steady O
state O
levels O
of O
dmpk O
mrna O
, O
and O
on O
the O
final O
dmpk O
protein O
levels O
in O
the O
presence O
of O
the O
expansion O
. O

the O
dm B-Disease
region O
of O
chromosome O
19 O
is O
gene O
rich O
, O
and O
it O
is O
possible O
that O
the O
repeat O
expansion O
may O
lead O
to O
dysfunction O
of O
a O
number O
of O
transcription O
units O
in O
the O
vicinity O
, O
perhaps O
as O
a O
consequence O
of O
chromatin O
disruption O
. O

we O
have O
searched O
for O
genes O
associated O
with O
a O
cpg O
island O
at O
the O
3 O
end O
of O
dmpk O
. O

sequencing O
of O
this O
region O
shows O
that O
the O
island O
extends O
over O
3 O
. O

5 O
kb O
and O
is O
interrupted O
by O
the O
( O
ctg O
) O
n O
repeat O
. O

comparison O
of O
genomic O
sequences O
downstream O
( O
centromeric O
) O
of O
the O
repeat O
in O
human O
and O
mouse O
identified O
regions O
of O
significant O
homology O
. O

these O
correspond O
to O
exons O
of O
a O
gene O
predicted O
to O
encode O
a O
homeodomain O
protein O
. O

rt O
- O
pcr O
analysis O
shows O
that O
this O
gene O
, O
which O
we O
have O
called O
dm B-Disease
locus O
- O
associated O
homeodomain O
protein O
( O
dmahp O
) O
, O
is O
expressed O
in O
a O
number O
of O
human O
tissues O
, O
including O
skeletal O
muscle O
, O
heart O
and O
brain O
. O

germline O
mutations O
in O
the O
rb1 O
gene O
in O
patients O
with O
hereditary B-Disease
retinoblastoma B-Disease
. O

we O
have O
analyzed O
the O
27 O
exons O
and O
the O
promoter O
region O
of O
the O
rb1 O
gene O
in O
familial B-Disease
or B-Disease
sporadic B-Disease
bilateral B-Disease
retinoblastoma B-Disease
by O
using O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

for O
improvement O
over O
previous O
studies O
, O
a O
new O
set O
of O
primers O
has O
been O
designed O
, O
which O
allow O
for O
amplification O
of O
the O
coding O
and O
splicing O
sequences O
only O
. O

the O
positioning O
of O
the O
polymerase O
chain O
reaction O
( O
pcr O
) O
primers O
was O
such O
that O
the O
resulting O
pcr O
products O
were O
of O
different O
sizes O
, O
which O
enabled O
us O
to O
analyze O
two O
different O
exons O
simultaneously O
and O
still O
distinguish O
between O
the O
banding O
profiles O
for O
both O
( O
biplex O
analysis O
) O
. O

by O
using O
this O
approach O
, O
we O
were O
able O
to O
identify O
mutation O
in O
22 O
new O
patients O
, O
but O
the O
overall O
efficiency O
of O
the O
procedure O
when O
we O
used O
a O
single O
- O
pass O
regimen O
was O
only O
48 O
% O
. O

the O
mutations O
were O
small O
insertions O
and O
deletions O
and O
point O
mutations O
in O
roughly O
equal O
proportions O
. O

. O

type B-Disease
ii B-Disease
human B-Disease
complement B-Disease
c2 B-Disease
deficiency B-Disease
. O

allele O
- O
specific O
amino O
acid O
substitutions O
( O
ser189 O
- O
- O
> O
phe O
; O
gly444 O
- O
- O
> O
arg O
) O
cause O
impaired O
c2 O
secretion O
. O

type B-Disease
ii B-Disease
complement B-Disease
protein B-Disease
c2 B-Disease
deficiency B-Disease
is O
characterized O
by O
a O
selective O
block O
in O
c2 O
secretion O
. O

the O
type O
ii O
c2 O
nan O
allele O
( O
c2q0 O
) O
is O
linked O
to O
two O
major O
histocompatibility O
haplotypes O
( O
mhc O
) O
that O
differ O
from O
the O
mhc O
of O
the O
more O
common O
type B-Disease
i B-Disease
c2 B-Disease
deficiency B-Disease
. O

to O
determine O
the O
molecular O
basis O
of O
type B-Disease
ii B-Disease
deficiency B-Disease
the O
two O
type O
ii O
c2q0 O
genes O
were O
isolated O
and O
transfected O
separately O
into O
l O
- O
cells O
. O

subsequent O
molecular O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
c2 O
secretion O
is O
impaired O
in O
type B-Disease
ii B-Disease
c2 B-Disease
deficiency B-Disease
because O
of O
different O
missense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
c2q0 O
alleles O
. O

one O
is O
in O
exon O
5 O
( O
nucleotide O
c566 O
- O
- O
> O
t O
; O
ser189 O
- O
- O
> O
phe O
) O
of O
the O
c2q0 O
gene O
linked O
to O
the O
mhc O
haplotype O
a11 O
, O
b35 O
, O
drw1 O
, O
bfs O
, O
c4a0b1 O
. O

the O
other O
is O
in O
exon O
11 O
( O
g1930 O
- O
- O
> O
a O
; O
gly444 O
- O
- O
> O
arg O
) O
of O
the O
c2q0 O
gene O
linked O
to O
the O
mhc O
haplotype O
a2 O
, O
b5 O
, O
drw4 O
, O
bfs O
, O
c4a3b1 O
. O

each O
mutant O
c2 O
gene O
product O
is O
retained O
early O
in O
the O
secretory O
pathway O
. O

these O
mutants O
provide O
models O
for O
elucidating O
the O
c2 O
secretory O
pathway O
. O

. O

defective O
dimerization O
of O
von B-Disease
willebrand B-Disease
factor O
subunits O
due O
to O
a O
cys O
- O
> O
arg O
mutation O
in O
type B-Disease
iid B-Disease
von B-Disease
willebrand B-Disease
disease B-Disease
. O

the O
same O
heterozygous O
t O
- O
> O
c O
transition O
at O
nt O
8567 O
of O
the O
von B-Disease
willebrand B-Disease
factor O
( O
vwf O
) O
transcript O
was O
found O
in O
two O
unrelated O
patients O
with O
type B-Disease
iid B-Disease
von B-Disease
willebrand B-Disease
disease B-Disease
, O
with O
no O
other O
apparent O
abnormality O
. O

in O
one O
family O
, O
both O
alleles O
were O
normal O
in O
the O
parents O
and O
one O
sister O
; O
thus O
, O
the O
mutation O
originated O
de O
novo O
in O
the O
proposita O
. O

the O
second O
patient O
also O
had O
asymptomatic O
parents O
who O
, O
however O
, O
were O
not O
available O
for O
study O
. O

the O
structural O
consequences O
of O
the O
identified O
mutation O
, O
resulting O
in O
the O
cys2010 O
- O
> O
arg O
substitution O
, O
were O
evaluated O
by O
expression O
of O
the O
vwf O
carboxyl O
- O
terminal O
domain O
containing O
residues O
1366 O
- O
2050 O
. O

insect O
cells O
infected O
with O
recombinant O
baculovirus O
expressing O
normal O
vwf O
sequence O
secreted O
a O
disulfide O
linked O
dimeric O
molecule O
with O
an O
apparent O
molecular O
mass O
of O
150 O
kda O
before O
reduction O
, O
yielding O
a O
single O
band O
of O
80 O
kda O
after O
disulfide O
bond O
reduction O
. O

in O
contrast O
, O
cells O
expressing O
the O
mutant O
fragment O
secreted O
a O
monomeric O
molecule O
of O
apparent O
molecular O
mass O
of O
80 O
kda O
, O
which O
remained O
unchanged O
after O
reduction O
. O

we O
conclude O
that O
cys2010 O
is O
essential O
for O
normal O
dimerization O
of O
vwf O
subunits O
through O
disulfide O
bonding O
of O
carboxyl O
- O
terminal O
domains O
and O
that O
a O
heterozygous O
mutation O
in O
the O
corresponding O
codon O
is O
responsible O
for O
defective O
multimer O
formation O
in O
type B-Disease
iid B-Disease
von B-Disease
willebrand B-Disease
disease B-Disease
. O

. O

wiskott B-Disease
- B-Disease
aldrich B-Disease
syndrome B-Disease
protein O
, O
a O
novel O
effector O
for O
the O
gtpase O
cdc42hs O
, O
is O
implicated O
in O
actin O
polymerization O
. O

the O
rho O
family O
of O
gtpases O
control O
diverse O
biological O
processes O
, O
including O
cell O
morphology O
and O
mitogenesis O
. O

we O
have O
identified O
wasp O
, O
the O
protein O
that O
is O
defective O
in O
wiskott B-Disease
- B-Disease
aldrich B-Disease
syndrome B-Disease
( O
was B-Disease
) O
, O
as O
a O
novel O
effector O
for O
cdc42hs O
, O
but O
not O
for O
the O
other O
rho O
family O
members O
, O
rac O
and O
rho O
. O

this O
interaction O
is O
dependent O
on O
the O
presence O
of O
the O
g O
protein O
- O
binding O
domain O
. O

cellular O
expression O
of O
epitope O
- O
tagged O
wasp O
produces O
clusters O
of O
wasp O
that O
are O
highly O
enriched O
in O
polymerized O
actin O
. O

this O
clustering O
is O
not O
observed O
with O
a O
c O
- O
terminally O
deleted O
wasp O
and O
is O
inhibited O
by O
coexpression O
with O
dominant O
negative O
cdc42hs O
- O
n17 O
, O
but O
not O
with O
dominant O
negative O
forms O
of O
rac O
or O
rho O
. O

thus O
, O
wasp O
provides O
a O
novel O
link O
between O
cdc42hs O
and O
the O
actin O
cytoskeleton O
, O
which O
suggests O
a O
molecular O
mechanism O
for O
many O
of O
the O
cellular O
abnormalities O
in O
was B-Disease
. O

the O
wasp O
sequence O
contains O
two O
novel O
domains O
that O
are O
homologous O
to O
other O
proteins O
involved O
in O
action O
organization O
. O

. O

x B-Disease
- B-Disease
linked B-Disease
adrenoleukodystrophy B-Disease
is O
a O
frequent O
cause O
of O
idiopathic O
addison B-Disease
' B-Disease
s B-Disease
disease B-Disease
in O
young O
adult O
male O
patients O
. O

x B-Disease
- B-Disease
linked B-Disease
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
is O
a O
genetic B-Disease
disease B-Disease
associated O
with O
demyelination B-Disease
of B-Disease
the B-Disease
central B-Disease
nervous B-Disease
system B-Disease
, O
adrenal B-Disease
insufficiency B-Disease
, O
and O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
in O
tissue O
and O
body O
fluids O
. O

ald B-Disease
is O
due O
to O
mutation O
of O
a O
gene O
located O
in O
xq28 O
that O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
unknown O
function O
. O

the O
most O
common O
phenotype O
of O
ald B-Disease
is O
the O
cerebral O
form O
( O
45 O
% O
) O
that O
develops O
in O
boys O
between O
5 O
- O
12 O
yr O
. O

adrenomyeloneuropathy B-Disease
( O
amn B-Disease
) O
involves O
the O
spinal O
cord O
and O
peripheral O
nerves O
in O
young O
adults O
( O
35 O
% O
) O
. O

adrenal B-Disease
insufficiency B-Disease
( O
addisons B-Disease
disease B-Disease
) O
is O
frequently O
associated O
with O
amn B-Disease
or O
cerebral B-Disease
ald B-Disease
and O
may O
remain O
the O
only O
clinical O
expression O
of O
ald B-Disease
( O
8 O
% O
of O
cases O
) O
. O

the O
prevalence O
of O
ald B-Disease
among O
adults O
with O
addisons B-Disease
disease B-Disease
remains O
unknown O
. O

to O
evaluate O
this O
prevalence O
, O
we O
performed O
biochemical O
analysis O
of O
very O
long O
chain O
fatty O
acids O
in O
14 O
male O
patients O
( O
age O
ranging O
from O
12 O
- O
45 O
yr O
at O
diagnosis O
) O
previously O
diagnosed O
as O
having O
primary O
idiopathic O
adrenocortical B-Disease
insufficiency B-Disease
. O

in O
5 O
of O
14 O
patients O
( O
35 O
% O
) O
, O
elevated O
plasma O
concentrations O
of O
very O
long O
chain O
fatty O
acids O
were O
detected O
. O

none O
of O
these O
patients O
had O
adrenocortical O
antibodies O
. O

by O
electrophysiological O
tests O
and O
magnetic O
resonance O
imaging O
it O
was O
determined O
that O
two O
patients O
had O
cerebral B-Disease
ald B-Disease
, O
one O
had O
adrenomyeloneuropathy B-Disease
with O
cerebral O
involvement O
, O
and O
two O
had O
preclinical O
amn B-Disease
. O

our O
data O
support O
the O
hypothesis O
that O
ald B-Disease
is O
a O
frequent O
cause O
of O
idiopathic O
addisons B-Disease
disease B-Disease
in O
children O
and O
adults O
. O

. O

tumor B-Disease
suppression O
and O
apoptosis O
of O
human O
prostate B-Disease
carcinoma B-Disease
mediated O
by O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
. O

prostate B-Disease
cancer B-Disease
is O
the O
second O
leading O
cause O
of O
male O
cancer B-Disease
deaths O
in O
the O
united O
states O
. O

yet O
, O
despite O
a O
large O
international O
effort O
, O
little O
is O
known O
about O
the O
molecular O
mechanisms O
that O
underlie O
this O
devastating O
disease O
. O

prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
dependent O
prostate B-Disease
carcinomas B-Disease
undergo O
apoptosis O
in O
response O
to O
androgen O
deprivation O
and O
, O
furthermore O
, O
most O
prostate B-Disease
carcinomas B-Disease
become O
androgen O
independent O
and O
refractory O
to O
further O
therapeutic O
manipulations O
during O
disease O
progression O
. O

definition O
of O
the O
genetic O
events O
that O
trigger O
apoptosis O
in O
the O
prostate O
could O
provide O
important O
insights O
into O
critical O
pathways O
in O
normal O
development O
as O
well O
as O
elucidate O
the O
perturbations O
of O
those O
key O
pathways O
in O
neoplastic O
transformation O
. O

we O
report O
the O
functional O
definition O
of O
a O
novel O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
that O
mediates O
both O
in O
vivo O
tumor O
suppression O
and O
in O
vitro O
apoptosis O
of O
prostatic B-Disease
adenocarcinoma B-Disease
cells O
. O

a O
defined O
fragment O
of O
human O
chromosome O
10 O
was O
transferred O
via O
microcell O
fusion O
into O
a O
prostate B-Disease
adenocarcinoma B-Disease
cell O
line O
. O

microcell O
hybrids O
containing O
only O
the O
region O
10pter O
- O
q11 O
were O
suppressed O
for O
tumorigenicity O
following O
injection O
of O
microcell O
hybrids O
into O
nude O
mice O
. O

furthermore O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
death O
in O
vitro O
via O
a O
mechanism O
that O
does O
not O
require O
nuclear O
localization O
of O
p53 O
. O

these O
data O
functionally O
define O
a O
novel O
genetic O
locus O
, O
designated O
pac1 O
, O
for O
prostate O
adenocarcinoma O
1 O
, O
involved O
in O
tumor O
suppression O
of O
human O
prostate B-Disease
carcinoma B-Disease
and O
furthermore O
strongly O
suggest O
that O
the O
cell O
death O
pathway O
can O
be O
functionally O
restored O
in O
prostatic B-Disease
adenocarcinoma B-Disease
. O

. O

low O
incidence O
of O
brca2 O
mutations O
in O
breast B-Disease
carcinoma B-Disease
and O
other O
cancers B-Disease
. O

inherited O
mutant O
alleles O
of O
familial O
tumour B-Disease
suppressor O
genes O
predispose O
individuals O
to O
particular O
types O
of O
cancer B-Disease
. O

in O
addition O
to O
an O
involvement O
in O
inherited O
susceptibility O
to O
cancer B-Disease
, O
these O
tumour B-Disease
suppressor O
genes O
are O
targets O
for O
somatic O
mutations O
in O
sporadic B-Disease
cancers B-Disease
of O
the O
same O
type O
found O
in O
the O
familial O
forms O
. O

an O
exception O
is O
brca1 O
, O
which O
contributes O
to O
a O
significant O
fraction O
of O
familial B-Disease
breast B-Disease
and B-Disease
ovarian B-Disease
cancer B-Disease
, O
but O
undergoes O
mutation O
at O
very O
low O
rates O
in O
sporadic B-Disease
breast B-Disease
and B-Disease
ovarian B-Disease
cancers B-Disease
. O

this O
finding O
suggests O
that O
other O
genes O
may O
be O
the O
principal O
targets O
for O
somatic O
mutation O
in O
breast B-Disease
carcinoma B-Disease
. O

a O
second O
, O
recently O
identified O
familial B-Disease
breast B-Disease
cancer B-Disease
gene O
, O
brca2 O
( O
refs O
5 O
- O
8 O
) O
, O
accounts O
for O
a O
proportion O
of O
breast B-Disease
cancer B-Disease
roughly O
equal O
to O
brca1 O
. O

like O
brca1 O
, O
brca2 O
behaves O
as O
a O
dominantly O
inherited O
tumour B-Disease
suppressor O
gene O
. O

individuals O
who O
inherit O
one O
mutant O
allele O
are O
at O
increased O
risk O
for O
breast B-Disease
cancer B-Disease
, O
and O
the O
tumours B-Disease
they O
develop O
lose O
the O
wild O
- O
type O
allele O
by O
heterozygous O
deletion O
. O

the O
brca2 O
coding O
sequence O
is O
huge O
, O
composed O
of O
26 O
exons O
that O
span O
10 O
, O
443 O
bp O
. O

here O
we O
investigate O
the O
rate O
of O
brca2 O
mutation O
in O
sporadic B-Disease
breast B-Disease
cancers B-Disease
and O
in O
a O
set O
of O
cell O
lines O
that O
represent O
twelve O
other O
tumour B-Disease
types O
. O

surprisingly O
, O
mutations O
in O
brca2 O
are O
infrequent O
in O
cancers B-Disease
including O
breast B-Disease
carcinoma B-Disease
. O

however O
, O
a O
probable O
germline O
mutation O
in O
a O
pancreatic B-Disease
tumour B-Disease
cell O
line O
suggests O
a O
role O
for O
brca2 O
in O
susceptibility O
to O
pancreatic B-Disease
cancer B-Disease
. O

. O

founding O
brca1 O
mutations O
in O
hereditary B-Disease
breast B-Disease
and B-Disease
ovarian B-Disease
cancer B-Disease
in O
southern O
sweden O
. O

nine O
different O
germ O
- O
line O
mutations O
in O
the O
brca1 O
breast B-Disease
and B-Disease
ovarian B-Disease
cancer B-Disease
susceptibility O
gene O
were O
identified O
in O
15 O
of O
47 O
kindreds O
from O
southern O
sweden O
, O
by O
use O
of O
sscp O
and O
heteroduplex O
analysis O
of O
all O
exons O
and O
flanking O
intron O
region O
and O
by O
a O
protein O
- O
truncation O
test O
for O
exon O
11 O
, O
followed O
by O
direct O
sequencing O
. O

all O
but O
one O
of O
the O
mutations O
are O
predicted O
to O
give O
rise O
to O
premature O
translation O
termination O
and O
include O
seven O
frameshift O
insertions O
or O
deletions O
, O
a O
nonsense O
mutation O
, O
and O
a O
splice O
acceptor O
site O
mutation O
. O

the O
remaining O
mutation O
is O
a O
missense O
mutation O
( O
cys61gly O
) O
in O
the O
zinc O
- O
binding O
motif O
. O

four O
novel O
swedish O
founding O
mutations O
were O
identified O
the O
nucleotide O
2595 O
deletion O
a O
was O
found O
in O
five O
families O
, O
the O
c O
1806 O
t O
nonsense O
mutation O
in O
three O
families O
, O
the O
3166 O
insertion O
tgaga O
in O
three O
families O
, O
and O
the O
nucleotide O
1201 O
deletion O
11 O
in O
two O
families O
. O

analysis O
of O
the O
intragenic O
polymorphism O
d17s855 O
supports O
common O
origins O
of O
the O
mutations O
. O

eleven O
of O
the O
15 O
kindreds O
manifesting O
brca1 O
mutations O
were O
breast B-Disease
- B-Disease
ovarian B-Disease
cancer B-Disease
families O
, O
several O
of O
them O
with O
a O
predominant O
ovarian B-Disease
cancer B-Disease
phenotype O
. O

the O
set O
of O
32 O
families O
in O
which O
no O
brca1 O
alterations O
were O
detected O
included O
1 O
breast B-Disease
- B-Disease
ovarian B-Disease
cancer B-Disease
kindred O
manifesting O
clear O
linkage O
to O
the O
brca1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
tumors B-Disease
. O

other O
tumor B-Disease
types O
found O
in O
brca1 O
mutation O
/ O
haplotype O
carriers O
included O
prostatic B-Disease
, B-Disease
pancreas B-Disease
, B-Disease
skin B-Disease
, B-Disease
and B-Disease
lung B-Disease
cancer B-Disease
, O
a O
malignant B-Disease
melanoma B-Disease
, O
an O
oligodendroglioma B-Disease
, O
and O
a O
carcinosarcoma B-Disease
. O

in O
all O
, O
12 O
of O
16 O
kindreds O
manifesting O
brca1 O
mutation O
or O
linkage O
contained O
ovarian B-Disease
cancer B-Disease
, O
as O
compared O
with O
only O
6 O
of O
the O
remaining O
31 O
families O
( O
p O
< O
. O

001 O
) O
. O

the O
present O
study O
confirms O
the O
involvement O
of O
brca1 O
in O
disease O
predisposition O
for O
a O
subset O
of O
hereditary B-Disease
breast B-Disease
cancer B-Disease
families O
often O
characterized O
by O
ovarian B-Disease
cancers B-Disease
. O

rapid O
detection O
of O
regionally O
clustered O
germ O
- O
line O
brca1 O
mutations O
by O
multiplex O
heteroduplex O
analysis O
. O

ukcccr O
familial O
ovarian B-Disease
cancer B-Disease
study O
group O
. O

germ O
- O
line O
mutations O
of O
the O
brca1 O
gene O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
with O
multiple O
cases O
of O
early O
- O
onset O
breast B-Disease
and B-Disease
/ B-Disease
or B-Disease
ovarian B-Disease
cancer B-Disease
. O

since O
the O
isolation O
of O
brca1 O
last O
year O
, O
> O
65 O
distinct O
mutations O
scattered O
throughout O
the O
coding O
region O
have O
been O
detected O
, O
making O
analysis O
of O
the O
gene O
time O
consuming O
and O
technically O
challenging O
. O

we O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
brca1 O
mutations O
so O
far O
reported O
in O
breast B-Disease
/ B-Disease
ovarian B-Disease
cancer B-Disease
families O
. O

we O
have O
used O
this O
technique O
to O
analyze O
brca1 O
in O
162 O
families O
with O
a O
history O
of O
breast B-Disease
and B-Disease
/ B-Disease
or B-Disease
ovarian B-Disease
cancer B-Disease
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O

. O

a O
previously O
undescribed O
mutation O
within O
the O
tetramerisation O
domain O
of O
tp53 O
in O
a O
family O
with O
li B-Disease
- B-Disease
fraumeni B-Disease
syndrome B-Disease
. O

we O
report O
details O
of O
a O
family O
with O
classic O
li B-Disease
- B-Disease
fraumeni B-Disease
syndrome B-Disease
in O
which O
there O
is O
a O
mutation O
in O
codon O
344 O
of O
the O
tumour B-Disease
suppressor O
gene O
tp53 O
. O

codon O
344 O
is O
a O
key O
residue O
within O
the O
tetramerisation O
domain O
, O
and O
the O
amino O
acid O
substitution O
of O
a O
proline O
for O
a O
leucine O
is O
predicted O
to O
have O
profound O
implications O
for O
tetramerisation O
and O
potentially O
dna O
binding O
. O

this O
is O
the O
first O
report O
of O
a O
mutation O
at O
this O
residue O
in O
either O
sporadic B-Disease
tumours B-Disease
or O
in O
the O
germline O
and O
the O
first O
report O
of O
a O
germline O
mutation O
within O
the O
tetramerisation O
domain O
. O

the O
family O
does O
not O
appear O
to O
be O
remarkable O
in O
the O
spectrum O
of O
tumours B-Disease
, O
and O
there O
is O
loss O
of O
the O
wild O
- O
type O
allele O
in O
a O
leiomyosarcoma B-Disease
from O
the O
proband O
. O

a O
cell O
line O
has O
been O
established O
from O
the O
tumour B-Disease
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
studies O
carried O
out O
, O
providing O
an O
extensive O
analysis O
in O
this O
family O
. O

. O

the O
spectrum O
of O
rb1 O
germ O
- O
line O
mutations O
in O
hereditary B-Disease
retinoblastoma B-Disease
. O

we O
have O
searched O
for O
germ O
- O
line O
rb1 O
mutations O
in O
119 O
patients O
with O
hereditary B-Disease
retinoblastoma B-Disease
. O

previous O
investigations O
by O
southern O
blot O
hybridization O
and O
pcr O
fragment O
- O
length O
analysis O
had O
revealed O
mutations O
in O
48 O
patients O
. O

here O
we O
report O
on O
the O
analysis O
of O
the O
remaining O
71 O
patients O
. O

by O
applying O
heteroduplex O
analysis O
, O
nonisotopic O
sscp O
, O
and O
direct O
sequencing O
, O
we O
detected O
germ O
- O
line O
mutations O
resulting O
in O
premature O
termination O
codons O
or O
disruption O
of O
splice O
signals O
in O
51 O
( O
72 O
% O
) O
of O
the O
71 O
patients O
. O

four O
patients O
also O
showed O
rare O
sequence O
variants O
. O

no O
region O
of O
the O
rb1 O
gene O
was O
preferentially O
involved O
in O
single O
base O
substitutions O
. O

recurrent O
transitions O
were O
observed O
at O
most O
of O
the O
14 O
codons O
within O
the O
rb1 O
. O

no O
mutation O
was O
observed O
in O
exons O
25 O
- O
27 O
, O
although O
this O
region O
contains O
two O
cga O
codons O
. O

this O
suggests O
that O
mutations O
within O
the O
3 O
- O
terminal O
region O
of O
the O
rb1 O
gene O
may O
not O
be O
oncogenic O
. O

when O
these O
data O
were O
combined O
with O
the O
results O
of O
our O
previous O
investigations O
, O
mutations O
were O
identified O
in O
a O
total O
of O
99 O
( O
83 O
% O
) O
of O
119 O
patients O
. O

the O
spectrum O
comprises O
15 O
% O
large O
deletions O
, O
26 O
% O
small O
length O
alterations O
, O
and O
42 O
% O
base O
substitutions O
. O

no O
correlation O
between O
the O
location O
of O
frameshift O
or O
nonsense O
mutations O
and O
phenotypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor B-Disease
foci O
, O
and O
manifestation O
of O
nonocular B-Disease
tumors B-Disease
was O
observed O
. O

. O

phenotypic O
characterization O
of O
individuals O
with O
30 O
- O
40 O
cag O
repeats O
in O
the O
huntington B-Disease
disease B-Disease
( O
hd B-Disease
) O
gene O
reveals O
hd B-Disease
cases O
with O
36 O
repeats O
and O
apparently O
normal O
elderly O
individuals O
with O
36 O
- O
39 O
repeats O
. O

abnormal O
cag O
expansions O
in O
the O
it O
- O
15 O
gene O
are O
associated O
with O
huntington B-Disease
disease B-Disease
( O
hd B-Disease
) O
. O

in O
the O
diagnostic O
setting O
it O
is O
necessary O
to O
define O
the O
limits O
of O
the O
cag O
size O
ranges O
on O
normal O
and O
hd B-Disease
- O
associated O
chromosomes O
. O

most O
large O
analyses O
that O
defined O
the O
limits O
of O
the O
normal O
and O
pathological O
size O
ranges O
employed O
pcr O
assays O
, O
which O
included O
the O
cag O
repeats O
and O
a O
ccg O
repeat O
tract O
that O
was O
thought O
to O
be O
invariant O
. O

many O
of O
these O
experiments O
found O
an O
overlap O
between O
the O
normal O
and O
disease O
size O
ranges O
. O

subsequent O
findings O
that O
the O
ccg O
repeats O
vary O
by O
8 O
trinucleotide O
lengths O
suggested O
that O
the O
limits O
of O
the O
normal O
and O
disease O
size O
ranges O
should O
be O
reevaluated O
with O
assays O
that O
exclude O
the O
ccg O
polymorphism O
. O

since O
patients O
with O
between O
30 O
and O
40 O
repeats O
are O
rare O
, O
a O
consortium O
was O
assembled O
to O
collect O
such O
individuals O
. O

all O
178 O
samples O
were O
reanalyzed O
in O
cambridge O
by O
using O
assays O
specific O
for O
the O
cag O
repeats O
. O

we O
have O
optimized O
methods O
for O
reliable O
sizing O
of O
cag O
repeats O
and O
show O
cases O
that O
demonstrate O
the O
dangers O
of O
using O
pcr O
assays O
that O
include O
both O
the O
cag O
and O
ccg O
polymorphisms O
. O

seven O
hd B-Disease
patients O
had O
36 O
repeats O
, O
which O
confirms O
that O
this O
allele O
is O
associated O
with O
disease O
. O

individuals O
without O
apparent O
symptoms O
or O
signs O
of O
hd B-Disease
were O
found O
at O
36 O
repeats O
( O
aged O
74 O
, O
78 O
, O
79 O
, O
and O
87 O
years O
) O
, O
37 O
repeats O
( O
aged O
69 O
years O
) O
, O
38 O
repeats O
( O
aged O
69 O
and O
90 O
years O
) O
, O
and O
39 O
repeats O
( O
aged O
67 O
, O
90 O
, O
and O
95 O
years O
) O
. O

the O
detailed O
case O
histories O
of O
an O
exceptional O
case O
from O
this O
series O
will O
be O
presented O
a O
95 O
- O
year O
- O
old O
man O
with O
39 O
repeats O
who O
did O
not O
have O
classical O
features O
of O
hd B-Disease
. O

the O
apparently O
healthy O
survival O
into O
old O
age O
of O
some O
individuals O
with O
36 O
- O
39 O
repeats O
suggests O
that O
the O
hd B-Disease
mutation O
may O
not O
always O
be O
fully O
penetrant O
. O

. O

identification O
and O
expression O
of O
eight O
novel O
mutations O
among O
non O
- O
jewish O
patients O
with O
canavan B-Disease
disease B-Disease
. O

canavan B-Disease
disease B-Disease
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
that O
is O
caused O
by O
the O
deficiency B-Disease
of B-Disease
aspartoacylase B-Disease
( O
aspa O
) O
. O

the O
majority O
of O
patients O
with O
canavan B-Disease
disease B-Disease
are O
from O
an O
ashkenazi O
jewish O
background O
. O

mutations O
in O
aspa O
that O
lead O
to O
loss O
of O
enzymatic O
activity O
have O
been O
identified O
, O
and O
e285a O
and O
y231x O
are O
the O
two O
predominant O
mutations O
that O
account O
for O
97 O
% O
of O
the O
mutant O
chromosomes O
in O
ashkenazi O
jewish O
patients O
. O

the O
current O
study O
was O
aimed O
at O
finding O
the O
molecular O
basis O
of O
canavan B-Disease
disease B-Disease
in O
25 O
independent O
patients O
of O
non O
- O
jewish O
background O
. O

eight O
novel O
and O
three O
previously O
characterized O
mutations O
accounted O
for O
80 O
% O
( O
40 O
/ O
50 O
) O
of O
mutant O
chromosomes O
. O

the O
a305e O
missense O
mutation O
accounted O
for O
48 O
% O
( O
24 O
/ O
50 O
) O
of O
mutant O
chromosomes O
in O
patients O
of O
western O
european O
descent O
, O
while O
the O
two O
predominant O
jewish O
mutations O
each O
accounted O
for O
a O
single O
mutant O
chromosome O
. O

the O
eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
4 O
- O
bp O
deletions O
( O
32 O
deltat O
and O
876 O
deltaagaa O
, O
respectively O
) O
and O
i16t O
, O
g27r O
, O
d114e O
, O
g123e O
, O
c152y O
, O
and O
r168c O
missense O
mutations O
. O

the O
homozygous O
32 O
deltat O
deletion O
was O
identified O
in O
the O
only O
known O
patient O
of O
african O
- O
american O
origin O
with O
canavan B-Disease
disease B-Disease
. O

the O
heterozygosity O
for O
876 O
deltaagaa O
mutation O
was O
identified O
in O
three O
independent O
patients O
from O
england O
. O

six O
single O
- O
base O
changes O
leading O
to O
missense O
mutations O
were O
identified O
in O
patients O
from O
turkey O
( O
d114e O
, O
r168c O
) O
, O
the O
netherlands O
( O
i16t O
) O
, O
germany O
( O
g27r O
) O
, O
ireland O
( O
c152y O
) O
, O
and O
canada O
( O
g123e O
) O
. O

a O
pcr O
- O
based O
protocol O
is O
described O
that O
was O
used O
to O
introduce O
mutations O
in O
wild O
- O
type O
cdna O
. O

in O
vitro O
expression O
of O
mutant O
cdna O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to O
a O
deficiency B-Disease
of B-Disease
aspa B-Disease
and O
should O
therefore O
result O
in O
canavan B-Disease
disease B-Disease
. O

. O

identification O
and O
chromosomal O
localization O
of O
atm O
, O
the O
mouse O
homolog O
of O
the O
ataxia B-Disease
- B-Disease
telangiectasia B-Disease
gene O
. O

atm O
, O
the O
mouse O
homolog O
of O
the O
human O
atm O
gene O
defective O
in O
ataxia B-Disease
- B-Disease
telangiectasia B-Disease
( O
a B-Disease
- B-Disease
t B-Disease
) O
, O
has O
been O
identified O
. O

the O
entire O
coding O
sequence O
of O
the O
atm O
transcript O
was O
cloned O
and O
found O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
protein O
of O
3066 O
amino O
acids O
with O
84 O
% O
overall O
identity O
and O
91 O
% O
similarity O
to O
the O
human O
atm O
protein O
. O

variable O
levels O
of O
expression O
of O
atm O
were O
observed O
in O
different O
tissues O
. O

fluorescence O
in O
situ O
hybridization O
and O
linkage O
analysis O
located O
the O
atm O
gene O
on O
mouse O
chromosome O
9 O
, O
band O
9c O
, O
in O
a O
region O
homologous O
to O
the O
atm O
region O
on O
human O
chromosome O
11q22 O
- O
q23 O
. O

. O

the O
mouse O
homolog O
of O
the O
wiskott B-Disease
- B-Disease
aldrich B-Disease
syndrome B-Disease
protein O
( O
wasp O
) O
gene O
is O
highly O
conserved O
and O
maps O
near O
the O
scurfy O
( O
sf O
) O
mutation O
on O
the O
x O
chromosome O
. O

the O
mouse O
wasp O
gene O
, O
the O
homolog O
of O
the O
gene O
mutated O
in O
wiskott B-Disease
- B-Disease
aldrich B-Disease
syndrome B-Disease
, O
has O
been O
isolated O
and O
sequenced O
. O

the O
predicted O
amino O
acid O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
wasp O
sequence O
. O

a O
distinct O
feature O
of O
the O
mouse O
gene O
is O
an O
expanded O
polymorphic O
gga O
trinucleotide O
repeat O
that O
codes O
for O
polyglycine O
and O
varies O
from O
15 O
to O
17 O
triplets O
in O
different O
mus O
musculus O
strains O
. O

the O
genomic O
structure O
of O
the O
mouse O
wasp O
gene O
is O
expressed O
as O
an O
approximately O
2 O
. O

4 O
- O
kb O
mrna O
in O
thymus O
and O
spleen O
. O

chromosomal O
mapping O
in O
an O
interspecific O
m O
. O

musculus O
/ O
m O
. O

spretus O
backcross O
placed O
the O
wasp O
locus O
near O
the O
centromere O
of O
the O
mouse O
x O
chromosome O
, O
inseparable O
from O
gata1 O
, O
tcfe3 O
, O
and O
scurfy O
( O
sf O
) O
. O

this O
localization O
makes O
wasp O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
t O
cell O
- O
mediated O
fatal B-Disease
lymphoreticular B-Disease
disease B-Disease
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of O
wiskott B-Disease
- B-Disease
aldrich B-Disease
syndrome B-Disease
. O

northern O
analysis O
of O
sf O
tissue O
samples O
indicated O
the O
presence O
of O
wasp O
mrna O
in O
liver O
and O
skin O
, O
presumably O
as O
a O
consequence O
of O
lymphocytic O
infiltration O
, O
but O
non O
abnormalities O
in O
the O
amount O
or O
size O
of O
mrna O
present O
. O

colchicine O
in O
breast O
milk O
of O
patients O
with O
familial B-Disease
mediterranean B-Disease
fever B-Disease
. O

objective O
. O

to O
clarify O
whether O
colchicine O
is O
excreted O
in O
breast O
milk O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
lactating O
women O
who O
have O
familial B-Disease
mediterranean B-Disease
fever B-Disease
( O
fmf B-Disease
) O
. O

methods O
. O

using O
a O
specific O
radioimmunoassay O
, O
we O
determined O
colchicine O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
4 O
patients O
at O
various O
time O
points O
, O
following O
oral O
administration O
of O
the O
drug O
. O

the O
study O
evaluated O
4 O
patients O
with O
fmf B-Disease
who O
had O
been O
taking O
colchicine O
on O
a O
long O
- O
term O
basis O
. O

results O
. O

colchicine O
was O
found O
to O
be O
excreted O
in O
breast O
milk O
. O

its O
levels O
ranged O
between O
1 O
. O

9 O
and O
8 O
. O

6 O
ng O
/ O
ml O
, O
which O
were O
similar O
to O
those O
found O
in O
the O
serum O
( O
parallel O
concentration O
time O
curves O
) O
. O

however O
, O
there O
appeared O
to O
be O
a O
considerable O
variation O
in O
colchicine O
milk O
concentration O
among O
the O
different O
patients O
, O
which O
might O
be O
related O
to O
individual O
breast O
milk O
composition O
and O
, O
possibly O
, O
to O
other O
nutritional O
or O
metabolic O
factors O
. O

conclusion O
. O

the O
extensive O
peripheral O
tissue O
binding O
and O
relatively O
low O
concentration O
of O
colchicine O
in O
breast O
milk O
suggests O
that O
the O
amount O
ingested O
by O
the O
infant O
is O
small O
. O

furthermore O
, O
based O
on O
our O
clinical O
experience O
, O
nursing O
appears O
to O
be O
safe O
for O
lactating O
women O
with O
fmf B-Disease
who O
continue O
to O
take O
colchicine O
. O

abnormal O
myotonic B-Disease
dystrophy B-Disease
protein O
kinase O
levels O
produce O
only O
mild O
myopathy B-Disease
in O
mice O
. O

myotonic B-Disease
dystrophy B-Disease
( O
dm B-Disease
) O
is O
commonly O
associated O
with O
ctg O
repeat O
expansions O
within O
the O
gene O
for O
dm O
- O
protein O
kinase O
( O
dmpk O
) O
. O

the O
effect O
of O
altered O
expression O
levels O
of O
dmpk O
, O
which O
is O
ubiquitously O
expressed O
in O
all O
muscle O
cell O
lineages O
during O
development O
, O
was O
examined O
by O
disrupting O
the O
endogenous O
dmpk O
gene O
and O
overexpressing O
a O
normal O
human O
dmpk O
transgene O
in O
mice O
. O

nullizygous O
( O
- O
/ O
- O
) O
mice O
showed O
only O
inconsistent O
and O
minor O
size O
changes O
in O
head O
and O
neck O
muscle O
fibres O
at O
older O
age O
, O
animals O
with O
the O
highest O
dmpk O
transgene O
expression O
showed O
hypertrophic B-Disease
cardiomyopathy B-Disease
and O
enhanced O
neonatal O
mortality O
. O

however O
, O
both O
models O
lack O
other O
frequent O
dm B-Disease
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B-Disease
, O
myotonia B-Disease
, O
cataract B-Disease
and O
male B-Disease
- B-Disease
infertility B-Disease
. O

these O
results O
strengthen O
the O
contention O
that O
simple O
loss O
- O
or O
gain O
- O
of O
- O
expression O
of O
dmpk O
is O
not O
the O
only O
crucial O
requirement O
for O
development O
of O
the O
disease O
. O

. O

mice O
lacking O
the O
myotonic B-Disease
dystrophy B-Disease
protein O
kinase O
develop O
a O
late O
onset O
progressive O
myopathy B-Disease
. O

myotonic B-Disease
dystrophy B-Disease
( O
dm B-Disease
) O
is O
an O
autosomal B-Disease
dominant B-Disease
disorder B-Disease
resulting O
from O
the O
expansion O
of O
a O
ctg O
repeat O
in O
the O
3 O
untranslated O
region O
of O
a O
putative O
protein O
kinase O
( O
dmpk O
) O
. O

to O
elucidate O
the O
role O
of O
dmpk O
in O
dm B-Disease
pathogenesis O
we O
have O
developed O
dmpk B-Disease
deficient B-Disease
( O
dmpk O
- O
/ O
- O
) O
mice O
. O

dmpk O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive B-Disease
skeletal B-Disease
myopathy B-Disease
that O
shares O
some O
pathological O
features O
with O
dm B-Disease
. O

muscles O
from O
mature O
mice O
show O
variation O
in O
fibre O
size O
, O
increased O
fibre B-Disease
degeneration B-Disease
and O
fibrosis B-Disease
. O

adult O
dmpk O
- O
/ O
- O
mice O
show O
ultrastructural O
changes O
in O
muscle O
and O
a O
50 O
% O
decrease O
in O
force O
generation O
compared O
to O
young O
mice O
. O

our O
results O
indicate O
that O
dmpk O
may O
be O
necessary O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
and O
function O
and O
suggest O
that O
a O
decrease O
in O
dmpk O
levels O
may O
contribute O
to O
dm B-Disease
pathology O
. O

. O

the O
tumor B-Disease
suppressor O
gene O
brca1 O
is O
required O
for O
embryonic O
cellular O
proliferation O
in O
the O
mouse O
. O

mutations O
of O
the O
brca1 O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B-Disease
and B-Disease
ovarian B-Disease
cancers B-Disease
. O

we O
show O
here O
that O
brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
and O
lack O
tumors B-Disease
by O
age O
eleven O
months O
. O

homozygous O
brca1 O
( O
5 O
- O
6 O
) O
mutant O
mice O
die O
before O
day O
7 O
. O

5 O
of O
embryogenesis O
. O

mutant O
embryos O
are O
poorly O
developed O
, O
with O
no O
evidence O
of O
mesoderm O
formation O
. O

the O
extraembryonic O
region O
is O
abnormal O
, O
but O
aggregation O
with O
wild O
- O
type O
tetraploid O
embryos O
does O
not O
rescue O
the O
lethality O
. O

in O
vivo O
, O
mutant O
embryos O
do O
not O
exhibit O
increased O
apoptosis O
but O
show O
reduced O
cell O
proliferation O
accompanied O
by O
decreased O
expression O
of O
cyclin O
e O
and O
mdm O
- O
2 O
, O
a O
regulator O
of O
p53 O
activity O
. O

the O
expression O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O
the O
mutant O
embryos O
. O

buttressing O
these O
in O
vivo O
observations O
is O
the O
fact O
that O
mutant O
blastocyst O
growth O
is O
grossly O
impaired O
in O
vitro O
. O

thus O
, O
the O
death O
of O
brca1 O
( O
5 O
- O
6 O
) O
mutant O
embryos O
prior O
to O
gastrulation O
may O
be O
due O
to O
a O
failure O
of O
the O
proliferative O
burst O
required O
for O
the O
development O
of O
the O
different O
germ O
layers O
. O

increased O
coronary B-Disease
heart B-Disease
disease B-Disease
in O
japanese O
- O
american O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
despite O
increased O
hdl O
levels O
. O

plasma O
high O
density O
lipoprotein O
( O
hdl O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
inverse O
relationship O
with O
coronary B-Disease
heart B-Disease
disease B-Disease
( O
chd B-Disease
) O
. O

the O
cholesteryl O
ester O
transfer O
protein O
( O
cetp O
) O
mediates O
the O
transfer O
of O
cholesteryl O
esters O
from O
hdl O
to O
other O
lipoproteins O
and O
is O
a O
key O
participant O
in O
the O
reverse O
transport O
of O
cholesterol O
from O
the O
periphery O
to O
the O
liver O
. O

a O
high O
prevalence O
of O
two O
different O
cetp O
gene O
mutations O
( O
d442g O
, O
5 O
. O

1 O
% O
; O
intron O
14g O
a O
, O
0 O
. O

5 O
% O
) O
, O
was O
found O
in O
3 O
, O
469 O
men O
of O
japanese O
ancestry O
in O
the O
honolulu O
heart O
program O
and O
mutations O
were O
associated O
with O
decreased O
cetp O
( O
- O
35 O
% O
) O
and O
increased O
hdl O
chol O
levels O
( O
+ O
10 O
% O
for O
d442g O
) O
. O

however O
, O
the O
overall O
prevalence O
of O
definite O
chd B-Disease
was O
21 O
% O
in O
men O
with O
mutations O
and O
16 O
% O
in O
men O
without O
mutations O
. O

the O
relative O
risk O
( O
rr O
) O
of O
chd B-Disease
was O
1 O
. O

43 O
in O
men O
with O
mutations O
( O
p O
< O
. O

05 O
) O
; O
after O
adjustment O
for O
chd B-Disease
risk O
factors O
, O
the O
rr O
was O
1 O
. O

55 O
( O
p O
= O
. O

02 O
) O
; O
after O
additional O
adjustment O
for O
hdl O
levels O
, O
the O
rr O
was O
1 O
. O

68 O
( O
p O
= O
. O

008 O
) O
. O

similar O
rr O
values O
were O
obtained O
for O
the O
d442g O
mutation O
alone O
. O

increased O
chd B-Disease
in O
men O
with O
mutations O
was O
primarily O
observed O
for O
hdl O
chol O
41 O
- O
60 O
mg O
/ O
dl O
; O
for O
hdl O
chol O
> O
60 O
mg O
/ O
dl O
men O
with O
and O
without O
mutations O
had O
low O
chd B-Disease
prevalence O
. O

thus O
, O
genetic O
cetp B-Disease
deficiency B-Disease
appears O
to O
be O
an O
independent O
risk O
factor O
for O
chd B-Disease
, O
primarily O
due O
to O
increased O
chd B-Disease
prevalence O
in O
men O
with O
the O
d442g O
mutation O
and O
hdl O
cholesterol O
between O
41 O
and O
60 O
mg O
/ O
dl O
. O

the O
findings O
suggest O
that O
both O
hdl O
concentration O
and O
the O
dynamics O
of O
cholesterol O
transport O
through O
hdl O
( O
i O
. O

e O
. O

, O
reverse O
cholesterol O
transport O
) O
determine O
the O
anti O
- O
atherogenicity O
of O
the O
hdl O
fraction O
. O

mapping O
the O
homolog O
of O
the O
human O
rb1 O
gene O
to O
chromosome O
14 O
of O
higher O
primates O
. O

the O
rb1 O
gene O
has O
been O
implicated O
with O
retinoblastoma B-Disease
and O
is O
located O
on O
human O
chromosome O
( O
chr O
) O
13q14 O
. O

furthermore O
rgse B-Plant
administration O
protected O
against O
cia B-Disease
induced O
oxidative O
tissue O
damage O
by O
restoring O
the O
increased O
malondialdehyde O
levels O
and O
the O
decreased O
glutathione O
levels O
and O
catalase O
activities O
almost O
to O
control O
levels O

therefore O
rgse B-Plant
may O
be O
a O
beneficial O
supplement O
which O
can O
improve O
human O
arthritis B-Disease

objectives O
to O
assess O
the O
evidence O
for O
tobacco B-Plant
smoking O
as O
a O
risk O
factor O
for O
the O
causation O
of O
chronic O
pancreatitis B-Disease

conclusions O
tobacco B-Plant
smoking O
may O
enhance O
the O
risk O
of O
developing O
chronic O
pancreatitis B-Disease

we O
have O
previously O
reported O
that O
eriobotrya B-Plant
japonica I-Plant
seed O
extract O
ese O
is O
effective O
for O
the O
treatment O
of O
various O
gastric B-Disease
mucosal I-Disease
injuries I-Disease

in O
this O
study O
we O
prepared O
dsw O
containing O
ese B-Plant
ese B-Plant
dsw O
and O
evaluated O
its O
usefulness O
for O
the O
prevention O
of O
gastric B-Disease
mucosal I-Disease
injuries I-Disease
using O
non O
steroidal O
anti O
inflammatory O
drug O
induced O
acute O
gastric B-Disease
mucosal I-Disease
injury I-Disease
models O
in O
male O
wistar O
st O
rats O

agarwood B-Plant
induced O
laxative O
effects O
via O
acetylcholine O
receptors O
on O
loperamide O
induced O
constipation B-Disease
in O
mice O

eea1 O
eea2 O
the O
main O
constituents O
of O
eeas O
mangiferin O
and O
genkwanin O
5 O
o O
primeveroside O
and O
senna B-Plant
increased O
the O
frequency O
and O
weight O
of O
stools O
in O
loperamide O
induced O
constipation B-Disease
model O
mice O

eea1 O
and O
eea2 O
did O
not O
induce O
diarrhea B-Disease
as O
a O
side O
effect O
but O
senna B-Plant
induced O
severe O
diarrhea B-Disease

cardiac B-Disease
contractile I-Disease
dysfunction I-Disease
and O
apoptosis O
in O
streptozotocin O
induced O
diabetic B-Disease
rats O
are O
ameliorated O
by O
garlic B-Plant
oil O
supplementation O

however O
the O
mechanism O
by O
which O
garlic B-Plant
oil O
protects O
diabetes B-Disease
induced O
cardiomyopathy B-Disease
is O
unclear O

in O
this O
study O
streptozotocin O
stz O
induced O
diabetic B-Disease
rats O
received O
garlic B-Plant
oil O
0 O
10 O
50 O
or O
100 O
mg O
kg O
of O
body O
weight O
by O
gastric O
gavage O
every O
2 O
days O
for O
16 O
days O

however O
these O
diabetes B-Disease
related O
cardiac O
dysfunctions O
were O
almost O
dose O
dependently O
ameliorated O
by O
garlic B-Plant
oil O

in O
conclusion O
garlic B-Plant
oil O
possesses O
significant O
potential O
for O
protecting O
hearts O
from O
diabetes B-Disease
induced O
cardiomyopathy B-Disease

argemone B-Plant
mexicana I-Plant
am B-Plant
a O
validated O
herbal O
medicine O
for O
uncomplicated O
malaria B-Disease
seems O
to O
prevent O
severe O
malaria B-Disease
without O
completely O
clearing O
parasites O
in O
most O
patients O

activity O
of O
melaleuca B-Plant
alternifolia I-Plant
tea B-Plant
tree I-Plant
oil O
on O
influenza B-Disease
virus O
a O
pr O
8 O
study O
on O
the O
mechanism O
of O
action O

our O
previous O
study O
demonstrated O
that O
melaleuca B-Plant
alternifolia I-Plant
tea B-Plant
tree I-Plant
oil O
tto B-Plant
had O
an O
interesting O
antiviral O
activity O
against O
influenza B-Disease
a I-Disease
in O
mdck O
cells O

in O
fact O
when O
we O
tested O
tto B-Plant
and O
some O
of O
its O
components O
we O
found O
that O
tto B-Plant
had O
an O
inhibitory O
effect O
on O
influenza B-Disease
virus O
replication O
at O
doses O
below O
the O
cytotoxic O
dose O
terpinen O
4 O
ol O
terpinolene O
and O
alfa O
terpineol O
were O
the O
main O
active O
components O

the O
aim O
of O
this O
study O
was O
to O
investigate O
the O
mechanism O
of O
action O
of O
tto B-Plant
and O
its O
active O
components O
against O
influenza B-Disease
a I-Disease
pr O
8 O
virus O
subtype O
h1n1 O
in O
mdck O
cells O

thus O
the O
effect O
of O
tto B-Plant
and O
its O
active O
components O
on O
different O
steps O
of O
the O
replicative O
cycle O
of O
influenza B-Disease
virus O
was O
studied O
by O
adding O
the O
test O
compounds O
at O
various O
times O
after O
infection B-Disease

these O
experiments O
revealed O
that O
viral O
replication O
was O
significantly O
inhibited O
if O
tto B-Plant
was O
added O
within O
2h O
of O
infection O
indicating O
an O
interference O
with O
an O
early O
step O
of O
the O
viral O
replicative O
cycle O
of O
influenza B-Disease
virus O

tto B-Plant
did O
not O
inhibit O
influenza B-Disease
virus O
neuraminidase O
activity O
as O
shown O
by O
the O
experiment O
measuring O
the O
amount O
of O
4 O
methylumbelliferone O
cleaved O
by O
the O
influenza B-Disease
virus O
neuraminidase O
from O
the O
fluorogenic O
substrate O
2 O
o O
4 O
methylumbelliferyl O
n O
acetylneuraminic O
acid O

green O
and O
black B-Plant
tea I-Plant
suppress O
hyperglycemia O
and O
insulin B-Disease
resistance I-Disease
by O
retaining O
the O
expression O
of O
glucose O
transporter O
4inch O
muscle O
of O
high O
fat O
diet O
fed O
c57bl O
6j O
mice O

to O
investigate O
the O
preventive O
effects O
of O
tea B-Plant
on O
hyperglycemia B-Disease
and O
insulin B-Disease
resistance I-Disease
male O
c57bl O
6j O
mice O
were O
given O
a O
high O
fat O
diet O
containing O
29 O
lard O
and O
also O
green B-Plant
or O
black B-Plant
tea I-Plant
ad O
libitum O
for O
14 O
weeks O

the O
results O
strongly O
suggest O
that O
green B-Plant
and O
black I-Plant
tea I-Plant
suppress O
high O
fat O
diet O
evoked O
hyperglycemia B-Disease
and O
insulin B-Disease
resistance I-Disease
by O
retaining O
the O
level O
of O
glut4 O
and O
increasing O
the O
level O
of O
glut4 O
on O
the O
plasma O
membrane O
in O
muscle O

zingiber B-Plant
officinale I-Plant
mitigates O
brain B-Disease
damage I-Disease
and O
improves O
memory B-Disease
impairment I-Disease
in O
focal O
cerebral B-Disease
ischemic I-Disease
rat O

in O
this O
study O
possible O
protective O
effect O
of O
zingiber B-Plant
officinale I-Plant
a O
medicinal O
plant O
reputed O
for O
neuroprotective O
effect O
against O
oxidative O
stress O
related O
brain B-Disease
damage I-Disease
on O
brain O
damage O
and O
memory O
deficit O
induced O
by O
focal O
cerebral B-Disease
ischemia I-Disease
was O

elucidated O
male O
adult O
wistar O
rats O
were O
administrated O
an O
alcoholic O
extract O
of O
ginger B-Plant
rhizome O
orally O
14 O
days O
before O
and O
21 O
days O
after O
the O
permanent O
occlusion B-Disease
of O
right O
middle O
cerebral O
artery O
mcao O

the O
results O
showed O
that O
cognitive O
function O
and O
neurons O
density O
in O
hippocampus O
of O
rats O
receiving O
ginger B-Plant
rhizome O
extract O
were O
improved O
while O
the O
brain O
infarct B-Disease
volume O
was O
decreased O

in O
conclusion O
our O
study O
demonstrated O
the O
beneficial O
effect O
of O
ginger B-Plant
rhizome O
to O
protect O
against O
focal O
cerebral B-Disease
ischemia I-Disease

new O
cancer B-Disease
treatment O
strategy O
using O
combination O
of O
green B-Plant
tea I-Plant
catechins O
and O
anti O
cancer B-Disease
drugs O

in O
one O
study O
10 O
japanese O
size O
cups O
of O
green B-Plant
tea I-Plant
daily O
supplemented O
with O
tablets O
of O
green B-Plant
tea I-Plant
extract O
limited O
the O
recurrence O
of O
colorectal B-Disease
polyps I-Disease
in O
humans O
to O
50 O

thus O
cancer B-Disease
patients O
who O
consume O
green B-Plant
tea I-Plant
and O
take O
anti O
cancer B-Disease
drugs O
will O
have O
double O
prevention O

hibiscus B-Plant
sabdariffa I-Plant
linne I-Plant
is O
a O
traditional O
chinese B-Plant
rose I-Plant
tea I-Plant
and O
has O
been O
effectively O
used O
in O
folk O
medicines O
for O
treatment O
of O
hypertension B-Disease
inflammatory B-Disease
conditions I-Disease

pca B-Plant
and O
has B-Plant
protected O
against O
oxidative B-Disease
damage I-Disease
induced O
by O
tert O
butyl O
droperoxide O
t O
bhp O
in O
rat O
primary O
hepatocytes O

in O
rabbits O
fed O
cholesterol O
and O
human O
experimental O
studies O
these O
studies O
imply O
hse B-Plant
could O
be O
pursued O
as O
atherosclerosis B-Disease
chemopreventive O
agents O
as O
they O
inhibit O
ldl O
oxidation O
foam O
cell O
formation O
as O
well O
as O
smooth O
muscle O
cell O
migration O
and O
proliferation O

has B-Plant
and O
hpe B-Plant
were O
demonstrated O
to O
cause O
cancer B-Disease
cell O
apoptosis O
especially O
in O
leukemia B-Disease
and O
gastric B-Disease
cancer I-Disease

more O
recent O
studies O
investigated O
the O
protective O
effect O
of O
hse B-Plant
and O
hpe B-Plant
in O
streptozotocin O
induced O
diabetic B-Disease
nephropathy I-Disease

from O
all O
these O
studies O
it O
is O
clear O
that O
various O
h B-Plant
sabdariffa I-Plant
extracts O
exhibit O
activities O
against O
atherosclerosis B-Disease
liver B-Disease
disease I-Disease
cancer B-Disease
diabetes B-Disease
and O
other O
metabolic B-Disease
syndromes I-Disease

association O
between O
areca B-Plant
stimulated O
vimentin O
expression O
and O
the O
progression O
of O
head B-Disease
and O
neck B-Disease
cancers I-Disease

conclusions O
areca B-Plant
nut O
chewing O
has O
a O
significant O
association O
with O
systemic B-Disease
inflammation I-Disease

the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impacts O
of O
areca B-Plant
nut I-Plant
chewing O
on O
neoplastic O
process O
of O
head B-Disease
and O
neck B-Disease
carcinoma I-Disease

methods O
head B-Disease
and O
neck B-Disease
carcinoma I-Disease
cells O
were O
treated O
with O
areca B-Plant
nut I-Plant
extract O
to O
perceive O
the O
phenotypic O
impacts O

tumor B-Disease
tissues O
were O
analyzed O
with O
immunohistochemistry O
ihc O
to O
understand O
the O
association O
between O
areca B-Plant
associated O
molecular O
changes O
and O
clinical O
variables O

results O
upon O
treatment O
with O
areca B-Plant
nut I-Plant
extract O
carcinoma B-Disease
cells O
showed O
the O
increase O
of O
vimentin O

conclusion O
areca B-Plant
modulated O
vimentin O
expression O
enhanced O
the O
progression O
of O
head B-Disease
and O
neck B-Disease
carcinoma I-Disease

tobacco B-Plant
smoking O
and O
cutaneous B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease
a O
16 O
year O
longitudinal O
population O
based O
study O

background O
although O
tobacco B-Plant
smoking O
is O
commonly O
cited O
as O
a O
risk O
factor O
for O
cutaneous B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease
scc B-Disease
the O
evidence O
from O
previous O
clinical O
and O
case O
control O
studies O
is O
conflicting O

we O
therefore O
aimed O
to O
prospectively O
examine O
the O
role O
of O
tobacco B-Plant
smoking O
in O
the O
development O
of O
scc B-Disease
of O
the O
skin O
in O
a O
population O
based O
study O

conclusions O
in O
this O
australian O
follow O
up O
study O
tobacco B-Plant
smoking O
did O
not O
increase O
the O
risk O
of O
scc B-Disease
of O
the O
skin O

impact O
these O
prospective O
adjusted O
data O
provide O
strong O
evidence O
which O
suggests O
that O
cutaneous O
scc B-Disease
should O
not O
be O
on O
the O
list O
of O
tobacco B-Plant
related O
cancers B-Disease

lemon B-Plant
verbena I-Plant
infusion O
consumption O
attenuates O
oxidative O
stress O
in O
dextran O
sulfate O
sodium O
induced O
colitis B-Disease
in O
the O
rat O

aims O
this O
study O
evaluated O
the O
preventive O
effects O
of O
lemon B-Plant
verbena I-Plant
infusion O
consumption O
against O
mild O
to O
moderate O
dextran O
sulfate O
sodium O
dss O
induced O
colitis B-Disease
in O
rats O

conclusion O
our O
study O
shows O
that O
the O
preventive O
consumption O
of O
lemon B-Plant
verbena I-Plant
infusion O
offered O
some O
antioxidative O
protection O
during O
experimental O
colitis B-Disease
by O
stimulating O
sod O
activity O
and O
decreasing O
lipid O
peroxidation O

dietary O
wolfberry B-Plant
ameliorates O
retinal B-Disease
structure I-Disease
abnormalities I-Disease
in O
db O
mice O
at O
the O
early O
stage O
of O
diabetes B-Disease

wolfberry B-Plant
is O
a O
traditional O
asian O
fruit O
consumed O
for O
years O
to O
prevent O
aging O
eye B-Disease
diseases I-Disease
in O
asian O
contries O

here O
we O
report O
that O
dietary O
wolfberry B-Plant
ameliorated O
mouse O
retinal B-Disease
abnormality I-Disease
at O
the O
early O
stage O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
in O
db O
mice O

taken O
together O
dietary O
wolfberry B-Plant
on O
retinal O
protection O
in O
diabetic B-Disease
mice O
is O
at O
least O
partially O
due O
to O
zeaxanthin O
and O
or O
lutenin O
the O
ethanol O
extract O
from O
the O
dried O
exudate O
of O
bursera B-Plant
fagaroides I-Plant
burseraceae B-Plant
showed O
significant O
cytotoxic O
activity O
in O
the O
ht O
29 O
human O
colon B-Disease
adenocarcinoma I-Disease
test O
system O

benefits O
of O
whole O
ginger B-Plant
extract O
in O
prostate B-Disease
cancer I-Disease

here O
we O
show O
that O
whole O
ginger O
extract O
ge B-Plant
exerts O
significant O
growth O
inhibitory O
and O
death O
inductory O
effects O
in O
a O
spectrum O
of O
prostate B-Disease
cancer I-Disease

comprehensive O
studies O
have O
confirmed O
that O
ge B-Plant
perturbed O
cell O
cycle O
progression O
impaired O
reproductive O
capacity O
modulated O
cell O
cycle O
and O
apoptosis O
regulatory O
molecules O
and O
induced O
a O
caspase O
driven O
mitochondrially O
mediated O
apoptosis O
in O
human O
prostate B-Disease
cancer I-Disease
cells O

remarkably O
daily O
oral O
feeding O
of O
100 O
mg O
kg O
body O
weight O
of O
ge B-Plant
inhibited O
growth O
and O
progression O
of O
pc O
3 O
xenografts O
by O
approximately O
56 O
in O
nude O
mice O
as O
shown O
by O
measurements O
of O
tumour B-Disease
volume O

tumour B-Disease
tissue O
from O
ge B-Plant
treated O
mice O
showed O
reduced O
proliferation O
index O
and O
widespread O
apoptosis O
compared O
with O
controls O
as O
determined O
by O
immunoblotting O
and O
immunohistochemical O
methods O

most O
importantly O
ge B-Plant
did O
not O
exert O
any O
detectable O
toxicity B-Disease
in O
normal O
rapidly O
dividing O
tissues O
such O
as O
gut O
and O
bone O
marrow O

to O
the O
best O
of O
our O
knowledge O
this O
is O
the O
first O
report O
to O
demonstrate O
the O
in O
vitro O
and O
in O
vivo O
anticancer O
activity O
of O
whole O
ge B-Plant
for O
the O
management O
of O
prostate B-Disease
cancer I-Disease
vision O
preservation O
during O
retinal B-Disease
inflammation I-Disease
by O
anthocyanin O
rich O
bilberry B-Plant
extract O
cellular O
and O
molecular O
mechanism O

at O
the O
cellular O
level O
we O
found O
that O
the O
eiu B-Disease
associated O
rhodopsin O
decreased O
and O
the O
shortening O
of O
outer O
segments O
in O
photoreceptor O
cells O
were O
suppressed O
in O
the O
bilberry B-Plant
extract O
treated O
animals O

in O
addition O
to O
its O
anti O
inflammatory O
effect O
the O
anthocyanin O
rich O
bilberry B-Plant
extract O
ameliorated O
the O
intracellular O
elevation O
of O
reactive O
oxygen O
species O
and O
activated O
nf O
kb O
a O
redox O
sensitive O
transcription O
factor O
in O
the O
inflamed B-Disease
retina I-Disease

our O
findings O
indicate O
that O
anthocyanin O
rich O
bilberry B-Plant
extract O
has O
a O
protective O
effect O
on O
visual O
function O
during O
retinal B-Disease
inflammation I-Disease

in O
vitro O
antioxidant O
and O
anticancer O
activity O
of O
young O
zingiber B-Plant
officinale I-Plant
against O
human O
breast B-Disease
carcinoma I-Disease
cell O
lines O

the O
present O
work O
is O
aimed O
to O
find O
out O
antioxidant O
and O
anticancer O
activities O
of O
two O
bangladeshi O
ginger B-Plant
varieties O
fulbaria O
and O
syedpuri O
at O
young O
age O
grown O
under O
ambient O
400 O
mol O
and O
elevated O
800 O
mol O
co2 O
concentrations O
against O
two O
human O
breast B-Disease
cancer I-Disease
cell O
lines O
mcf O
7 O
and O
mda O
mb O
231 O